A N N U A L
R E P O R T
2 016MARCH 2017
TO OUR
SHAREHOLDERS
ALEX GORSKY
Chairman and Chief Executive Officer
I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED
nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED
a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO,
a company that touches the lives of over and disciplines – working together toward WHICH RINGS
a billion people every day, around the a common goal. AS TRUE TODAY
world. As I look at today’s health care AS IT DID WHEN
landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN
pace of change has never been greater, leaders who are committed to working MORE THAN 70
or frankly, more exciting. together to help bring improved health YEARS AGO.
and wellness to every person in every
Today’s rapid change brings both corner of the globe. As the world’s largest
opportunities and risks for any company and most broadly based health care
in health care, and we are prepared company, we are uniquely positioned to help
to address both. There are significant transform global health care; to shine a light
challenges to overcome, but the tools, the on the most important issues we are facing;
insights, the technologies, the innovations to collaborate across boundaries and
– both evolutions and revolutions – all borders; to uncover scientific insights and
combine to make today one of the most ideas; and to dedicate resources towards
promising times for human health and for creating tomorrow’s breakthroughs.
Johnson & Johnson.
We are united and inspired by Our Credo,
For over 130 years, our company has been which rings as true today as it did when
inventing the future of health care. From it was written more than 70 years ago.
the beginning, we learned that innovation It reminds us that our first responsibility
is seldom the product of a solitary genius. is to our customers and patients, and it
CHAIRMAN’S LETTER • Icompels us to deliver on our responsibilities world’s largest and most comprehensive
to our employees, our communities, our health care company, no one is better
environment, and our shareholders. positioned than Johnson & Johnson to
lead this important work.
With that strong foundation, we will
continue to use our breadth to In addition to our commitment to advance
comprehensively advance human health; health comprehensively, we also employ
invest for enduring, long-term impact; disciplined portfolio management to
position our businesses to deliver strong, ensure we are focused on solving the
consistent and sustainable results; most important medical and consumer
hold ourselves accountable for our health needs, investing in promising future
responsibilities; and put people first. growth areas and that all of our businesses
continue meeting our expectations. During
ADVANCING HUMAN HEALTH 2016, we completed 14 acquisitions or
WE HAVE TO We believe having a business that significant licensing deals, as well as eight
PUT THE PATIENT is broadly based in health care has divestitures, positioning us for continued
IN THE CENTER been and will continue to be a major profitable growth.
AND REWARD factor in our success. It has allowed us
INNOVATIONS to deliver strong and consistent growth, Our acquisition of Abbott Medical Optics,
THAT DRIVE as well as return significant value to which closed in early 2017, is an excellent
BETTER our shareholders, throughout various example of our flexibility to invest in areas
OUTCOMES & economic cycles. of opportunity across the spectrum of
LONG-TERM health care. Our consumer expertise,
VALUE. Our company’s structure also allows us particularly in the vision care space,
to interconnect our breadth and depth to combined with our medical device
drive innovation, and to take advantage of expertise, made this opportunity uniquely
growth opportunities wherever they may complementary to our portfolio. We
be across the dynamic health industry. This are excited about adding a strong and
is particularly important as the industry differentiated surgical ophthalmic offering
continues to evolve, and as the political – particularly in cataract surgery – to our
environment poses new challenges and vision care business. That, coupled with
opportunities. In 2016, this was incredibly our world-leading ACUVUE® contact lens
clear in the emerging area of HealthTech. business, will help us become a broad-
The potential for the intersection of based leader in vision care. This transaction
technology and health care to completely is an excellent example of our approach
change and disrupt the existing health care to acquisitions – it was the right deal,
ecosystem has never been more imminent. at the right time and at the right price,
This new HealthTech space is becoming to drive growth and create value for our
integral to everything that we do, and as the shareholders.
II • CHAIRMAN’S LETTEROur broad base across health care and INVESTING FOR LONG-TERM
strong global footprint also gives us unique GROWTH
insight and opportunities to work with In the same way that we are driven to OUR BROAD
governments and health care systems save and improve lives, we have a very BASE IN HUMAN
around the world to influence investments clear perspective on the imperatives for HEALTH CARE
in health. The volatility that we see in our financial performance: our objective EXTENDS
emerging markets, and the health care cost is for Johnson & Johnson to grow sales OUR REACH,
challenges that exist in both developed organically at a faster rate than the market, CAPABILITIES
and emerging markets, clearly demonstrate and grow our earnings faster than sales; AND STRATEGIC
the importance of advocating for improved an objective we met in 2016. ADVANTAGES
access to quality health care, as well as FOR PATIENTS,
rewards for innovations that drive better Additionally, our focus on having a strong PROVIDERS AND
outcomes and long-term value. We will cash flow ensures we are able to make CONSUMERS
continue to be a leading voice in these the appropriate investments in our AROUND THE
discussions, advocating for solutions that business, and then capitalize on the right WORLD.
are in the best interests of the health and opportunities to create greater long-term
wellness of patients and consumers. value for our shareholders.
We start by funding our internal growth
initiatives, including our investments in
research and development.
$9.1B In 2016, our R&D
investments totaled
After funding our organic growth,
$9.1 billion.
we have a strategic capital allocation
framework that outlines how we will
use our remaining free cash flow.
$15.5B In 2016, our free Our first priority is delivering a competitive
cash flow was dividend to our shareholders, which we
$15.5 billion*. have increased for 54 consecutive years.
$8.6B In 2016, we paid
$8.6 billion in
dividends.
After meeting our dividend goals, we
target value creating acquisitions.
$5B In 2016, we invested
approximately $5 billion Finally, we consider other prudent ways to
in acquisitions and major return value to shareholders, such as
licensing deals. share repurchase programs.
$10B In 2016, we completed
two-thirds of our
$10 billion share
repurchase program.
CHAIRMAN’S LETTER • IIIOur total shareholder return for 2016 For 2017, we expect our key catalysts for
was a strong 15.3%, significantly exceeding growth will include:
our competitor composite, as well as
• Continued strong performance of our
exceeding most major indices, including
in-line products – increasing penetration
the S&P 500. This is not only true for 2016,
in markets such as anti-coagulants,
but I’m proud to say it’s also the case over
psoriasis, and long-acting anti-psychotics
the last three, five, ten and twenty year
• Capitalizing on the early launch success
periods. Historically, approximately 70
from key products such as DARZALEX®,
percent of our free cash flow deployed
IMBRUVICA®, and STELARA® for
over the last 10 years has been returned
Crohn’s Disease
to shareholders in the form of dividends or
• Anticipated regulatory approval for two
share repurchases.
new immunology products, guselkumab
ALL THREE OF
and sirukumab, each with greater than
OUR BUSINESS Our strong record of total shareholder
$1 billion in sales potential
SECTORS returns is the result of our approach to
ARE WELL- managing for the long term, our relentless Further, we will continue to vigorously
POSITIONED drive for innovation, our disciplined portfolio defend our patents on REMICADE®, while
TO MEET THE management and our capital allocation remaining competitive against at-risk
CHANGING strategy – all of which are regularly biosimilar entries, given the product’s long
NEEDS OF discussed as part of our ongoing strategic track record of efficacy and safety.
PATIENTS AND planning with our Board of Directors.
CONSUMERS We are confident in our robust
DRIVING STRONG, CONSISTENT, Pharmaceutical pipeline and will continue
SUSTAINABLE RESULTS working toward our goal of filing 10 new
As the health care landscape continues to products by 2019, each with at least $1
evolve, all three of our business sectors are billion in potential sales, as well as filing an
well-positioned to meet the changing needs additional 40 line extensions by 2019, 10
of patients and consumers. In terms of our of which have more than $500 million in
financial performance, we expect each potential sales.
business segment to grow and contribute
to our sales and income growth in 2017. In addition, in January 2017 we announced
a definitive agreement to acquire Actelion
PHARMACEUTICALS Ltd. for approximately $30 billion. The
In our Pharmaceuticals business, our transaction is expected to accelerate
priority is to drive continued growth while our near- and long-term revenue and
delivering on our near-term pipeline. We earnings growth rates and be immediately
will do this by focusing on our therapeutic accretive to Johnson & Johnson’s adjusted
areas of high unmet medical need, our earnings per share**. The acquisition would
robust innovation engine and strong expand and complement our existing
commercial capabilities. Janssen portfolio with differentiated in-
IV • CHAIRMAN’S LETTERmarket medicines for pulmonary arterial opportunities in large, growing markets with
hypertension, and reinforces Janssen’s significant unmet needs.
already robust late-stage pipeline. The
transaction is subject to satisfaction of Our goal is to return to above market
closing conditions and is expected to close growth by the second half of this year, and
by the end of the second quarter of 2017. we plan to drive that growth through:
• More than doubling the number of new
CONSUMER
products in 2016, with at least 12 major
In our Consumer segment, in the near-term,
launches planned for 2017
our priority is to enhance our leadership in
• Accelerating the impact from strategic
priority categories and continue to improve
acquisitions made in 2016
profitability to benchmark levels by focusing
• Incorporating a suite of holistic, insights-
WE HAVE
on critical geographies and our iconic
driven capabilities to help health systems
A UNIQUE
mega-brands.
navigate value-based care through our
PERSPECTIVE
CareAdvantage & Orthopaedic Episode-
Our plans for Consumer growth in ON THE HEALTH
of-Care partnerships
2017 include: AND WELLNESS
• Continuing progress on the restructuring
NEEDS, WANTS,
• Continuing to grow faster than the
initiative in our hospital medical device
HOPES AND
market, and gaining market share across
businesses, which is on track to achieve
FEARS OF THE
our mega brands
savings of $800 million to $1 billion, with
PEOPLE WHOSE
• Bringing innovation to the market, and the majority expected to be realized by
LIVES WE TOUCH
launching key, science-based new the end of 2018
AROUND THE
products
OUR RESPONSIBILITY WORLD EVERY
• Accelerating the growth from recent
As the world’s largest and most broadly- DAY.
acquisitions in our Beauty franchise,
including Vogue International with OGX® based health care company, we have a
and PROGANIX® hair care brands unique perspective on the health and
wellness needs, wants, hopes and fears
• Continuing to utilize supply chain and
operational efficiencies to ensure of the people whose lives we touch around
operating margins are at benchmark the world every day.
levels
We will continue providing leadership on
MEDICAL DEVICES the health and wellness issues that we
Our near-term priority in Medical Devices understand better than anyone else. And
is to accelerate growth through innovation, we will continue reporting on the social and
portfolio management and new business environmental performance of our business
models. We are driving growth in priority through our Citizenship & Sustainability
platforms, sustaining leadership in our Report, available at www.jnj.com/caring.
core platforms, implementing novel
commercial models and seeking expansion In September 2016, in addition to our
CHAIRMAN’S LETTER • VCitizenship & Sustainability 2020 goals, health care system to address the important
we announced a comprehensive UN issue of U.S. health care costs.
Sustainable Development Goals (SDG)
commitment focused on five key areas We will continue to defend the interests
where we are uniquely positioned to of all of the stakeholders defined in Our
create sustainable and scalable impact: Credo: the doctors, nurses and patients; the
Global Disease Challenges, Essential mothers and fathers and all others who use
Surgery, Women’s & Children’s Health, our products; our employees and suppliers;
Health Workforce, and Environmental and the communities in which we live and
Health. Our SDG vision for 2030 is that work. We will also continue to provide
by galvanizing partners, mobilizing positive economic impact wherever we do
employees and engaging communities, business, pay our fair share of taxes and
we will profoundly improve the course of deliver a fair return to our shareholders.
human health.
PUTTING PEOPLE FIRST
We are also an industry leader in keeping Whether it is a human-centered insight
the patient and consumer at the center that drives the innovation of a breakthrough
WE ARE of everything we do. In the last few years, product, our advocacy for access to health
COMMITTED TO we have taken unprecedented steps care, or our humanitarian work treating
ALWAYS PUTTING like creating the Johnson & Johnson some of the world’s most debilitating
PEOPLE FIRST. Bioethics Committee and the industry’s first diseases, we are committed to always
Compassionate Use Advisory Committee; putting people first.
collaborating to develop massive real world
data sets, such as the Observational Health This is also true in how we support our
Data Sciences and Informatics (OHDSI); more than 126,000 employees around
and developing industry-leading clinical trial the world. All of our compelling strategies
data transparency through the Yale Open and strong results would not be possible
Data Access (YODA) Project. without our talented, diverse and dedicated
employees. Their commitment and
In the first quarter of 2017, we were also passion has helped Johnson & Johnson
pleased to release the inaugural Janssen to be named by top industry and business
U.S. Transparency Report, in which we publications as being among the most
are disclosing more information about admired, most respected, most innovative
our business practices, including those and best places to work year after year.
related to pricing. This report builds on our
history of responsible pricing practices For all they do to ensure our success, we
and our ongoing efforts to provide more believe employers have an opportunity and
transparency into how we operate. These responsibility, as well as an incentive, to
disclosures are just one way we are ensure their employees are healthy and
continuing to work with others in the engaged. Our goal for 2020 and beyond is
VI • CHAIRMAN’S LETTERto lead by example, cultivating the world’s and resilience; and one way to achieve
healthiest workforce. this is through the practice of gratitude. I
would like to say how grateful I am to be
We have a number of programs in place the Chairman and Chief Executive Officer
to help us achieve that goal across many of Johnson & Johnson. I am grateful for
facets of our employees’ lives. From the passion, commitment and unique
programs that encourage healthy eating, contributions of our more than 126,000
movement, and resilience; to ensuring the employees around the world. I am grateful
financial health of our employees through to the billions of health care workers,
competitive compensation programs, parents and consumers who place their
Health and Wellness benefits, recognition trust in our products every day. And finally,
programs, long-term incentives, and robust I am grateful to our Board of Directors and
retirement plans – including a defined you, our shareholders, for entrusting me
benefit pension plan in the U.S.; as well with the great responsibility of leading
as supporting healthy families, through this amazing company. Thank you for
programs such as our new parental leave your support.
policy, fertility benefits, and global breast
milk shipping benefits. With Our Credo as our inspiration, the
strength of our broad base across human
We not only feel that this is the right thing health care, and our commitment to
to do, but we also believe these programs delivering strong, consistent, long-term
help us to achieve our goals of attracting, growth, I am incredibly confident in the
developing, and retaining the best talent to continued success of Johnson & Johnson.
deliver the best outcomes; positioning us to
deliver another 130 years of strong growth Sincerely,
and shareholder returns.
CONFIDENT IN THE FUTURE OF
JOHNSON & JOHNSON Alex Gorsky
One of the teachings from our wellness Chairman and Chief Executive Officer
business is the importance of mindfulness Johnson & Johnson
* Non-GAAP measure – Free cash flow is defined as operating cash flow less capital spending ($18.7 billion -
$3.2 billion = $15.5 billion)
** Non-GAAP measure; excludes intangible amortization expense and special items
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter contains forward-looking statements relating to, among other things, future operating and financial
performance, product development, market position and business strategy. The reader is cautioned not to rely on
these statements, which are based on current expectations of future events. For important information about these
statements, including the risks, uncertainties and other factors that could cause actual results to vary materially from the
assumptions, expectations, and projections expressed in any forward-looking statements, the reader should review the
enclosed Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned
“Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors”. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or developments.
CHAIRMAN’S LETTER • VIIUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
ForthefiscalyearendedJanuary1,2017 Commissionfilenumber1-3215
JOHNSON & JOHNSON
(Exactnameofregistrantasspecifiedinitscharter)
NewJersey 22-1024240
(Stateofincorporation) (I.R.S.EmployerIdentificationNo.)
OneJohnson&JohnsonPlaza
NewBrunswick,NewJersey 08933
(Addressofprincipalexecutiveoffices) (ZipCode)
Registrant’stelephonenumber,includingareacode:(732)524-0400
SECURITIESREGISTEREDPURSUANTTOSECTION12(b)OFTHEACT
Titleofeachclass Nameofeachexchangeonwhichregistered
CommonStock,ParValue$1.00 NewYorkStockExchange
4.75%NotesDueNovember2019 NewYorkStockExchange
0.250%NotesDueJanuary2022 NewYorkStockExchange
0.650%NotesDueMay2024 NewYorkStockExchange
5.50%NotesDueNovember2024 NewYorkStockExchange
1.150%NotesDueNovember2028 NewYorkStockExchange
1.650%NotesDueMay2035 NewYorkStockExchange
Indicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefinedinRule405oftheSecurities
Act. Yes Í No ‘
IndicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13orSection15(d)ofthe
ExchangeAct. Yes ‘ No Í
Indicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)ofthe
ExchangeActduringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtofilesuch
reports),and(2)hasbeensubjecttosuchfilingrequirementsforthepast90days. Yes Í No ‘
Indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyandpostedonitscorporatewebsite,ifany,
everyInteractiveDataFilerequiredtobesubmittedandpostedpursuanttoRule405ofRegulationS-Tduringthe
preceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtosubmitandpostsuch
files). Yes Í No ‘
IndicatebycheckmarkifdisclosureofdelinquentfilerspursuanttoItem405ofRegulationS-Kisnotcontainedherein,
andwillnotbecontained,tothebestofregistrant’sknowledge,indefinitiveproxyorinformationstatements
incorporatedbyreferenceinPartIIIofthisForm10-KoranyamendmenttothisForm10-K. ‘
Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,or
asmallerreportingcompany.Seethedefinitionsof“largeacceleratedfiler,”“acceleratedfiler”and“smallerreporting
company”inRule12b-2oftheExchangeAct.
Largeacceleratedfiler Í Acceleratedfiler ‘ Non-acceleratedfiler ‘ Smallerreportingcompany ‘
(Donotcheckifasmallerreportingcompany)
Indicatebycheckmarkwhethertheregistrantisashellcompany(asdefinedinRule12b-2oftheExchange
Act). Yes ‘ No Í
TheaggregatemarketvalueoftheCommonStockheldbynon-affiliatescomputedbyreferencetothepriceatwhich
theCommonStockwaslastsoldasofthelastbusinessdayoftheregistrant’smostrecentlycompletedsecondfiscal
quarterwasapproximately$332billion.
OnFebruary23,2017,therewere2,713,346,602sharesofCommonStockoutstanding.
DOCUMENTSINCORPORATEDBYREFERENCE
PartsIandIII: Portionsofregistrant’sproxystatementforits2017annualmeetingofshareholdersfiled
within120daysafterthecloseoftheregistrant’sfiscalyear(the“ProxyStatement”),are
incorporatedbyreferencetothisreportonForm10-K(this“Report”).Item Page
PARTI
1 Business 1
General 1
SegmentsofBusiness 1
GeographicAreas 2
RawMaterials 2
Patents 2
Trademarks 3
Seasonality 3
Competition 3
ResearchandDevelopment 4
Environment 4
Regulation 4
AvailableInformation 4
1A. RiskFactors 5
1B. UnresolvedStaffComments 9
2 Properties 9
3 LegalProceedings 10
4 MineSafetyDisclosures 10
ExecutiveOfficersoftheRegistrant 11
PARTII
5 MarketforRegistrant’sCommonEquity,RelatedStockholderMattersandIssuerPurchasesof
EquitySecurities 13
6 SelectedFinancialData 14
7 Management’sDiscussionandAnalysisofResultsofOperationsandFinancialCondition 15
7A. QuantitativeandQualitativeDisclosuresAboutMarketRisk 35
8 FinancialStatementsandSupplementaryData 35
9 ChangesinandDisagreementsWithAccountantsonAccountingandFinancialDisclosure 89
9A. ControlsandProcedures 89
9B. OtherInformation 89
PARTIII
10 Directors,ExecutiveOfficersandCorporateGovernance 90
11 ExecutiveCompensation 90
12 SecurityOwnershipofCertainBeneficialOwnersandManagementandRelatedStockholder
Matters 90
13 CertainRelationshipsandRelatedTransactions,andDirectorIndependence 91
14 PrincipalAccountantFeesandServices 91
PARTIV
15 ExhibitsandFinancialStatementSchedules 92
16 Form10-KSummary 92
Signatures 93
ExhibitIndex 94CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
ThisAnnualReportonForm10-KandJohnson&Johnson’sotherpubliclyavailabledocumentscontain“forward-looking
statements”withinthemeaningofthesafeharborprovisionsoftheU.S.PrivateSecuritiesLitigationReformActof1995.
ManagementandrepresentativesofJohnson&Johnsonanditssubsidiaries(the“Company”)alsomayfromtimetotime
makeforward-lookingstatements.Forward-lookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsandreflect
management’sassumptions,views,plans,objectivesandprojectionsaboutthefuture.Forward-lookingstatementsmaybe
identifiedbytheuseofwordssuchas“plans,”“expects,”“will,”“anticipates,”“estimates”andotherwordsofsimilar
meaninginconjunctionwith,amongotherthings:discussionsoffutureoperations;expectedoperatingresultsand
financialperformance;impactofplannedacquisitionsanddispositions;theCompany’sstrategyforgrowth;product
development;regulatoryapprovals;marketpositionandexpenditures.
Becauseforward-lookingstatementsarebasedoncurrentbeliefs,expectationsandassumptionsregardingfutureevents,
theyaresubjecttouncertainties,risksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe
Company’scontrol.Investorsshouldrealizethatifunderlyingassumptionsproveinaccurate,orknownorunknownrisksor
uncertaintiesmaterialize,theCompany’sactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand
projectionsexpressedorimpliedinitsforward-lookingstatements.Investorsarethereforecautionednottorelyonthese
forward-lookingstatements.Risksanduncertaintiesinclude,butarenotlimitedto:
RisksRelatedtoProductDevelopment,MarketSuccessandCompetition
• Challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies
onwhichtheCompany’scontinuedgrowthandsuccessdepend,includinguncertaintyofclinicaloutcomes,obtaining
regulatoryapprovals,healthplancoverageandcustomeraccess,andinitialandcontinuedcommercialsuccess;
• ChallengestotheCompany’sabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew
andexistingproductsandtechnologiesintheU.S.andotherimportantmarkets;
• Theimpactofpatentexpirations,typicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand
resultingrevenueandmarketsharelosses;
• IncreasinglyaggressiveandfrequentchallengestotheCompany’spatentsbycompetitorsandothersseekingtolaunch
competinggeneric,biosimilarorotherproducts,potentiallyresultinginlossofmarketexclusivityandrapiddeclinein
salesfortherelevantproduct;
• Competitioninresearchanddevelopmentofnewandimprovedproducts,processesandtechnologies,whichcanresult
inproductandprocessobsolescence;
• Competitiontoreachagreementwiththirdpartiesforcollaboration,licensing,developmentandmarketingagreements
forproductsandtechnologies;
• Competitiononthebasisofcost-effectiveness,productperformance,technologicaladvancesandpatentsattainedby
competitors;and
• AllegationsthattheCompany’sproductsinfringethepatentsandotherintellectualpropertyrightsofthirdparties,which
couldadverselyaffecttheCompany’sabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages
andfutureroyalties.
RisksRelatedtoProductLiability,LitigationandRegulatoryActivity
• Productefficacyorsafetyconcerns,whetherornotbasedonscientificevidence,potentiallyresultinginproduct
withdrawals,recalls,regulatoryactiononthepartoftheU.S.FoodandDrugAdministration(orinternational
counterparts),decliningsalesandreputationaldamage;
• ImpactofsignificantlitigationorgovernmentactionadversetotheCompany,includingproductliabilityclaims;
• Increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin
investigationsandprosecutions,whichcarrytheriskofsignificantcivilandcriminalpenalties,including,butnotlimited
to,debarmentfromgovernmentbusiness;
• FailuretomeetcomplianceobligationsintheMcNEIL-PPC,Inc.ConsentDecreeortheCorporateIntegrityAgreements
oftheJohnson&JohnsonPharmaceuticalAffiliates,oranyothercomplianceagreementswithgovernmentsor
governmentagencies,whichcouldresultinsignificantsanctions;
• PotentialchangestoapplicablelawsandregulationsaffectingU.S.andinternationaloperations,includingrelatingto:
approvalofnewproducts;licensingandpatentrights;salesandpromotionofhealthcareproducts;accessto,and
reimbursementandpricingfor,healthcareproductsandservices;environmentalprotectionandsourcingofrawmaterials;
Johnson&Johnson2016AnnualReport •• Changesintaxlawsandregulations,increasingauditscrutinybytaxauthoritiesaroundtheworldandexposuresto
additionaltaxliabilitiespotentiallyinexcessofreserves;and
• IssuanceofneworrevisedaccountingstandardsbytheFinancialAccountingStandardsBoardandtheSecuritiesand
ExchangeCommission.
RisksRelatedtotheCompany’sStrategicInitiativesandHealthCareMarketTrends
• Pricingpressuresresultingfromtrendstowardhealthcarecostcontainment,includingthecontinuedconsolidation
amonghealthcareproviders,trendstowardmanagedcareandtheshifttowardgovernmentsincreasinglybecomingthe
primarypayersofhealthcareexpenses;
• Restrictedspendingpatternsofindividual,institutionalandgovernmentalpurchasersofhealthcareproductsand
servicesduetoeconomichardshipandbudgetaryconstraints;
• ChallengestotheCompany’sabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations,
suchasdevelopmentcollaborations,strategicacquisitions,licensingandmarketingagreements,andthepotential
heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures;
• Thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor
divestiturebytheCompany,includingtheplannedacquisitionofActelionLtd.,maynotberealizedormaytakelongerto
realizethanexpected;
• ThepotentialthattheexpectedbenefitsandopportunitiesrelatedtotheplannedrestructuringactionsintheMedical
Devicesegmentmaynotberealizedormaytakelongertorealizethanexpected,includingduetoanyrequired
consultationproceduresrelatingtorestructuringofworkforce;and
• MarketconditionsandthepossibilitythattheCompany’ssharerepurchaseprogrammaybedelayed,suspendedor
discontinued.
RisksRelatedtoEconomicConditions,FinancialMarketsandOperatingInternationally
• Impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch
fluctuationsonrevenues,expensesandresultingmargins;
• Potentialchangesinexport/importandtradelaws,regulationsandpoliciesoftheU.S.,U.K.andothercountries,
includinganyincreasedtraderestrictionsandpotentialdrugreimportationlegislation;
• Theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomies,sovereignrisk,possible
impositionofgovernmentalcontrolsandrestrictiveeconomicpolicies,andunstableinternationalgovernmentsandlegal
systems;
• Changestoglobalclimate,extremeweatherandnaturaldisastersthatcouldaffectdemandfortheCompany’sproducts
andservices,causedisruptionsinmanufacturinganddistributionnetworks,altertheavailabilityofgoodsandservices
withinthesupplychain,andaffecttheoveralldesignandintegrityoftheCompany’sproductsandoperations;and
• TheimpactofarmedconflictsandterroristattacksintheU.S.andotherpartsoftheworldincludingsocialand
economicdisruptionsandinstabilityoffinancialandothermarkets.
RisksRelatedtoSupplyChainandOperations
• Difficultiesanddelaysinmanufacturing,internallyorwithinthesupplychain,thatmayleadtovoluntaryorinvoluntary
businessinterruptionsorshutdowns,productshortages,withdrawalsorsuspensionsofproductsfromthemarket,and
potentialregulatoryaction;
• InterruptionsandbreachesoftheCompany’sinformationtechnologysystems,andthoseoftheCompany’svendors,
couldresultinreputational,competitive,operationalorotherbusinessharmaswellasfinancialcostsandregulatory
action;and
• Relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing
regulatoryrequirementsthatmayadverselyaffectsupply,sourcingandpricingofmaterialsusedintheCompany’s
products.
InvestorsalsoshouldcarefullyreadtheRiskFactorsdescribedinItem1AofthisAnnualReportonForm10-Kfora
descriptionofcertainrisksthatcould,amongotherthings,causetheCompany’sactualresultstodiffermateriallyfrom
thoseexpressedinitsforward-lookingstatements.Investorsshouldunderstandthatitisnotpossibletopredictoridentify
allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinItem1Atobeacompletestatementofall
potentialrisksanduncertainties.TheCompanydoesnotundertaketopubliclyupdateanyforward-lookingstatementthat
maybemadefromtimetotime,whetherasaresultofnewinformationorfutureeventsordevelopments.
• Johnson&Johnson2016AnnualReportPART I
Item 1. BUSINESS
General
Johnson&Johnsonanditssubsidiaries(the“Company”)haveapproximately126,400employeesworldwideengagedin
theresearchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.Johnson&
Johnsonisaholdingcompany,whichhasmorethan230operatingcompaniesconductingbusinessinvirtuallyall
countriesoftheworld.TheCompany’sprimaryfocusisproductsrelatedtohumanhealthandwell-being.Johnson&
JohnsonwasincorporatedintheStateofNewJerseyin1887.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
Company’sthreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.Withinthestrategicparameters
providedbytheCommittee,seniormanagementgroupsatU.S.andinternationaloperatingcompaniesareeach
responsiblefortheirownstrategicplansandtheday-to-dayoperationsofthosecompanies.Eachsubsidiarywithinthe
businesssegmentsis,withlimitedexceptions,managedbyresidentsofthecountrywherelocated.
Segments of Business
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.Additional
informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments
andoperatingresultsunder:“Item7.Management’sDiscussionandAnalysisofResultsofOperationsandFinancial
Condition”ofthisReport;andNote18“SegmentsofBusinessandGeographicAreas”oftheNotestoConsolidated
FinancialStatementsincludedinItem8ofthisReport.
Consumer
TheConsumersegmentincludesabroadrangeofproductsusedinthebabycare,oralcare,beauty(previouslyreferredto
asskincare),over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.BabyCareincludesthe
JOHNSON’S®lineofproducts.OralCareincludestheLISTERINE®productline.MajorbrandsinBeautyincludethe
AVEENO®;CLEAN&CLEAR®;DABAO™;JOHNSON’S®Adult;LEPETITEMARSEILLAIS®;NEUTROGENA®;RoC®
andOGX®productlines.Over-the-countermedicinesincludethebroadfamilyofTYLENOL®acetaminophenproducts;
SUDAFED®cold,fluandallergyproducts;BENADRYL®andZYRTEC®allergyproducts;MOTRIN®IBibuprofen
products;andthePEPCID®lineofacidrefluxproducts.MajorbrandsinWomen’sHealthoutsideofNorthAmericaare
STAYFREE®andCAREFREE®sanitarypadsando.b.®tamponbrands.WoundCarebrandsincludetheBAND-AID®
BrandAdhesiveBandagesandNEOSPORIN®FirstAidproductlines.Theseproductsaremarketedtothegeneralpublic
andsoldbothtoretailoutletsanddistributorsthroughouttheworld.
Pharmaceutical
ThePharmaceuticalsegmentisfocusedonfivetherapeuticareas:immunology(e.g.,rheumatoidarthritis,inflammatory
boweldiseaseandpsoriasis),infectiousdiseasesandvaccines(e.g.,HIV,hepatitis,respiratoryinfectionsand
tuberculosis),neuroscience(e.g.,Alzheimer’sdisease,mooddisordersandschizophrenia),oncology(e.g.,prostate
cancer,hematologicmalignanciesandlungcancer),andcardiovascularandmetabolicdiseases(e.g.,thrombosisand
diabetes).Productsinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealthcare
professionalsforprescriptionuse.KeyproductsinthePharmaceuticalsegmentinclude:REMICADE®(infliximab),a
treatmentforanumberofimmune-mediatedinflammatorydiseases;SIMPONI®(golimumab),asubcutaneoustreatment
foradultswithmoderatetosevererheumatoidarthritis,activepsoriaticarthritis,activeankylosingspondylitisand
moderatelyactivetoseverelyactiveulcerativecolitis;SIMPONIARIA®(golimumab),anintravenoustreatmentforadults
withmoderatetosevererheumatoidarthritis;STELARA®(ustekinumab),atreatmentforadultswithmoderatetosevere
plaquepsoriasisandactivepsoriaticarthritis,andforadultswithmoderatelytoseverelyactiveCrohn’sdisease;
PREZISTA®(darunavir),EDURANT®(rilpivirine),andPREZCOBIX®/REZOLSTA®(darunavir/cobicistat),antiretroviral
medicinesforthetreatmentofhumanimmunodeficiencyvirus(HIV-1)incombinationwithotherantiretroviralproducts;
Johnson&Johnson2016AnnualReport • 1CONCERTA®(methylphenidateHCl)extended-releasetabletsCII,atreatmentforattentiondeficithyperactivitydisorder;
INVEGA®(paliperidone)extended-releasetablets,forthetreatmentofschizophreniaandschizoaffectivedisorder;
INVEGASUSTENNA®/XEPLION®(paliperidonepalmitate),forthetreatmentofschizophreniaandschizoaffective
disorderinadults;INVEGATRINZA®/TREVICTA®(paliperidonepalmitate),forthetreatmentofschizophreniainpatients
aftertheyhavebeenadequatelytreatedwithINVEGASUSTENNA®foratleastfourmonths;RISPERDALCONSTA®
(risperidonelong-actinginjection),forthetreatmentofschizophreniaandthemaintenancetreatmentofBipolar1Disorder
inadults;VELCADE®(bortezomib),atreatmentformultiplemyelomaandforuseincombinationwithrituximab,
cyclophosphamide,doxorubicinandprednisoneforthetreatmentofadultpatientswithpreviouslyuntreatedmantlecell
lymphoma;ZYTIGA®(abirateroneacetate),usedincombinationwithprednisoneasatreatmentformetastaticcastration-
resistantprostatecancer;IMBRUVICA®(ibrutinib),anoral,once-dailytherapyapprovedforuseintreatingcertainB-cell
malignancies,orbloodcancers,andWaldenström’sMacroglobulinemia;DARZALEX®(daratumumab),forthetreatmentof
relapsed/refractorymultiplemyeloma;PROCRIT®(epoetinalfa,soldoutsidetheU.S.asEPREX®),tostimulateredblood
cellproduction;XARELTO®(rivaroxaban),anoralanticoagulantforthepreventionofdeepveinthrombosis(DVT),which
mayleadtopulmonaryembolism(PE)inpatientsundergoinghiporkneereplacementsurgery,toreducetheriskofstroke
andsystemicembolisminpatientswithnonvalvularatrialfibrillation,forthetreatmentandreductionofriskofrecurrenceof
DVTandPE;INVOKANA®(canagliflozin),forthetreatmentofadultswithtype2diabetes;INVOKAMET®/VOKANAMET®
(canagliflozin/metforminHCl),acombinationtherapyoffixeddosesofcanagliflozinandmetforminhydrochlorideforthe
treatmentofadultswithtype2diabetes;andINVOKAMET®XR(canagliflozin/metforminhydrochlorideextended-release),
aonce-daily,fixed-dosecombinationtherapyofcanagliflozinandmetforminhydrochlorideextended-release,forthe
treatmentofadultswithtype2diabetes.Manyofthesemedicinesweredevelopedincollaborationwithstrategicpartners
orarelicensedfromothercompaniesandmaintainactivelifecycledevelopmentprograms.
MedicalDevices
TheMedicalDevicessegmentincludesabroadrangeofproductsusedintheorthopaedic,surgery,cardiovascular,
diabetescareandvisioncarefields.Theseproductsaredistributedtowholesalers,hospitalsandretailers,andused
principallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.Theyinclude
orthopaedicproducts;generalsurgery,biosurgical,endomechanicalandenergyproducts;electrophysiologyproductsto
treatcardiovasculardisease;sterilizationanddisinfectionproductstoreducesurgicalinfection;diabetescareproducts,
suchasbloodglucosemonitoringandinsulindeliveryproducts;anddisposablecontactlenses.
FordetailsregardingacquisitionsanddivestituresseeNote20totheConsolidatedFinancialStatementsincludedin
Item8.
Geographic Areas
ThebusinessofJohnson&Johnsonisconductedbymorethan230operatingcompanieslocatedin60countries,
includingtheU.S.,invirtuallyallcountriesthroughouttheworld.Theproductsmadeandsoldintheinternationalbusiness
includemanyofthosedescribedaboveunder“–SegmentsofBusiness–Consumer,”“–Pharmaceutical”and“–Medical
Devices.”However,theprincipalmarkets,productsandmethodsofdistributionintheinternationalbusinessvarywiththe
countryandtheculture.TheproductssoldininternationalbusinessincludethosedevelopedintheU.S.andby
subsidiariesabroad.
InvestmentsandactivitiesinsomecountriesoutsidetheU.S.aresubjecttohigherrisksthancomparableU.S.activities
becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies,
restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties.
Raw Materials
RawmaterialsessentialtotheCompany’sbusinessaregenerallyreadilyavailablefrommultiplesources.Wherethereare
exceptions,thetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe
financialresultsoftheCompany.
Patents
TheCompany’ssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere
possible.Theyown,orarelicensedunder,asignificantnumberofpatentsintheU.S.andothercountriesrelatingtotheir
products,productuses,formulationsandmanufacturingprocesses,whichintheaggregatearebelievedtobeofmaterial
2 • Johnson&Johnson2016AnnualReportimportancetotheCompanyintheoperationofitsbusinesses.TheCompany’ssubsidiariesfacepatentchallengesfrom
thirdparties,includingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsoftheCompany’s
keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Significantlegal
proceedingsandclaimsinvolvingtheCompany’spatentandotherintellectualpropertyaredescribedinNote21,“Legal
Proceedings–IntellectualProperty”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
SalesoftheCompany’slargestproduct,REMICADE®(infliximab),accountedforapproximately9.7%oftheCompany’s
totalrevenuesforfiscal2016.Accordingly,thepatentsrelatedtothisproductarebelievedtobematerialtotheCompany.
TherearetwosetsofpatentsrelatedspecificallytoREMICADE®.Thefirstsetofpatentsisco-ownedbyJanssen
Biotech,Inc.,awholly-ownedsubsidiaryofJohnson&Johnson,andNYULangoneMedicalCenter(NYU).Janssen
Biotech,Inc.hasanexclusivelicensetoNYU’sinterestsinthepatents.Thesepatentshaveexpiredinallcountriesoutside
theUnitedStates.IntheUnitedStates,theoneremainingpatent,whichexpiresinSeptember2018,standsrejected
followingreexaminationproceedingsinstitutedbyathirdpartyintheUnitedStatesPatentandTrademarkOffice(USPTO).
ThepatenthasalsobeenheldinvalidbytheFederalDistrictCourtintheDistrictofMassachusetts.Thedecisionsbythe
USPTOandtheFederalDistrictCourthavebeenappealedtotheU.S.CourtofAppealsfortheFederalCircuit.The
appealsarepending.
ThesecondsetofpatentsspecificallyrelatedtoREMICADE®wasgrantedtoTheKennedyInstituteofRheumatologyin
Europe,Canada,AustraliaandtheUnitedStates.JanssenBiotech,Inc.haslicenses(exclusiveforhumananti-TNF
antibodiesandsemi-exclusivefornon-humananti-TNFantibodies)tothesepatents,whichexpirein2017outsideofthe
UnitedStatesand2018intheUnitedStates.Certainofthesepatentshavebeensuccessfullychallengedandinvalidated,
andothersareunderreviewinvariouspatentofficesaroundtheworldandarealsosubjecttolitigationinCanada.
TheCompanydoesnotexpectthatanyextensionswillbeavailablefortheabovedescribedpatentsspecificallyrelatedto
REMICADE®.In2016,athirdpartyreceivedapprovalfromtheFoodandDrugAdministrationforsaleofitsinfliximab
biosimilarintheUnitedStatesandintroduceditsbiosimilartotheU.S.marketinlate2016.Foramoreextensive
descriptionoflegalmattersregardingthepatentsrelatedtoREMICADE®,seeNote21“LegalProceedings–Intellectual
Property–Pharmaceutical–REMICADE®RelatedCases”oftheNotestoConsolidatedFinancialStatementsincludedin
Item8ofthisReport.
InadditiontocompetingintheimmunologymarketwithREMICADE®,theCompanyiscurrentlymarketingSTELARA®
(ustekinumab),SIMPONI®(golimumab)andSIMPONIARIA®(golimumab),nextgenerationimmunologyproductswith
remainingpatentlivesofuptosevenyears.
Trademarks
TheCompany’ssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection
forthesetrademarksbyallavailablemeans.ThesetrademarksareprotectedbyregistrationintheU.S.andothercountries
wheresuchproductsaremarketed.TheCompanyconsidersthesetrademarksintheaggregatetobeofmaterial
importanceintheoperationofitsbusinesses.
Seasonality
Worldwidesalesdonotreflectanysignificantdegreeofseasonality;however,spendinghasbeenheavierinthefourth
quarterofeachyearthaninotherquarters.Thisreflectsincreasedspendingdecisions,principallyforadvertisingand
researchanddevelopmentactivity.
Competition
Inalloftheirproductlines,theCompany’ssubsidiariescompetewithcompaniesbothlocallyandglobally.Competition
existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.Competitionin
research,bothinternallyandexternallysourced,involvingthedevelopmentandtheimprovementofnewandexisting
productsandprocesses,isparticularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotecting
theunderlyingintellectualpropertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareas
ofitsbusiness.Thecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,the
developmentandmaintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvesignificant
expendituresforadvertisingandpromotion.
Johnson&Johnson2016AnnualReport • 3Research and Development
ResearchactivitiesrepresentasignificantpartoftheCompany’sbusinesses.Researchanddevelopmentexpenditures
relatetotheprocessesofdiscovering,testinganddevelopingnewproducts,improvingexistingproducts,aswellas
demonstratingproductefficacyandregulatorycompliancepriortolaunch.TheCompanyremainscommittedtoinvesting
inresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproducts.Worldwidecostsofresearch
anddevelopmentactivitiesamountedto$9.1billion,$9.0billionand$8.5billionforfiscalyears2016,2015and2014,
respectively.ResearchfacilitiesarelocatedintheUnitedStates,Belgium,Brazil,Canada,China,France,Germany,India,
Israel,Japan,theNetherlands,Singapore,SwitzerlandandtheUnitedKingdom.
Environment
TheCompanyissubjecttoavarietyofU.S.andinternationalenvironmentalprotectionmeasures.TheCompanybelieves
thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulations.TheCompany’s
compliancewiththeserequirementsdidnotchangeduringthepastyear,andisnotexpectedtohaveamaterialeffect
uponitscapitalexpenditures,cashflows,earningsorcompetitiveposition.
Regulation
TheCompany’sbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations
areconducted,andthegeneraltrendistowardincreasinglystringentregulation.IntheU.S.,thedrug,deviceandcosmetic
industrieshavelongbeensubjecttoregulationbyvariousfederalandstateagencies,primarilyastoproductsafety,
efficacy,manufacturing,advertising,labelingandsafetyreporting.TheexerciseofbroadregulatorypowersbytheU.S.
FoodandDrugAdministration(the“FDA”)continuestoresultinincreasesintheamountsoftestinganddocumentation
requiredforFDAapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseofproductintroduction.
SimilartrendsarealsoevidentinmajormarketsoutsideoftheU.S.
Thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudy,investigationandregulationby
governmentalagenciesandlegislativebodiesaroundtheworld.IntheU.S.,attentionhasbeenfocusedondrugprices
andprofitsandprogramsthatencouragedoctorstowriteprescriptionsforparticulardrugs,ortorecommend,useor
purchaseparticularmedicaldevices.Payershavebecomeamorepotentforceinthemarketplaceandincreasedattention
isbeingpaidtodrugandmedicaldevicepricing,appropriatedrugandmedicaldeviceutilizationandthequalityandcosts
ofhealthcaregenerally.
U.S.governmentagenciescontinuetoimplementtheextensiverequirementsofthePatientProtectionandAffordableCare
Act(the“ACA”).ThesehavebothpositiveandnegativeimpactsontheU.S.healthcareindustrywithmuchremaining
uncertainastohowvariousprovisionsoftheACA,andpotentialmodificationorrepealofACAprovisions,willultimately
affecttheindustry.
TheregulatoryagenciesunderwhosepurviewtheCompanyoperateshaveadministrativepowersthatmaysubjectitto
actionssuchasproductwithdrawals,recalls,seizureofproductsandothercivilandcriminalsanctions.Insomecases,the
Company’ssubsidiariesmaydeemitadvisabletoinitiateproductrecalls.
Inaddition,businesspracticesinthehealthcareindustryhavecomeunderincreasedscrutiny,particularlyintheUnited
States,bygovernmentagenciesandstateattorneysgeneral,andresultinginvestigationsandprosecutionscarrytheriskof
significantcivilandcriminalpenalties.
Further,theCompanyreliesonglobalsupplychains,andproductionanddistributionprocesses,thatarecomplex,are
subjecttoincreasingregulatoryrequirementsthatmayaffectsourcing,supplyandpricingofmaterialsusedinthe
Company’sproducts.Theseprocessesalsoaresubjecttolengthyregulatoryapprovals.
Available Information
TheCompany’smaincorporatewebsiteaddressiswww.jnj.com.CopiesoftheCompany’sQuarterlyReportson
Form10-Q,AnnualReportonForm10-KandCurrentReportsonForm8-KfiledorfurnishedtotheU.S.Securitiesand
ExchangeCommission(the“SEC”),andanyamendmentstotheforegoing,willbeprovidedwithoutchargetoany
shareholdersubmittingawrittenrequesttotheSecretaryattheprincipalexecutiveofficesoftheCompanyorbycalling
1-800-950-5089.AlloftheCompany’sSECfilingsarealsoavailableontheCompany’swebsiteatwww.investor.jnj.com/
sec.cfm,assoonasreasonablypracticableafterhavingbeenelectronicallyfiledorfurnishedtotheSEC.AllSECfilings
4 • Johnson&Johnson2016AnnualReportarealsoavailableattheSEC’swebsiteatwww.sec.gov.Inaddition,thewrittenchartersoftheAuditCommittee,the
Compensation&BenefitsCommittee,theNominating&CorporateGovernanceCommittee,theRegulatory,Compliance&
GovernmentAffairsCommitteeandtheScience,Technology&SustainabilityCommitteeoftheBoardofDirectorsandthe
Company’sPrinciplesofCorporateGovernance,CodeofBusinessConduct(foremployees),CodeofBusiness
Conduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers,andothercorporategovernance
materials,areavailableatwww.investor.jnj.com/gov.cfmontheCompany’swebsiteandwillbeprovidedwithoutchargeto
anyshareholdersubmittingawrittenrequest,asprovidedabove.TheinformationontheCompany’swebsiteisnot,and
willnotbedeemed,apartofthisReportorincorporatedintoanyotherfilingstheCompanymakeswiththeSEC.
Item 1A. Risk Factors
TheCompanyfacesanumberofuncertaintiesandrisksthataredifficulttopredictandmanyofwhichareoutsideofthe
Company’scontrol.InadditiontotheotherinformationinthisreportandtheCompany’sotherfilingswiththeSEC,
investorsshouldconsidercarefullythefactorssetforthbelow.Investorsshouldbeawarethatitisnotpossibletopredict
oridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacompletediscussionofallpotentialrisksor
uncertainties.Ifknownorunknownrisksoruncertaintiesmaterialize,theCompany’sbusiness,resultsofoperationsor
financialconditioncouldbeadverselyaffected,potentiallyinamaterialway.
OneoftheCompany’skeyproducts,REMICADE®(infliximab),isexperiencingbiosimilarcompetition,which
willresultinareductioninU.S.salesofREMICADE®.
TheCompanyhasexperiencedsignificantchallengestopatentscoveringitslargestproduct,REMICADE®(infliximab)
(accountingforapproximately9.7%oftheCompany’stotalrevenuesforfiscal2016),andcontinuestoassertcertain
patentsrelatedtotheproduct.InApril2016,theFDAapprovedforsaleintheUnitedStatesaninfliximabbiosimilartobe
marketedbyasubsidiaryofPfizerInc.InOctober2016,thenoticeoflaunchperiodundertheU.S.BiologicsPrice
CompetitionandInnovationAct(theBPCIA)passedandinNovember2016Pfizerbeganshipmentofaninfliximab
biosimilartowholesalersintheUnitedStates.SalesofaninfliximabbiosimilarintheU.S.marketwillresultinareductionin
U.S.salesofREMICADE®.
GlobalsalesintheCompany’sPharmaceuticalandMedicalDevicessegmentsmaybenegativelyimpacted
byhealthcarereformsandincreasingpricingpressures.
SalesoftheCompany’spharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby
third-partypayerssuchasgovernmenthealthcareprograms,privateinsuranceplansandmanagedcareorganizations.As
partofvariouseffortstocontainhealthcarecosts,thesepayersareputtingdownwardpressureonpricesatwhich
productswillbereimbursed.IntheUnitedStates,increasedpurchasingpowerofentitiesthatnegotiateonbehalfof
Medicare,Medicaid,andprivatesectorbeneficiaries,inpartduetocontinuedconsolidationamonghealthcareproviders,
couldresultinfurtherpricingpressures.OutsidetheUnitedStates,numerousmajormarkets,includingtheEUandJapan,
havepervasivegovernmentinvolvementinfundinghealthcareand,inthatregard,directlyorindirectlyimposeprice
controls,limitaccessto,orreimbursementfor,theCompany’sproducts,orreducethevalueofitsintellectualproperty
protection.
TheCompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpenses,finesand
reputationaldamage.
Intheordinarycourseofbusiness,Johnson&Johnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits
involvingvariousissuessuchaspatentdisputes,productliabilityandclaimsthattheirproductsales,marketingandpricing
practicesviolatevariousantitrust,unfairtradepracticesand/orconsumerprotectionlaws.Themostsignificantofthese
proceedingsaredescribedinNote21,“LegalProceedings”underNotestotheConsolidatedFinancialStatements
includedinItem8ofthisReport.WhiletheCompanybelievesithassubstantialdefensesinthesematters,itisnotfeasible
topredicttheultimateoutcomeoflitigation.TheCompanycouldinthefutureberequiredtopaysignificantamountsasa
resultofsettlementsorjudgmentsinthesematters,potentiallyinexcessofaccruals.Theresolutionof,orincreasein
accrualsfor,oneormoreofthesemattersinanyreportingperiodcouldhaveamaterialadverseeffectontheCompany’s
resultsofoperationsandcashflowsforthatperiod.Furthermore,asaresultofcostandavailabilityfactors,effective
November1,2005,theCompanyceasedpurchasingthird-partyproductliabilityinsurance.
Productreliability,safetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand
resultsofoperations,leadtolitigationandcausereputationaldamage.
Concernsaboutproductsafety,whetherraisedinternallyorbyregulatorsorconsumeradvocates,andwhetherornot
basedonscientificevidence,canresultinsafetyalerts,productrecalls,governmentalinvestigations,regulatoryactionon
Johnson&Johnson2016AnnualReport • 5thepartoftheFDA(oritscounterpartinothercountries),privateclaimsandlawsuits,paymentoffinesandsettlements,
decliningsalesandreputationaldamage.Thesecircumstancescanalsoresultindamagetobrandimage,brandequity
andconsumertrustintheCompany’sproducts.Productrecallshaveinthepast,andcouldinthefuture,prompt
governmentinvestigationsandinspections,theshutdownofmanufacturingfacilities,continuedproductshortagesand
relatedsalesdeclines,significantremediationcosts,reputationaldamage,possiblecivilpenaltiesandcriminalprosecution.
ChangesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpacttheCompany’s
operatingresults.
Changesintaxlawsorregulations,includingtaxreformproposalsintheU.S.,BelgiumandSwitzerland,couldnegatively
impacttheCompany’seffectivetaxrateandresultsofoperations.Achangeinstatutorytaxratemayresultinthe
revaluationoftheCompany’sdeferredtaxassetsandliabilitiesrelatedtotherelevantjurisdictionintheperiodinwhichthe
newtaxlawisenacted,potentiallyresultinginamaterialexpenseorbenefitrecordedtotheCompany’sConsolidated
StatementofEarningsforthatperiod.Foradiscussionofrisksofchangesintaxratesinothercountries,including
Belgium,pleasesee“Management’sDiscussionandAnalysisofResultsofOperationsandFinancialCondition–Other
Information–EconomicandMarketFactors”inItem7ofthisReport.
TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxauditsinprogresswith
manytaxauthorities.InconnectionwiththeOrganizationforEconomicCooperationandDevelopmentBaseErosionand
ProfitShifting(BEPS)project,startingin2017,companiesarerequiredtodisclosemoreinformationtotaxauthoritieson
operationsaroundtheworld,whichmayleadtogreaterauditscrutinyofprofitsearnedinothercountries.TheCompany
regularlyassessesthelikelyoutcomesofitstaxauditstodeterminetheappropriatenessofitstaxreserves.However,any
taxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytotheCompany’sexpectations,whichcouldresultintax
liabilitiesinexcessofreserves.
TheCompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto
theCompany’sbusinesses.
TheCompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrights,determinedbypatentoffices,
courtsandlawmakersinvariouscountries,relatingtoitsproductsandmanufacturingprocesses.Theserightsareessential
totheCompany’sbusinessesandmateriallyimportanttotheCompany’sresultsofoperations.Publicpolicy,bothwithin
andoutsidetheU.S.,hasbecomeincreasinglyunfavorabletowardintellectualpropertyrights.TheCompanycannotbe
certainthatitwillobtainadequatepatentprotectionfornewproductsandtechnologiesintheU.S.andotherimportant
marketsorthatsuchprotections,oncegranted,willlastaslongasoriginallyanticipated.
CompetitorsroutinelychallengethevalidityorextentoftheCompany’sownedorlicensedpatentsandproprietaryrights
throughlitigation,interferences,oppositionsandotherproceedings.Theseproceedingsabsorbresourcesandcanbe
protractedaswellasunpredictable.Inaddition,challengesthattheCompany’sproductsinfringethepatentsofthird
partiescouldresultintheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand
salesoftheproductsinquestion.
TheCompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand
biosimilarversionsoftheCompany’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering
thoseproducts.IntheUnitedStates,manufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay
challengethevalidity,orclaimnon-infringement,ofinnovatorproductsthroughtheAbbreviatedNewDrugApplication,or
ANDA,processwiththeFDA.TheBPCIA,enactedin2010,whichcreatedanewregulatorypathwayfortheapprovalby
theFDAofbiosimilaralternativestoinnovator-developedbiologicalproducts,alsocreatedmechanismsforbiosimilar
applicantstochallengethepatentsontheinnovatorbiologics.Theinterpartesreview(IPR)processwiththeUSPTO,
createdunderthe2011AmericaInventsAct,isalsobeingusedbycompetitorstochallengepatentsheldbythe
Company’ssubsidiaries.Forexample,akeypatentforZYTIGA®iscurrentlysubjecttopatentlitigationandseveralIPR
proceedingsbroughtbygenericcompaniesseekingtoinvalidatethepatent.
IntheeventtheCompanyisnotsuccessfulindefendingitspatentsagainstsuchchallenges,oruponthe“at-risk”launch
(despitependingpatentinfringementlitigation)bythegenericorbiosimilarfirmofitsproduct,theCompanycanlosea
majorportionofrevenuesforthereferencedproductinaveryshortperiodoftime.Currentlegalproceedingsinvolvingthe
Company’spatentsandotherintellectualpropertyrightsaredescribedinNote21,“LegalProceedings–Intellectual
Property”oftheNotestotheConsolidatedFinancialStatementsincludedinItem8ofthisReport.
6 • Johnson&Johnson2016AnnualReportTheCompany’sbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould
adverselyaffecttheCompany’searnings.
TheCompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarkets.TheCompany’s
businessescompetewithcompaniesofallsizesonthebasisofcost-effectiveness,technologicalinnovations,intellectual
propertyrights,productperformance,realorperceivedproductadvantages,pricingandavailabilityandrateof
reimbursement.TheCompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions,
collaborationsandlicensingagreementswiththirdparties.Competitionforrightstoproductcandidatesandtechnologies
mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsfortheCompany.Competitors’
developmentofmoreeffectiveorlesscostlyproducts,and/ortheirabilitytosecurepatentandotherintellectualproperty
rightsandsuccessfullymarketproductsaheadofus,couldnegativelyimpactsalesoftheCompany’sexistingproductsas
wellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproductdevelopment.
FortheCompany’spharmaceuticalbusinesses,lossofpatentexclusivityforaproductoftenisfollowedbyasubstantial
reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket.
Similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproduct.FortheCompany’smedicaldevice
businesses,technologicalinnovation,productquality,reputationandcustomerserviceareespeciallyimportantto
competitiveness.Developmentbyothercompaniesofneworimprovedproducts,processesandtechnologiescould
threatentomaketheCompany’sproductsortechnologieslessdesirable,lesseconomicalorobsolete.TheCompany’s
consumerbusinessesfaceintensecompetitionfromotherbrandedproductsandretailers’private-labelbrands.Ifthe
Companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproducts,thiscouldadverselyaffect
revenuesandprofitabilityofthoseproducts.
SignificantchallengesordelaysintheCompany’sinnovationanddevelopmentofnewproducts,
technologiesandindicationscouldhaveanadverseimpactontheCompany’slong-termsuccess.
TheCompany’scontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated
productsandservicesthataddresstheevolvinghealthcareneedsofpatients,providersandconsumers.Developmentof
successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhentheCompany’sexistingproducts
losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivity.Newproductsintroduced
withinthepastfiveyearsaccountedforapproximately22%of2016sales.TheCompanycannotbecertainwhenor
whetheritwillbeabletodevelop,licenseorotherwiseacquirecompanies,productsandtechnologies,whetherparticular
productcandidateswillbegrantedregulatoryapproval,and,ifapproved,whethertheproductswillbecommercially
successful.
TheCompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations,
acquisitions,jointventuresandlicensingorotherarrangementswiththirdparties.Inallofthesecontexts,developingnew
products,particularlypharmaceuticalandbiotechnologyproductsandmedicaldevices,requiressignificantinvestmentof
resourcesovermanyyears.Onlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially
viableproducts.Theprocessdependsonmanyfactorsincludingtheabilitytodiscernpatients’andhealthcareproviders’
futureneeds;developpromisingnewcompounds,strategiesandtechnologies;achievesuccessfulclinicaltrialresults;
secureeffectiveintellectualpropertyprotection;obtainregulatoryapprovalsonatimelybasis;and,ifandwhentheyreach
themarket,successfullydifferentiatetheCompany’sproductsfromcompetingproductsandapproachestotreatment.
Newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue
toproductandpricecompetition,changesincustomerpreferencesorhealthcarepurchasingpatterns,resistanceby
healthcareprovidersoruncertaintyoverthird-partyreimbursement.Evenfollowinginitialregulatoryapproval,thesuccess
ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulations,aswellas
marketentryofcompetitiveproducts.
TheCompanyfacesincreasingregulatoryscrutinywhichimposessignificantcompliancecostsandexposes
theCompanytogovernmentinvestigations,legalactionsandpenalties.
Likeothercompaniesinthehealthcareindustry,theCompanyissubjecttoextensiveregulation,investigationsandlegal
action,bynational,stateandlocalgovernmentagenciesintheUnitedStatesandothercountriesinwhichtheyoperate.
RegulatoryissuesregardingcompliancewithGoodManufacturingPractices(cGMP)(andcomparablequalityregulations
inforeigncountries)bymanufacturersofdrugs,devicesandconsumerproductscanleadtofinesandpenalties,product
recalls,productshortages,interruptionsinproduction,delaysinnewproductapprovalsandlitigation.Inaddition,the
marketing,pricingandsaleoftheCompany’sproductsaresubjecttoregulation,investigationsandlegalactionsincluding
undertheFederalFood,Drug,andCosmeticAct,theMedicaidRebateProgram,federalandstatefalseclaimsacts,state
unfairtradepracticesactsandconsumerprotectionlaws.Increasedscrutinyofhealthcareindustrybusinesspracticesin
Johnson&Johnson2016AnnualReport • 7recentyearsbygovernmentagenciesandstateattorneysgeneralintheU.S.,andanyresultinginvestigationsand
prosecutions,carryriskofsignificantcivilandcriminalpenaltiesincluding,butnotlimitedto,debarmentfromparticipation
ingovernmenthealthcareprograms.AnysuchdebarmentcouldhaveamaterialadverseeffectontheCompany’sbusiness
andresultsofoperations.Themostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesare
describedinNote21,“LegalProceedings–GovernmentProceedings”underNotestotheConsolidatedFinancial
StatementsincludedinItem8ofthisReport.
TheCompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally.
TheCompany’sextensiveoperationsandbusinessactivityoutsidetheU.S.areaccompaniedbycertainfinancial,
economicandpoliticalrisks,includingthoselistedbelow.
ForeignCurrencyExchange:Infiscal2016,approximately47%oftheCompany’ssalesoccurredoutsideoftheU.S.,with
approximately22%inEurope,8%intheWesternHemisphere,excludingtheU.S.,and17%intheAsia-PacificandAfrica
region.Changesinnon-U.S.currenciesrelativetotheU.S.dollarimpacttheCompany’srevenuesandexpenses.While
theCompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows,
unhedgedexposurescontinuetobesubjecttocurrencyfluctuations.Inaddition,theweakeningorstrengtheningofthe
U.S.dollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe
Company’snon-U.S.businessactivityaretranslatedintoU.S.dollars.
InflationandCurrencyDevaluationRisks:TheCompanyfaceschallengesinmaintainingprofitabilityofoperationsin
economiesexperiencinghighinflationrates.TheCompanyhasaccountedforoperationsinVenezuelaashighly
inflationary,asthepriorthree-yearcumulativeinflationratesurpassed100%.WhiletheCompanystrivestomaintainprofit
marginsintheseareasthroughcostreductionprograms,productivityimprovementsandperiodicpriceincreases,itmight
experienceoperatinglossesasaresultofcontinuedinflation.Inaddition,theimpactofcurrencydevaluationsincountries
experiencinghighinflationratesorsignificantcurrencyexchangefluctuationscouldnegativelyimpacttheCompany’s
operatingresults.
IllegalImportationofPharmaceuticalProducts:Theillegalimportationofpharmaceuticalproductsfromcountrieswhere
governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffecttheCompany’ssalesand
profitabilityintheU.S.andothercountriesinwhichtheCompanyoperates.Withtheexceptionoflimitedquantitiesof
prescriptiondrugsforpersonaluse,foreignimportsofpharmaceuticalproductsareillegalundercurrentU.S.law.
However,thevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower-
pricedimportshasgrownsignificantly.
Anti-BriberyandOtherRegulations:TheCompanyissubjecttovariousfederalandforeignlawsthatgovernits
internationalbusinesspracticeswithrespecttopaymentstogovernmentofficials.ThoselawsincludetheU.S.Foreign
CorruptPracticesAct(FCPA),whichprohibitsU.S.publiclytradedcompanies,frompromising,offering,orgivinganything
ofvaluetoforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingtheCompany
obtainorretainbusinessorgainanyimproperadvantage.TheCompany’sbusinessisheavilyregulatedandtherefore
involvessignificantinteractionwithforeignofficials.Also,inmanycountriesoutsidetheU.S.,thehealthcareproviderswho
prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare
governmententities;therefore,theCompany’sinteractionswiththeseprescribersandpurchasersaresubjecttoregulation
undertheFCPA.InadditiontotheU.S.applicationandenforcementoftheFCPA,variousjurisdictionsinwhichthe
Companyoperateshavelawsandregulations,includingtheU.KBriberyAct2010,aimedatpreventingandpenalizing
corruptandanticompetitivebehavior.EnforcementactivitiesundertheselawscouldsubjecttheCompanytoadditional
administrativeandlegalproceedingsandactions,whichcouldincludeclaimsforcivilpenalties,criminalsanctions,and
administrativeremedies,includingexclusionfromhealthcareprograms.
OtherLegal,SocialandPoliticalRisks.Otherrisksinherentinconductingbusinessgloballyinclude:
• protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimport/exportlicensing
requirements;
• compliancewithlocalregulationsandlawsincluding,insomecountries,regulatoryrequirementsrestrictingthe
Company’sabilitytomanufactureorsellitsproductsintherelevantmarket;
• diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions;
• potentialnationalizationorexpropriationoftheCompany’sforeignassets;and
• disruptionstomarketsduetowar,armedconflict,terrorism,socialupheavalsorpandemics.
8 • Johnson&Johnson2016AnnualReportInterruptionsanddelaysinmanufacturingoperationscouldadverselyaffecttheCompany’sbusiness,sales
andreputation.
TheCompany’smanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplex,high-quality
componentsandmaterials.Thesesubsidiariesoperate119manufacturingfacilitiesaswellassourcingfromhundredsof
suppliersaroundtheworld.TheCompanyhasinthepast,andmayinthefuture,faceunanticipatedinterruptionsand
delaysinmanufacturingthroughitsinternalorexternalsupplychain.Manufacturingdisruptionscanoccurformanyreasons
includingregulatoryaction,productionqualitydeviationsorsafetyissues,labordisputes,site-specificincidents(suchas
fires),naturaldisasters,rawmaterialshortages,politicalunrestandterroristattacks.Suchdelaysanddifficultiesin
manufacturingcanresultinproductshortages,declinesinsalesandreputationalimpactaswellassignificantremediation
andrelatedcostsassociatedwithaddressingtheshortage.
Aninformationsecurityincident,includingacybersecuritybreach,couldhaveanegativeimpacttothe
Company’sbusinessorreputation.
Tomeetbusinessobjectives,theCompanyreliesonbothinternalinformationtechnology(IT)systemsandnetworks,and
thoseofthirdpartiesandtheirvendors,toprocessandstoresensitivedata,includingconfidentialresearch,business
plans,financialinformation,intellectualproperty,andpersonaldata.Theextensiveinformationsecurityandcybersecurity
threats,whichaffectcompaniesglobally,posearisktothesecurityandavailabilityoftheseITsystemsandnetworks,and
theconfidentiality,integrity,andavailabilityoftheCompany’ssensitivedata.TheCompanycontinuallyassessesthese
threatsandmakesinvestmentstoincreaseinternalprotection,detection,andresponsecapabilities,aswellasensurethe
Company’sthirdpartyprovidershaverequiredcapabilitiesandcontrols,toaddressthisrisk.Todate,theCompanyhas
notexperiencedanymaterialimpacttoourbusinessoroperationsresultingfrominformationorcybersecurityattacks;
however,becauseofthefrequentlychangingattacktechniques,alongwiththeincreasedvolumeandsophisticationofthe
attacks,thereisthepotentialfortheCompanytobeadverselyimpacted.Thisimpactcouldresultinreputational,
competitive,operationalorotherbusinessharmaswellasfinancialcostsandregulatoryaction.
Item 1B. UNRESOLVED STAFF COMMENTS
Notapplicable.
Item 2. PROPERTIES
TheCompany’ssubsidiariesoperate119manufacturingfacilitiesoccupyingapproximately21.5millionsquarefeetoffloor
space.ThemanufacturingfacilitiesareusedbytheindustrysegmentsoftheCompany’sbusinessapproximatelyas
follows:
SquareFeet
Segment (inthousands)
Consumer 6,928
Pharmaceutical 7,463
MedicalDevices 7,087
WorldwideTotal 21,478
WithintheUnitedStates,sevenfacilitiesareusedbytheConsumersegment,sevenbythePharmaceuticalsegmentand
21bytheMedicalDevicessegment.OutsideoftheUnitedStates,30facilitiesareusedbytheConsumersegment,17by
thePharmaceuticalsegmentand37bytheMedicalDevicessegment.
Thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows:
SquareFeet
GeographicArea NumberofFacilities (inthousands)
UnitedStates 35 6,015
Europe 37 7,770
WesternHemisphere,excludingU.S. 14 2,862
Africa,AsiaandPacific 33 4,831
WorldwideTotal 119 21,478
Johnson&Johnson2016AnnualReport • 9Inadditiontothemanufacturingfacilitiesdiscussedabove,theCompanymaintainsnumerousofficeandwarehouse
facilitiesthroughouttheworld.ResearchfacilitiesarealsodiscussedinItem1ofthisReportunder“Business–Research
andDevelopment.”
TheCompany’ssubsidiariesgenerallyseektoowntheirmanufacturingfacilities,althoughsome,principallyinnon-U.S.
locations,areleased.Officeandwarehousefacilitiesareoftenleased.TheCompanyalsoengagescontract
manufacturers.
TheCompanyiscommittedtomaintainingallofitspropertiesingoodoperatingconditionandrepair,andthefacilitiesare
wellutilized.
McNEIL-PPC,Inc.(nowJohnson&JohnsonConsumerInc.)(McNEIL-PPC)continuestooperateunderaconsentdecree,
signedin2011withtheFDA,whichgovernscertainMcNeilConsumerHealthcaremanufacturingoperations,andrequires
McNEIL-PPCtoremediatethefacilitiesitoperatesinLancaster,Pennsylvania,FortWashington,Pennsylvania,andLas
Piedras,PuertoRico(the“ConsentDecree”).TheFortWashingtonfacilitywasvoluntarilyshutdowninApril2010,and
subsequentlymanyproductsweretransferredtoothermanufacturingsitesandsuccessfullyreintroducedtothemarket.
AfterMcNEIL-PPCsuccessfullycompletedallrequirementscontainedintheConsentDecreeWorkplansforthe
LancasterandLasPiedrasmanufacturingsitesandcompletedthestepsrequiredforthird-partycertificationoftheFort
Washingtonplant,athird-partycGMPexpertsubmittedwrittencertificationstotheFDAforallthreemanufacturingsites.
FollowingFDAinspectionsin2015,McNEIL-PPCreceivednotificationsfromtheFDAthatallthreemanufacturingfacilities
areinconformitywithapplicablelawsandregulations.CommercialproductioninFortWashingtonstartedasof
September2015.
UndertheConsentDecree,afterreceivingnoticefromtheFDAofbeingincompliancewithapplicablelawsand
regulations,eachofthethreefacilitiesissubjecttoafive-yearauditperiodbyathird-partycGMPexpert.Thus,athird-
partyexpertwillcontinuetoreassessthesitesatvarioustimesforatleastfiveyears.Adiscussionoflegalproceedings
relatedtothismattercanbefoundinNote21“LegalProceedings–GovernmentProceedings–McNeilConsumer
Healthcare”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Forinformationregardingleaseobligations,seeNote16“RentalExpenseandLeaseCommitments”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.Segmentinformationonadditionstoproperty,plant
andequipmentiscontainedinNote18“SegmentsofBusinessandGeographicAreas”oftheNotestoConsolidated
FinancialStatementsincludedinItem8ofthisReport.
Item 3. LEGAL PROCEEDINGS
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinNote21“Legal
Proceedings”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Inaddition,Johnson&Johnsonanditssubsidiariesarefromtimetotimepartytogovernmentinvestigations,inspectionsor
otherproceedingsrelatingtoenvironmentalmatters,includingtheircompliancewithapplicableenvironmentallaws.
Item 4. MINE SAFETY DISCLOSURES
Notapplicable.
10 • Johnson&Johnson2016AnnualReportExecutive Officers of the Registrant
ListedbelowaretheexecutiveofficersoftheCompany.Therearenofamilyrelationshipsbetweenanyoftheexecutive
officers,andthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto
whichtheexecutiveofficerwasselected.AttheannualmeetingoftheBoardofDirectors,theexecutiveofficersare
electedbytheBoardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualified,oruntil
earlierresignationorremoval.
InformationwithregardtothedirectorsoftheCompany,includinginformationforAlexGorsky,isincorporatedhereinby
referencetothematerialcaptioned“Item1.ElectionofDirectors”intheProxyStatement.
Name Age Position
DominicJ.Caruso Member,ExecutiveCommittee;ExecutiveVicePresident;ChiefFinancial
59 Officer(a)
JoaquinDuato Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
54 Pharmaceuticals(b)
PeterM.Fasolo Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefHuman
54 ResourcesOfficer(c)
AlexGorsky Chairman,BoardofDirectors;Chairman,ExecutiveCommittee;ChiefExecutive
56 Officer
JorgeMesquita Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
55 Consumer(d)
SandraE.Peterson Member,ExecutiveCommittee;ExecutiveVicePresident,GroupWorldwide
58 Chairman(e)
GaryPruden Member,ExecutiveCommittee;ExecutiveVicePresident,WorldwideChairman,
55 MedicalDevices(f)
PaulusStoffels Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefScientific
55 Officer(g)
MichaelH.Ullmann 58 Member,ExecutiveCommittee;ExecutiveVicePresident,GeneralCounsel(h)
(a) Mr.D.J.CarusojoinedtheCompanyin1999whentheCompanyacquiredCentocor,Inc.Atthetimeofthatacquisition,hehadbeen
SeniorVicePresident,FinanceofCentocor.Mr.CarusowasnamedVicePresident,FinanceofOrtho-McNeilPharmaceutical,Inc.,a
subsidiaryoftheCompany,in2001andVicePresident,GroupFinanceoftheCompany’sMedicalDevicesandDiagnosticsGroupin
2003.In2005,Mr.CarusowasnamedVicePresidentoftheCompany’sGroupFinanceorganization.Mr.Carusobecameamember
oftheExecutiveCommitteeandVicePresident,FinanceandChiefFinancialOfficerin2007.InApril2016,hewasnamedExecutive
VicePresident,ChiefFinancialOfficer.
(b) Mr.J.DuatojoinedtheCompanyin1989withJanssen-FarmaceuticaS.A.(Spain)andin1997becameManagingDirectorof
Janssen-CilagS.p.A.(Italy).In2000,heledOrthoBiotechEuropebeforerelocatingtotheUnitedStatesin2002toserveasVice
President,and,in2005,PresidentofOrthoBiotechInc.In2008,hewasnamedCompanyGroupChairman,Ortho-Clinical
Diagnostics,andin2009CompanyGroupChairman,Pharmaceuticals,whereheoversawpharmaceuticalproductlaunchesandthe
majortherapeuticfranchisesinCanada,theUnitedStatesandLatinAmerica.In2011,hewasnamedWorldwideChairman,
Pharmaceuticals,responsiblefortheglobalcommercialbusinessesoftheJanssenPharmaceuticalCompanies,includingfunctional
supportfortheresearch&developmentorganizations.InApril2016,Mr.DuatobecameamemberoftheExecutiveCommitteeand
wasnamedExecutiveVicePresident,WorldwideChairman,Pharmaceuticals.
(c) Dr.P.M.FasolojoinedtheCompanyin2004asVicePresident,WorldwideHumanResourcesforCordisCorporation,asubsidiary
oftheCompany.HewasthennamedVicePresident,GlobalTalentManagementfortheCompany.HeleftJohnson&Johnsonin
2007tojoinKohlbergKravisRoberts&Co.,asChiefTalentOfficer.Dr.FasoloreturnedtotheCompanyin2010astheVice
President,GlobalHumanResources,andin2011,hebecameamemberoftheExecutiveCommittee.InApril2016,hewasnamed
ExecutiveVicePresident,ChiefHumanResourcesOfficer.
(d) Mr.J.MesquitajoinedtheCompanyin2014asWorldwideChairman,Consumer.PriortojoiningtheCompany,heservedinvarious
marketingandleadershipcapacitiesacrossLatinAmerica,includingrolesinOralCareandBeauty,atTheProcter&Gamble
Companyfrom1984to2013.InApril2016,Mr.MesquitabecameamemberoftheExecutiveCommitteeandwasnamedas
ExecutiveVicePresident,WorldwideChairman,Consumer.
(e) Ms.S.E.PetersonjoinedtheCompanyin2012asGroupWorldwideChairmanandamemberoftheExecutiveCommittee.She
overseestheConsumerandConsumerMedicalDevicebusinesses;theCompany’soperatinginfrastructure—SupplyChain,
InformationTechnology,GlobalServices;Health&Wellness;GlobalDesign;andHealthTechnology.PriortojoiningtheCompany,
Ms.PetersonwasChairmanandChiefExecutiveOfficerofBayerCropScienceAGinGermany,previouslyservingasPresidentand
ChiefExecutiveOfficerofBayerMedicalCareandPresidentofBayerHealthCareAG’sDiabetesCareDivision.BeforejoiningBayer
Johnson&Johnson2016AnnualReport • 11in2005,Ms.PetersonheldanumberofleadershiprolesatMedcoHealthSolutions(previouslyknownasMerck-Medco).InApril
2016,Ms.PetersonwasnamedExecutiveVicePresident,GroupWorldwideChairmanofJohnson&Johnson.EffectiveJune1,
2017,Ms.PetersonwillassumeleadershipoftheHospitalMedicalDevicebusiness,inadditiontohercurrentresponsibilities.
(f) Mr.G.PrudenjoinedtheCompanyin1985withJanssenPharmaceuticaInc.andheldanumberofseniorpositionsinsales,
marketing,andstrategicaccountmanagement.InApril2004,hebecamePresidentofJanssen-OrthoInc.inCanada.InJanuary
2006,Mr.PrudenwasappointedWorldwidePresident,EthiconProducts,andin2009becameCompanyGroupChairman,Ethicon.
In2012,hewasnamedWorldwideChairman,GlobalSurgeryGroup,andin2015,WorldwideChairman,MedicalDevices.InApril
2016,Mr.PrudenbecameamemberoftheExecutiveCommitteeandwasnamedExecutiveVicePresident,WorldwideChairman,
MedicalDevices.Mr.PrudenhasannouncedhisintentiontoretirefromtheCompanyeffectiveJune1,2017.
(g) Dr.P.StoffelsjoinedtheCompanyin2002withtheacquisitionofTibotecVircoNV,wherehewasChiefExecutiveOfficerofVirco
NVandChairmanofTibotecNV.In2005,hewasappointedCompanyGroupChairman,GlobalVirology.In2006,heassumedthe
roleofCompanyGroupChairman,Pharmaceuticals,withresponsibilityforworldwideresearchanddevelopmentfortheCentral
NervousSystemandInternalMedicineFranchises.Dr.StoffelswasappointedGlobalHead,Research&Development,
Pharmaceuticalsin2009,andin2011,becameWorldwideChairman,Pharmaceuticals,withresponsibilityfortheCompany’s
therapeuticpipelinethroughglobalresearchanddevelopmentandstrategicbusinessdevelopment.In2012,Dr.Stoffelswasalso
appointedChiefScientificOfficer,withresponsibilityforenterprise-wideinnovationandproductsafety,andamemberofthe
ExecutiveCommittee.InApril2016,Dr.StoffelswasnamedExecutiveVicePresident,ChiefScientificOfficer.
(h) Mr.M.H.UllmannjoinedtheCompanyin1989asacorporateattorneyintheLawDepartment.HewasappointedCorporate
Secretaryin1999andservedinthatroleuntil2006.Duringthattime,healsoheldvariousmanagementpositionsintheLaw
Department.In2006,hewasnamedGeneralCounsel,MedicalDevicesandDiagnosticsandwasappointedVicePresident,General
CounselandamemberoftheExecutiveCommitteein2012.InApril2016,Mr.UllmannwasnamedExecutiveVicePresident,
GeneralCounsel.
12 • Johnson&Johnson2016AnnualReportPART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities
AsofFebruary17,2017,therewere156,073recordholdersofcommonstockoftheCompany.Additionalinformation
calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisReport:“Item7.Management’s
DiscussionandAnalysisofResultsofOperationsandFinancialCondition–LiquidityandCapitalResources–Dividends”
and“–OtherInformation–CommonStockMarketPrices”;Note17“CommonStock,StockOptionPlansandStock
CompensationAgreements”oftheNotestoConsolidatedFinancialStatementsincludedinItem8;andItem12“Security
OwnershipofCertainBeneficialOwnersandManagementandRelatedStockholderMatters–EquityCompensationPlan
Information”.
Issuer Purchases of Equity Securities
OnOctober13,2015,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$10.0billionoftheCompany’sCommonStock.Sharerepurchasestakeplace
ontheopenmarketfromtimetotimebasedonmarketconditions.Therepurchaseprogramhasnotimelimitandmaybe
delayedorsuspendedforperiodsordiscontinuedatanytime.
ThefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbytheCompanyduringthefiscalfourth
quarterof2016.Commonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds
oftheCompany’scompensationprograms.Therepurchasesbelowalsoincludethestock-for-stockoptionexercisesthat
settledinthefiscalfourthquarter.
TotalNumberof MaximumNumber(or
Shares(orUnits) ApproximateDollar
PurchasedasPart Value)ofShares(orUnits)
TotalNumber ofPublicly thatMayYetBe
ofShares Avg.Price AnnouncedPlans PurchasedUnderthePlans
Period Purchased(1) PaidPerShare orPrograms(2) orPrograms(3)
October3,2016through
October30,2016 2,485,016 $116.76 – –
October31,2016through
November27,2016 9,324,574 116.53 8,775,704 –
November28,2016through
January1,2017 5,739,190 113.35 3,400,003 –
Total 17,548,780 12,175,707 23,543,007
(1) Duringthefiscalfourthquarterof2016,theCompanyrepurchasedanaggregateof17,548,780sharesofJohnson&Johnson
CommonStockinopen-markettransactions,ofwhich12,175,707shareswerepurchasedpursuanttotherepurchaseprogramthat
waspubliclyannouncedonOctober13,2015,andofwhich5,373,073shareswerepurchasedinopen-markettransactionsaspart
ofasystematicplantomeettheneedsoftheCompany’scompensationprograms.
(2) AsofJanuary1,2017,anaggregateof65,362,675shareswerepurchasedforatotalof$7.3billionsincetheinceptionofthe
repurchaseprogramannouncedonOctober13,2015.
(3) AsofJanuary1,2017,themaximumnumberofsharesthatmayyetbepurchasedundertheplanis23,543,007basedontheclosing
priceofJohnson&JohnsonCommonStockontheNewYorkStockExchangeonDecember30,2016of$115.21pershare.
Johnson&Johnson2016AnnualReport • 13Item 6. Selected Financial Data
Summary of Operations and Statistical Data 2006-2016
(DollarsinMillionsExcept
PerShareAmounts) 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
Salestocustomers–U.S. $37,811 35,687 34,782 31,910 29,830 28,908 29,450 30,889 32,309 32,444 29,775
Salestocustomers–
International 34,079 34,387 39,549 39,402 37,394 36,122 32,137 31,008 31,438 28,651 23,549
Totalsales 71,890 70,074 74,331 71,312 67,224 65,030 61,587 61,897 63,747 61,095 53,324
Costofproductssold 21,685 21,536 22,746 22,342 21,658 20,360 18,792 18,447 18,511 17,751 15,057
Selling,marketingand
administrativeexpenses 19,945 21,203 21,954 21,830 20,869 20,969 19,424 19,801 21,490 20,451 17,433
Researchanddevelopment
expense 9,095 9,046 8,494 8,183 7,665 7,548 6,844 6,986 7,577 7,680 7,125
In-processresearchand
development 29 224 178 580 1,163 – – – 181 807 559
Interestincome (368) (128) (67) (74) (64) (91) (107) (90) (361) (452) (829)
Interestexpense,netof
portioncapitalized 726 552 533 482 532 571 455 451 435 296 63
Other(income)expense,net 484 (2,064) (70) 2,498 1,626 2,743 (768) (526) (1,015) 534 (671)
Restructuring 491 509 – – – 569 – 1,073 – 745 –
52,087 50,878 53,768 55,841 53,449 52,669 44,640 46,142 46,818 47,812 38,737
Earningsbeforeprovisionfor
taxesonincome $19,803 19,196 20,563 15,471 13,775 12,361 16,947 15,755 16,929 13,283 14,587
Provisionfortaxesonincome 3,263 3,787 4,240 1,640 3,261 2,689 3,613 3,489 3,980 2,707 3,534
Netearnings 16,540 15,409 16,323 13,831 10,514 9,672 13,334 12,266 12,949 10,576 11,053
Add:Netlossattributableto
noncontrollinginterest – – – – 339 – – – – – –
Netearningsattributable
toJohnson&Johnson 16,540 15,409 16,323 13,831 10,853 9,672 13,334 12,266 12,949 10,576 11,053
Percentofsalestocustomers 23.0% 22.0 22.0 19.4 16.1 14.9 21.7 19.8 20.3 17.3 20.7
Dilutednetearningspershare
ofcommonstock(1) $5.93 5.48 5.70 4.81 3.86 3.49 4.78 4.40 4.57 3.63 3.73
Percentreturnonaverage
shareholders’equity 23.4% 21.9 22.7 19.9 17.8 17.0 24.9 26.4 30.2 25.6 28.3
Percentincrease
(decrease)overprevious
year:
Salestocustomers 2.6% (5.7) 4.2 6.1 3.4 5.6 (0.5) (2.9) 4.3 14.6 5.6
Dilutednetearningspershare 8.2% (3.9) 18.5 24.6 10.6 (27.0) 8.6 (3.7) 25.9 (2.7) 11.3
Supplementarybalance
sheetdata:
Property,plantand
equipment,net 15,912 15,905 16,126 16,710 16,097 14,739 14,553 14,759 14,365 14,185 13,044
Additionstoproperty,plant
andequipment 3,226 3,463 3,714 3,595 2,934 2,893 2,384 2,365 3,066 2,942 2,666
Totalassets 141,208 133,411 130,358 131,754 121,347 113,644 102,908 94,682 84,912 80,954 70,556
Long-termdebt 22,442 12,857 15,122 13,328 11,489 12,969 9,156 8,223 8,120 7,074 2,014
Operatingcashflow(2) 18,767 19,569 18,710 17,414 15,396 14,298 16,385 16,571 14,972 15,022 14,248
Commonstock
information
Dividendspaidpershare $3.15 2.95 2.76 2.59 2.40 2.25 2.11 1.93 1.795 1.62 1.455
Shareholders’equityper
share 26.02 25.82 25.06 26.25 23.33 20.95 20.66 18.37 15.35 15.25 13.59
Marketpricepershare(year-
endclose) $115.21 102.72 105.06 92.35 69.48 65.58 61.85 64.41 58.56 67.38 66.02
Averagesharesoutstanding
(millions)
–basic 2,737.3 2,771.8 2,815.2 2,809.2 2,753.3 2,736.0 2,751.4 2,759.5 2,802.5 2,882.9 2,936.4
–diluted 2,788.9 2,812.9 2,863.9 2,877.0 2,812.6 2,775.3 2,788.8 2,789.1 2,835.6 2,910.7 2,961.0
Employees(thousands) 126.4 127.1 126.5 128.1 127.6 117.9 114.0 115.5 118.7 119.2 122.2
(1) AttributabletoJohnson&Johnson.
(2) Amountshavebeenreclassifiedtoconformtocurrentyearpresentation.
14 • Johnson&Johnson2016AnnualReportItem 7. Management’s Discussion and Analysis of Results of Operations
and Financial Condition
Organization and Business Segments
DescriptionoftheCompanyandBusinessSegments
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately126,400employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.The
Consumersegmentincludesabroadrangeofproductsusedinthebabycare,oralcare,beauty(previouslyreferredtoas
skincare),over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.Theseproductsaremarketedto
thegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworld.ThePharmaceuticalsegmentis
focusedonfivetherapeuticareas,includingimmunology,infectiousdiseases,neuroscience,oncology,andcardiovascular
andmetabolicdiseases.Productsinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealth
careprofessionalsforprescriptionuse.TheMedicalDevicessegmentincludesabroadrangeofproductsusedinthe
orthopaedic,surgery,cardiovascular,diabetescareandvisioncarefieldswhicharedistributedtowholesalers,hospitals
andretailers,andusedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsand
clinics.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
Consumer,PharmaceuticalandMedicalDevicesbusinesssegments.
Inallofitsproductlines,theCompanycompeteswithcompaniesbothlocallyandglobally,throughouttheworld.
Competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.
Competitioninresearch,involvingthedevelopmentandtheimprovementofnewandexistingproductsandprocesses,is
particularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotectingtheunderlyingintellectual
propertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareasofitsbusiness.The
competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,thedevelopmentand
maintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvessignificantexpendituresforadvertising
andpromotion.
Management’sObjectives
TheCompanymanageswithinastrategicframeworkwithOurCredoasthefoundation.TheCompanybelievesthatour
strategicoperatingprinciples:beingbroadlybasedinhumanhealthcare,managingthebusinessforthelongterm,having
adecentralizedmanagementapproach,andbeingcommittedtoourpeopleandvalues,arecrucialtosuccessfullymeeting
thedemandsoftherapidlyevolvingmarketsinwhichwecompete.Tothisend,managementisfocusedonourlong-term
strategicgrowthdrivers:creatingvaluethroughinnovation,expandingourglobalreachwithalocalfocus,excellencein
executionandleadingwithpurpose.
TheCompanyisbroadlybasedinhumanhealthcare,andiscommittedtocreatingvaluebydevelopingaccessible,high
quality,innovativeproductsandservices.Newproductsintroducedwithinthepastfiveyearsaccountedforapproximately
22%of2016sales.In2016,$9.1billion,or12.7%ofsales,wasinvestedinresearchanddevelopment,reflecting
management’scommitmenttodeliveringnewanddifferentiatedproductsandservicestomeetevolvinghealthcareneeds
andsustaintheCompany’slong-termgrowth.
Ourdiversebusinesseswithmorethan230operatingcompanieslocatedin60countriesarethekeydriversofthe
Company’ssuccess.MaintainingtheCompany’sdecentralizedmanagementapproach,whileatthesametimeleveraging
theextensiveresourcesoftheenterprise,positionstheCompanywelltoinnovate,executestrategicplansandreach
marketsglobally,aswellasaddresstheneedsandchallengesofthelocalmarkets.
Inordertoremainaleaderinhealthcare,theCompanystrivestomaintainapurpose-drivenorganizationandiscommitted
todevelopingglobalbusinessleaderswhocanachievethesegrowthobjectives.Businessesaremanagedforthelong-
terminordertosustainmarketleadershippositionsandenablegrowth,whichprovidesanenduringsourceofvaluetoour
shareholders.
Johnson&Johnson2016AnnualReport • 15OurCredounifiesallJohnson&Johnsonemployeesinachievingtheseobjectives,andprovidesacommonsetofvalues
thatserveasthefoundationoftheCompany’sresponsibilitiestopatients,consumersandhealthcareprofessionals,
employees,communitiesandshareholders.TheCompanybelievesthatthesefoundationalvalues,itsstrategicframework
andlong-termgrowthdrivers,alongwithitsoverallmissionofimprovingthequalityoflifeforpeoplearoundtheworld,will
enableJohnson&Johnsontocontinuetobealeaderinthehealthcareindustry.
Results of Operations
AnalysisofConsolidatedSales
In2016,worldwidesalesincreased2.6%to$71.9billion,comparedtoadecreaseof5.7%in2015andanincreaseof
4.2%in2014.Thesesaleschangesconsistedofthefollowing:
Salesincrease/(decrease)dueto: 2016 2015 2014
Volume 3.2% 1.2% 6.3
Price 0.7 0.6 (0.2)
Currency (1.3) (7.5) (1.9)
Total 2.6% (5.7)% 4.2
In2016,acquisitionsanddivestitureshadanegativeimpactof1.1%ontheworldwideoperationalsalesgrowthand
competitiveproductstotheCompany’sHepatitisCproducts,OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®
(telaprevir),hadanegativeimpactof0.8%ontheworldwideoperationalsalesgrowth.OperationsinVenezuelanegatively
impactedtheworldwideoperationalsalesgrowth0.3%.
In2015,theintroductionofcompetitiveproductstotheCompany’sHepatitisCproducts,OLYSIO®/SOVRIAD®
(simeprevir)andINCIVO®(telaprevir),hadanegativeimpactof2.7%ontheworldwideoperationalsalesgrowth.In2015,
theimpactofacquisitionsanddivestituresontheworldwideoperationalsalesgrowthwasnegative2.0%.
In2014,salesoftheCompany’sHepatitisCproducts,OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®(telaprevir),had
apositiveimpactof2.8%,andthedivestitureoftheOrtho-ClinicalDiagnosticsbusinesshadanegativeimpactof1.4%on
theworldwideoperationalgrowth.
SalesbyU.S.companieswere$37.8billionin2016,$35.7billionin2015and$34.8billionin2014.Thisrepresents
increasesof6.0%in2016,2.6%in2015and9.0%in2014.Salesbyinternationalcompanieswere$34.1billionin2016,
$34.4billionin2015and$39.5billionin2014.Thisrepresentsdecreasesof0.9%in2016,and13.1%in2015andan
increaseof0.4%in2014.
Thefive-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere2.0%,5.5%and(1.2)%,
respectively.Theten-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere3.0%,2.4%and
3.8%,respectively.
SalesbycompaniesinEuropeexperiencedadeclineof1.4%ascomparedtotheprioryear,includingoperationalgrowth
of1.4%,offsetbyanegativecurrencyimpactof2.8%.SalesbycompaniesintheWesternHemisphere(excludingthe
U.S.)experiencedadeclineof5.1%ascomparedtotheprioryear,includingoperationalgrowthof4.0%offsetbya
negativecurrencyimpactof9.1%.SalesbycompaniesintheAsia-Pacific,Africaregionachievedgrowthof1.8%as
comparedtotheprioryear,includingoperationalgrowthof1.4%andapositivecurrencyimpactof0.4%.
The2016salesgrowthpercentageascomparedtotheprioryearwasnegativelyimpactedbyapproximately1.3%from
additionalshippingdaysin2015.(SeeNote1totheConsolidatedFinancialStatementsforAnnualClosingDatedetails).
Whiletheadditionalweekin2015addedafewdaystosales,italsoaddedafullweek’sworthofoperatingcosts;
therefore,thenetearningsimpactwasnegligible.
In2016,theCompanyhadtwowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately
13.5%and10.7%ofthetotalconsolidatedrevenues.In2015and2014,theCompanyhadonewholesalerdistributing
productsforallthreesegmentsthatrepresentedapproximately12.5%and11.0%,respectively,ofthetotalconsolidated
revenues.
16 • Johnson&Johnson2016AnnualReportAnalysis of Sales by Business Segments
ConsumerSegment
Consumersegmentsalesin2016were$13.3billion,adecreaseof1.5%from2015,whichincluded1.5%operational
growthoffsetbyanegativecurrencyimpactof3.0%.U.S.Consumersegmentsaleswere$5.4billion,anincreaseof
3.8%.Internationalsaleswere$7.9billion,adecreaseof4.8%,whichincluded0.1%operationalgrowthoffsetbya
negativecurrencyimpactof4.9%.In2016,theimpactofacquisitionsanddivestituresontheConsumersegment
operationalsalesgrowthwasnegative0.5%.In2016,theConsumersegmentoperationalsalesgrowthwasnegatively
impacted1.2%byoperationsinVenezuelaandnegativelyimpactedby1.1%duetoadditionalshippingdaysin2015.
MajorConsumerFranchiseSales:*
%Change
(DollarsinMillions) 2016 2015 2014 ’16vs.’15 ’15vs.’14
OTC $3,977 3,895 4,016 2.1% (3.0)
Beauty** 3,897 3,633 3,873 7.3 (6.2)
BabyCare 2,001 2,157 2,346 (7.2) (8.1)
OralCare 1,568 1,580 1,647 (0.8) (4.1)
Women’sHealth 1,067 1,200 1,302 (11.1) (7.8)
WoundCare/Other 797 1,042 1,312 (23.5) (20.6)
TotalConsumerSales $13,307 13,507 14,496 (1.5)% (6.8)
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearproductdisclosure.
** FormerlySkinCare
TheOver-the-Counter(OTC)franchisesalesof$4.0billionincreased2.1%ascomparedtotheprioryear,whichincluded
4.8%operationalgrowthandanegativecurrencyimpactof2.7%.Operationalgrowthwasprimarilydrivenbyanalgesics,
anti-smokingaidsanddigestivehealthproducts.
TheBeautyfranchisesalesof$3.9billionincreased7.3%ascomparedtotheprioryear,whichincluded9.4%operational
growthandanegativecurrencyimpactof2.1%.Operationalgrowthwasprimarilyduetosalesfromtherecent
acquisitionsofVogueInternationalLLC,whichcontributedapproximately4.6%,andNeoStrataCompany,Inc.,aswellas
salesgrowthofNEUTROGENA®,AVEENO®adultproductsandDABAO®products.
TheBabyCarefranchisesaleswere$2.0billionin2016,adecreaseof7.2%comparedtotheprioryear,primarilydueto
competitivepressurepartiallyoffsetbysalesgrowthofAVEENO®babyproducts.
TheOralCarefranchisesaleswere$1.6billionin2016,adecreaseof0.8%ascomparedtotheprioryear,which
included2.0%operationalgrowthandanegativecurrencyimpactof2.8%.Operationalgrowthwasdrivenbyincreased
salesofLISTERINE®products,attributabletonewproductlaunchesandsuccessfulmarketingcampaigns.
TheWomen’sHealthfranchisesaleswere$1.1billionin2016,adecreaseof11.1%ascomparedtotheprioryear,
primarilyduetooperationsinVenezuelaandtheU.S.divestitureofTUCKS®.
TheWoundCare/Otherfranchisesaleswere$0.8billionin2016,adecreaseof23.5%from2015,primarilyduetothe
SPLENDA®divestiture.
Consumersegmentsalesin2015were$13.5billion,adecreaseof6.8%from2014,whichincluded2.7%operational
growthoffsetbyanegativecurrencyimpactof9.5%.U.S.Consumersegmentsaleswere$5.2billion,anincreaseof
2.5%.Internationalsaleswere$8.3billion,adecreaseof11.9%,whichincluded2.7%operationalgrowthoffsetbya
negativecurrencyimpactof14.6%.In2015,divestitureshadanegativeimpactof1.4%ontheworldwideConsumer
segmentoperationalgrowth.
Johnson&Johnson2016AnnualReport • 17Pharmaceutical Segment
Pharmaceuticalsegmentsalesin2016were$33.5billion,anincreaseof6.5%from2015,whichincludedoperational
growthof7.4%partiallyoffsetbyanegativecurrencyimpactof0.9%.U.S.saleswere$20.1billion,anincreaseof9.8%.
Internationalsaleswere$13.3billion,anincreaseof1.8%,whichincluded4.0%operationalgrowthpartiallyoffsetbya
negativecurrencyimpactof2.2%.In2016,acquisitions,divestituresandcompetitiveproductstotheCompany’sHepatitis
Cproducts,OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®(telaprevir),hadanegativeimpactof2.5%onthe
operationalgrowthofthePharmaceuticalsegment.In2016,thePharmaceuticalsegmentoperationalgrowthwas
negativelyimpactedby1.5%duetoadditionalshippingdaysin2015.ThePharmaceuticalsegmentoperationalgrowthfor
2016,ascomparedtotheprioryear,wasnotimpactedbyadjustmentstopreviousreserveestimatesasbothperiods
includedapproximately$0.5billionofadjustments.
MajorPharmaceutical TherapeuticAreaSales:*
%Change
(DollarsinMillions) 2016 2015 2014 ’16vs.’15 ’15vs.’14
TotalImmunology $11,968 10,402 10,193 15.1% 2.1
REMICADE® 6,966 6,561 6,868 6.2 (4.5)
SIMPONI®/SIMPONIARIA® 1,745 1,328 1,187 31.4 11.9
STELARA® 3,232 2,474 2,072 30.6 19.4
OtherImmunology 25 39 66 (35.9) (40.9)
TotalInfectiousDiseases 3,208 3,656 5,599 (12.3) (34.7)
EDURANT®/rilpivirine 573 410 365 39.8 12.3
OLYSIO®/SOVRIAD® 106 621 2,302 (82.9) (73.0)
PREZISTA®/PREZCOBIX®/REZOLSTA® 1,851 1,810 1,831 2.3 (1.1)
OtherInfectiousDiseases 678 815 1,101 (16.8) (26.0)
TotalNeuroscience 6,085 6,259 6,487 (2.8) (3.5)
CONCERTA®/methylphenidate 863 821 599 5.1 37.1
INVEGA®/paliperidone 311 573 640 (45.7) (10.5)
INVEGASUSTENNA®/XEPLION®/TRINZA® 2,214 1,830 1,588 21.0 15.2
RISPERDAL®CONSTA® 893 970 1,190 (7.9) (18.5)
OtherNeuroscience 1,804 2,065 2,470 (12.6) (16.4)
TotalOncology 5,807 4,695 4,457 23.7 5.3
DARZALEX® 572 20 — ** —
IMBRUVICA® 1,251 689 200 81.6 **
VELCADE® 1,224 1,333 1,618 (8.2) (17.6)
ZYTIGA® 2,260 2,231 2,237 1.3 (0.3)
OtherOncology 500 422 402 18.5 5.0
Cardiovascular/Metabolism/Other 6,396 6,418 5,577 (0.3) 15.1
XARELTO® 2,288 1,868 1,522 22.5 22.7
INVOKANA®/INVOKAMET® 1,407 1,308 586 7.6 **
PROCRIT®/EPREX® 1,105 1,068 1,238 3.5 (13.7)
Other 1,596 2,174 2,231 (26.6) (2.6)
TotalPharmaceuticalSales $33,464 31,430 32,313 6.5% (2.7)
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
** Percentagegreaterthan100%
18 • Johnson&Johnson2016AnnualReportImmunologyproductsachievedsalesof$12.0billionin2016,representinganincreaseof15.1%ascomparedtotheprior
year.Immunologyproductsgrowthof15.1%includedoperationalgrowthof15.9%andanegativecurrencyimpactof
0.8%.ThestronggrowthofREMICADE®(infliximab),STELARA®(ustekinumab)andSIMPONI®/SIMPONIARIA®
(golimumab)wasprimarilydrivenbyimmunologymarketgrowthandincreasedpenetrationforbothSTELARA®
(ustekinumab)andSIMPONI®/SIMPONIARIA®(golimumab).
ThepatentsforREMICADE®(infliximab)incertaincountriesinEuropeexpiredinFebruary2015.Biosimilarversionsof
REMICADE®havebeenintroducedincertainmarketsoutsidetheUnitedStates,resultinginareductioninsalesof
REMICADE®inthosemarkets.AdditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninREMICADE®
salesinmarketsoutsidetheUnitedStates.TheintroductionofabiosimilarversionofREMICADE®intheUnitedStatesis
subjecttoenforcementofpatentrights,approvalbytheU.S.FoodandDrugAdministration(FDA)andcompliancewith
the180-daynoticeprovisionsoftheBiologicsPriceCompetitionandInnovationAct(theBPCIA).InApril2016,theFDA
approvedforsaleintheUnitedStatesaninfliximabbiosimilartobemarketedbyasubsidiaryofPfizerInc.InOctober
2016,theperiodfornoticeoflaunchundertheBPCIApassedandPfizerInc.,beganshipmentofaninfliximabbiosimilarto
wholesalersintheUnitedStatesinlateNovember2016.SalesofaninfliximabbiosimilarintheU.S.marketwillresultina
reductioninU.S.salesofREMICADE®.TheCompanycontinuestoassertREMICADE®relatedpatentrights.See
Note21totheConsolidatedFinancialStatementsforadescriptionoflegalmattersregardingtheREMICADE®patents.
Infectiousdiseaseproductssaleswere$3.2billion,adeclineof12.3%from2015,whichincludedanoperational
decreaseof11.2%andanegativecurrencyimpactof1.1%.CompetitiveproductstotheCompany’sHepatitisC
products,OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®(telaprevir),hadasignificantnegativeimpactonsales.The
declineofHepatitisCsaleswaspartiallyoffsetbysalesgrowthofEDURANT®(rilpivirine)andPREZCOBIX®(darunavir/
cobicistat).
Neuroscienceproductssaleswere$6.1billion,adecreaseof2.8%from2015,whichincludedanoperationaldecreaseof
2.3%andanegativecurrencyimpactof0.5%.StrongsalesofINVEGASUSTENNA®/XEPLION®/TRINZA®(paliperidone
palmitate)wereoffsetbylowersalesofINVEGA®(paliperidone)duetogenericcompetition,RISPERDALCONSTA®
(risperidone)andtheimpactofdivestitures.SalesgrowthofCONCERTA®/methylphenidatewasprimarilyduetoa
therapeuticequivalencereclassificationofgenericcompetitors.
Oncologyproductsachievedsalesof$5.8billionin2016,representinganincreaseof23.7%ascomparedtotheprior
year.Oncologyproductsgrowthof23.7%includedoperationalgrowthof25.2%andanegativecurrencyimpactof1.5%.
ContributorstothegrowthofOncologyproductswerestrongsalesofIMBRUVICA®(ibrutinib)andDARZALEX®
(daratumumab)duetopatientuptake,additionalcountrylaunchesandadditionalindicationsforIMBRUVICA®.Generic
competitionnegativelyimpactedthesalesgrowthofVELCADE®(bortezomib).SalesgrowthofZYTIGA®(abiraterone
acetate)intheAsiaPacificregion,primarilyduetothelaunchinChinaearlierthisyear,waspartiallyoffsetbylowersales
inEuropeduetocompetition.
Cardiovascular/Metabolism/Otherproductssaleswere$6.4billion,adeclineof0.3%from2015,whichincludedan
operationalincreaseof0.8%andanegativecurrencyimpactof1.1%.Contributorstothegrowthwerestrongsalesof
XARELTO®(rivaroxaban)duetomarketsharegrowthandINVOKANA®/INVOKAMET®(canagliflozin)duetomarket
growthandcontinueduptakeintheEuropeanUnionandCanada.Salesofhormonalcontraceptiveswerenegatively
impactedbygenericcompetitionandahigheradjustmenttopreviousreserveestimatesin2015ascomparedto2016,
whichnegativelyimpactedCardiovascular/Metabolism/Otherbyapproximately2.3%.
Johnson&Johnson2016AnnualReport • 19During2016,theCompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand
additionalindicationsforexistingdrugsasfollows:
ProductName(Chemical US EU US EU
Name) Indication Approv Approv Filing Filing
DARZALEX®(daratumumab) Incombinationwithlenalidomideanddexamethasone,or
bortezomibanddexamethasone,forthetreatmentofpatientswith
multiplemyelomawhohavereceivedatleastonepriortherapy ✓ ✓
Forthetreatmentofdoublerefractorymultiplemyeloma ✓
darunavirSTR SingletabletregimenforHIVintreatmentnaivepatientsand
treatmentexperiencedpatients ✓
guselkumab Treatmentofadultslivingwithmoderatetosevereplaque
psoriasis ✓ ✓
IMBRUVICA®(ibrutinib) Additionalindicationforfirst-linetreatmentofchroniclymphocytic
leukemia ✓ ✓
Expandedlabeltoincludeoverallsurvivalandcombinationdatain
chroniclymphocyticleukemia/smalllymphocyticlymphoma(CLL/
SLL) ✓
Expandedlabeltoincludetreatmentforpatientswithrelapsedor
refractorychroniclymphocyticleukemia(CLL)orsmall
lymphocyticlymphomaincombinationwithbendamustineand
rituximab ✓ ✓
INVOKAMET®(canagliflozin) InitialTherapyFDCwithMetformin,ImmediateRelease ✓
INVOKAMET®XR(canagliflozin) Aonce-dailytherapycombiningfixeddosesofcanagliflozinand
metforminhydrochlorideextendedreleaseforthetreatmentof
adultswithtype2diabetes ✓
SIMPONI®(golimumab) Treatmentofpolyarticularjuvenileidiopathicarthritis ✓
SIMPONIARIA®(golimumab) Treatmentofadultslivingwithactivepsoriaticarthritisandthe
treatmentofadultslivingwithactiveankylosingspondylitis ✓
sirukumab TreatmentofRheumatoidArthritis ✓ ✓
STELARA®(ustekinumab) TreatmentofadultswithmoderatelytoseverelyactiveCrohn’s
disease ✓ ✓
Treatmentofadolescents(12to17yearsofage)withmoderate
tosevereplaquepsoriasis ✓
TREVICTA®(paliperidone Maintenancetreatmentofschizophreniainadultpatients
palmitatea3monthlyinjection) ✓
Pharmaceuticalsegmentsalesin2015were$31.4billion,adecreaseof2.7%from2014,whichincludedoperational
growthof4.2%offsetbyanegativecurrencyimpactof6.9%.U.S.saleswere$18.3billion,anincreaseof5.2%.
Internationalsaleswere$13.1billion,adecreaseof12.0%,whichincluded3.0%operationalgrowthoffsetbyanegative
currencyimpactof15.0%.ThePharmaceuticalsegmentoperationalgrowthwasnegativelyimpactedby6.5%duetothe
introductionofcompetitiveproductstotheCompany’sHepatitisCproducts,OLYSIO®/SOVRIAD®(simeprevir)and
INCIVO®(telaprevir),andpositivelyimpactedby1.4%duetoanadjustmenttopreviousreserveestimates,including
ManagedMedicaidrebatesprimarilyintheCardiovascular/Metabolism/Othertherapeuticarea.In2015,divestitureshada
negativeimpactof0.3%ontheworldwidePharmaceuticalsegmentoperationalgrowth.
MedicalDevicesSegment
TheMedicalDevicessegmentsalesin2016were$25.1billion,adecreaseof0.1%from2015,whichincludedan
operationalincreaseof0.9%andanegativecurrencyimpactof1.0%.U.S.saleswere$12.3billion,anincreaseof1.1%
ascomparedtotheprioryear.Internationalsaleswere$12.9billion,adecreaseof1.2%ascomparedtotheprioryear,
withanoperationalincreaseof0.7%andanegativecurrencyimpactof1.9%.In2016,acquisitionsanddivestitureshada
negativeimpactof1.8%ontheworldwideoperationalgrowthoftheMedicalDevicessegmentascomparedto2015.In
2016,theMedicalDevicessegmentoperationalgrowthwasnegativelyimpactedby0.9%duetoadditionalshippingdays
in2015.
20 • Johnson&Johnson2016AnnualReportMajorMedicalDevicesFranchiseSales:
%Change
(DollarsinMillions) 2016 2015 2014 ’16vs.’15 ’15vs.’14
Orthopaedics $9,334 9,262 9,675 0.8% (4.3)
Hips 1,361 1,332 1,368 2.2 (2.6)
Knees 1,524 1,496 1,533 1.9 (2.4)
Trauma 2,569 2,528 2,640 1.6 (4.2)
Spine&Other 3,880 3,906 4,134 (0.7) (5.5)
Surgery 9,296 9,217 9,717 0.9 (5.1)
Advanced 3,517 3,275 3,237 7.4 1.2
General 4,362 4,482 4,970 (2.7) (9.8)
Specialty 1,417 1,460 1,510 (2.9) (3.3)
VisionCare 2,785 2,608 2,818 6.8 (7.5)
Cardiovascular 1,849 2,036 2,208 (9.2) (7.8)
DiabetesCare 1,789 1,928 2,142 (7.2) (10.0)
Diagnostics* 66 86 962 (23.3) (91.1)
TotalMedicalDevicesSales $25,119 25,137 27,522 (0.1)% (8.7)
* OnJune30,2014,theCompanydivestedtheOrtho-ClinicalDiagnosticsbusiness(theDiagnosticsFranchise)
TheOrthopaedicsfranchisesaleswere$9.3billionin2016,anincreaseof0.8%from2015,whichincludedoperational
growthof1.8%andanegativecurrencyimpactof1.0%.Salesgrowthwasprimarilydrivenbymarketgrowth,U.S.salesof
thetraumaTFNAnailingsystem,worldwidesalesofthehipprimarystemplatformandtheATTUNE®KneeSystem.
Growthwasnegativelyimpactedbycontinuedpricingpressures.
TheSurgeryfranchisesaleswere$9.3billionin2016,anincreaseof0.9%from2015,whichincludedoperationalgrowth
of2.3%andanegativecurrencyimpactof1.4%.OperationalgrowthinAdvancedSurgerywasdrivenbyendocutter,
energyandbiosurgeryproducts,primarilyattributabletomarketgrowth,increasedpenetrationincertainmarketsandnew
productlaunches.TheacquisitionofNeuWaveMedical,Inc.alsocontributedtogrowth.Theoperationaldeclinein
GeneralSurgerywasduetolowersalesofwomen’shealthandurologyproductsandpricingpressurespartiallyoffsetby
growthofsutures.TheoperationaldeclineinSpecialtySurgerywasprimarilyduetolowersalesofAcclarentproductsand
AdvancedSterilizationProductsoutsidetheU.S.,divestituresandcompetitivepressuresinSterilmedpartiallyoffsetby
growthofMentorproductsoutsidetheU.S.
TheVisionCarefranchiseachievedsalesof$2.8billionin2016,anincreaseof6.8%from2015,whichincluded
operationalgrowthof6.4%andapositivecurrencyimpactof0.4%.Growthinallthemajorregionswasprimarilydrivenby
newproductlaunches.
TheCardiovascularfranchisesaleswere$1.8billion,adecreaseof9.2%from2015,whichrepresentedanoperational
declineof9.2%.Strongoperationalgrowthintheelectrophysiologybusinessdrivenbymarketgrowth,sharegrowthand
newproductlauncheswasmorethanoffsetbytheimpactofdivestingtheCordisbusiness.TheCompanycompletedthe
divestitureoftheCordisbusinesstoCardinalHealthonOctober4,2015.ForadditionaldetailsseeNote20tothe
ConsolidatedFinancialStatements.
TheDiabetesCarefranchisesaleswere$1.8billion,adecreaseof7.2%from2015,whichrepresentedanoperational
declineof5.9%andanegativecurrencyimpactof1.3%.Theoperationaldeclinewasprimarilyduetopricedeclinesand
competitivepressures.OnJanuary26,2017,subsequenttoyear-end,theCompanyannounceditisengagingina
processtoevaluatepotentialstrategicoptionsfortheDiabetesCarefranchise.
TheMedicalDevicessegmentsalesin2015were$25.1billion,adecreaseof8.7%from2014,whichincludedan
operationaldeclineof1.4%andanegativecurrencyimpactof7.3%.U.S.saleswere$12.1billion,adecreaseof1.0%as
comparedtotheprioryear.Internationalsaleswere$13.0billion,adecreaseof14.8%ascomparedtotheprioryear,with
anoperationaldecreaseof1.7%andanegativecurrencyimpactof13.1%.ThedivestituresoftheOrtho-Clinical
DiagnosticsandtheCordisBusinesseshadanegativeimpactof3.2%and0.6%,respectively,ontheworldwide
operationalgrowthoftheMedicalDevicessegmentascomparedto2014.
Johnson&Johnson2016AnnualReport • 21Analysis of Consolidated Earnings Before Provision for Taxes on Income
Consolidatedearningsbeforeprovisionfortaxesonincomeincreasedto$19.8billionin2016,ascomparedto
$19.2billionin2015,anincreaseof3.2%.Theincreasewasprimarilyattributabletohighersalesvolume,favorablemixin
thebusinessandlowerselling,marketingandadministrativecosts.Thiswaspartiallyoffsetbyhighernetlitigationexpense
of$0.7billionandahigherrestructuringchargeof$0.1billionascomparedto2015.Additionally,thefiscalyear2015
includedhighergainsonthesaleofassets/businessesascomparedto2016.Thefiscalyearof2016includedgainsof
$0.6billionfromthedivestituresofthecontrolledsubstancerawmaterialandAPIbusiness,certainanestheticproductsin
Europeandcertainnon-strategicConsumerbrandsversusgainsof$2.6billionrecordedin2015primarilyfromthe
divestitureoftheCordisbusiness,theU.S.divestitureofNUCYNTA®andtheSPLENDA®brand.Thiswaspartiallyoffset
bya$0.3billionintangibleassetwrite-downrelatedtoAcclarentincludedin2015.
Consolidatedearningsbeforeprovisionfortaxesonincomedecreasedto$19.2billionin2015,ascomparedto
$20.6billionin2014,adecreaseof6.6%.ThedecreasewasprimarilyattributabletosignificantlylowersalesofOLYSIO®
/SOVRIAD®(simeprevir),negativecurrencyimpacts,arestructuringchargeof$0.6billionandhigherintangibleasset
write-downsof$0.1billionin2015ascomparedto2014.Thedecreasewaspartiallyoffsetbylowernetlitigation
expenseof$1.1billion,lowerSynthesintegrationcostsof$0.6billion,apositiveadjustmentof$0.4billiontoprevious
reserveestimatesincludingManagedMedicaidrebates,andhighergainsof$0.3billionfromdivestituresascomparedto
theprioryear.Thefiscalyear2015includedhighergainsof$0.3billionprimarilyfromthedivestituresoftheCordis
business,theSPLENDA®brandandtheU.S.divestitureofNUCYNTA®versusthegainsrecordedin2014fromthe
divestituresoftheOrtho-ClinicalDiagnosticsbusinessandtheK-Y®brand.Additionally,2014includedanadditionalyear
oftheBrandedPrescriptionDrugFeeof$0.2billion.
Asapercenttosales,consolidatedearningsbeforeprovisionfortaxesonincomein2016was27.5%versus27.4%in
2015.
CostofProductsSoldandSelling,MarketingandAdministrativeExpenses:Costofproductssoldandselling,
marketingandadministrativeexpensesasapercenttosaleswereasfollows:
%ofSales 2016 2015 2014
Costofproductssold 30.2% 30.7 30.6
Percentpointincrease/(decrease)overtheprioryear (0.5) 0.1 (0.7)
Selling,marketingandadministrativeexpenses 27.7% 30.3 29.5
Percentpointincrease/(decrease)overtheprioryear (2.6) 0.8 (1.1)
In2016,costofproductssoldasapercenttosalesdecreasedto30.2%from30.7%ascomparedtothesameperioda
yearago.Favorablemixinthebusinessandcostimprovementprogramswaspartiallyoffsetbytheunfavorableimpactof
transactionalcurrency.Intangibleassetamortizationexpenseof$1.2billionwasincludedincostofproductssoldfor2016
and2015.Therewasadecreaseinthepercenttosalesofselling,marketingandadministrativeexpensesin2016
comparedtotheprioryear,primarilyduetocostmanagementinallthesegmentsandfavorablemix.
In2015,costofproductssoldasapercenttosalesincreasedslightlyascomparedtotheprioryear.Favorablemix
betweenthesegmentswasoffsetby$81millionassociatedwiththerestructuringactivityintheMedicalDevicessegment,
negativetransactionalcurrencyandlowersalesofOLYSIO®/SOVRIAD®(simeprevir)in2015.Intangibleasset
amortizationexpenseincludedincostofproductssoldfor2015and2014was$1.2billionand$1.4billion,respectively.
Therewasanincreaseinthepercenttosalesofselling,marketingandadministrativeexpensesin2015comparedtothe
prioryear,primarilyduetoincrementalinvestmentspendinginallthesegmentsandtheimpactfromlowersalesof
OLYSIO®/SOVRIAD®(simeprevir),partiallyoffsetbyfavorablemixandtheinclusionofanadditionalyearoftheBranded
PrescriptionDrugFeeof$0.2billionin2014.
22 • Johnson&Johnson2016AnnualReportResearchandDevelopmentExpense:Researchanddevelopmentexpensebysegmentofbusinesswasasfollows:
2016 2015 2014
(DollarsinMillions) Amount %ofSales* Amount %ofSales* Amount %ofSales*
Consumer $580 4.4% 625 4.6 629 4.3
Pharmaceutical 6,967 20.8 6,821 21.7 6,213 19.2
MedicalDevices 1,548 6.2 1,600 6.4 1,652 6.0
Totalresearchanddevelopmentexpense $9,095 12.7% 9,046 12.9 8,494 11.4
Percentincrease/(decrease)overtheprior
year 0.5% 6.5 3.8
* Asapercenttosegmentsales
ResearchanddevelopmentactivitiesrepresentasignificantpartoftheCompany’sbusiness.Theseexpendituresrelateto
theprocessesofdiscovering,testinganddevelopingnewproducts,upfrontpaymentsandmilestones,improvingexisting
products,aswellasensuringproductefficacyandregulatorycompliancepriortolaunch.TheCompanyremains
committedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproducts.In
2016,worldwidecostsofresearchanddevelopmentactivitiesincreasedby0.5%comparedto2015butdecreasedasa
percentofsales.ThedecreaseasapercentofsaleswasattributabletohigheroverallsalesinthePharmaceutical
segment.TheincreaseddollarspendinthePharmaceuticalsegmentwasforinvestmentspendingtoadvancethepipeline.
In2015,worldwidecostsofresearchanddevelopmentactivitiesincreasedby6.5%comparedto2014.Theincreaseasa
percenttosaleswasattributabletoincreasedinvestmentspendingprimarilyinthePharmaceuticalsegment,loweroverall
salesandbusinessmix.
In-ProcessResearchandDevelopment(IPR&D):In2016,theCompanyrecordedanIPR&Dchargeof$29million
forthediscontinuationofadevelopmentprogramrelatedtoCrucell.In2015,theCompanyrecordedanIPR&Dchargeof
$0.2billionprimarilyforthediscontinuationofcertaindevelopmentprojectsrelatedtoCovagen.In2014,theCompany
recordedanIPR&Dchargeof$0.2billionfortheimpairmentofvariousIPR&DprojectsrelatedtoRespiVert,Crucell,
MentorandSynthesforthedelayordiscontinuationofcertaindevelopmentprojects.
Other(Income)Expense,Net:Other(income)expense,netistheaccountwheretheCompanyrecordsgainsand
lossesrelatedtothesaleandwrite-downofcertaininvestmentsinequitysecuritiesheldbyJohnson&Johnson
Innovation—JJDC,Inc.(JJDC),gainsandlossesondivestitures,transactionalcurrencygainsandlosses,acquisition-
relatedcosts,litigationaccrualsandsettlements,aswellasroyaltyincome.Thechangeinother(income)expense,netfor
thefiscalyear2016wasanunfavorablechangeof$2.5billionascomparedtotheprioryearprimarilyduetohighergains
onthesaleofassets/businessesinthefiscalyear2015ascomparedto2016.Thefiscalyearof2016includedgainsof
$0.6billionfromthedivestituresofthecontrolledsubstancerawmaterialandAPIbusiness,certainanestheticproductsin
Europeandcertainnon-strategicConsumerbrandsversusgainsof$2.6billionrecordedin2015primarilyfromthe
divestitureoftheCordisbusiness,theU.S.divestitureofNUCYNTA®andtheSPLENDA®brand.Additionally,thefiscal
yearof2016includedhigherlitigationexpenseof$0.7billionascomparedto2015.Thiswaspartiallyoffsetbya
$0.3billionintangibleassetwrite-downrelatedtoAcclarentincludedinthefiscalyear2015.
Thechangeinother(income)expense,netforthefiscalyear2015wasafavorablechangeof$2.0billionascomparedto
theprioryearprimarilyduetolowerlitigationexpenseof$1.1billion,lowerSynthesintegrationcostsof$0.6billionand
higherJJDCportfoliogainsof$0.2billionascomparedtotheprioryear.Additionally,thefiscalyear2015includedhigher
gainsof$0.3billionprimarilyfromthedivestituresoftheCordisbusiness,theSPLENDA®brandandtheU.S.divestiture
ofNUCYNTA®versusthegainsrecordedin2014fromthedivestituresoftheOrtho-ClinicalDiagnosticsbusinessandthe
K-Y®brand.Thiswaspartiallyoffsetbyhigherintangibleassetwrite-downsof$0.1billionin2015.
Interest(Income)Expense:Interestincomein2016increasedby$240millionascomparedto2015duetoahigher
averagebalanceofcash,cashequivalentsandmarketablesecuritiesandhigherinterestrates.Cash,cashequivalentsand
marketablesecuritiestotaled$41.9billionattheendof2016,andaveraged$40.1billionascomparedtothe
$35.7billionaveragecashbalancein2015.
Interestexpensein2016washigherascomparedto2015.Theaveragedebtbalancewas$23.5billionin2016versus
$19.3billionin2015.Thetotaldebtbalanceattheendof2016was$27.1billionascomparedto$19.9billionattheend
of2015.Thehigherdebtbalanceofapproximately$7.2billionwasprimarilyduetoincreasedborrowingsinFebruaryand
Mayof2016.TheCompanyincreasedborrowings,capitalizingonfavorabletermsinthecapitalmarkets.Theproceedsof
theborrowingswereusedforgeneralcorporatepurposes,primarilythestockrepurchaseprogram.
Johnson&Johnson2016AnnualReport • 23Interestincomein2015increasedby$61millionascomparedto2014duetoahigheraveragebalanceofcash,cash
equivalentsandmarketablesecuritiesandhigherinterestrates.Cash,cashequivalentsandmarketablesecuritiestotaled
$38.4billionattheendof2015,andaveraged$35.7billionascomparedtothe$31.1billionaveragecashbalancein
2014.Theincreaseintheyear-endcashbalancewasprimarilyduetocashgeneratedfromoperatingactivities.
Interestexpensein2015increasedslightlyascomparedto2014.Theaveragedebtbalancewas$19.3billionin2015
versus$18.5billionin2014.Thetotaldebtbalanceattheendof2015was$19.9billionascomparedto$18.8billionat
theendof2014.Thehigherdebtbalanceofapproximately$1.1billionwasanincreaseincommercialpaperforgeneral
corporatepurposes,primarilythestockrepurchaseprogram.
IncomeBeforeTaxbySegment
Incomebeforetaxbysegmentofbusinesswereasfollows:
Percentof
IncomeBeforeTax SegmentSales SegmentSales
(DollarsinMillions) 2016 2015 2016 2015 2016 2015
Consumer $2,441 1,787 $13,307 13,507 18.3% 13.2
Pharmaceutical 12,827 11,734 33,464 31,430 38.3 37.3
MedicalDevices 5,578 6,826 25,119 25,137 22.2 27.2
Total(1) 20,846 20,347 71,890 70,074 29.0 29.0
Less:Expensesnotallocatedtosegments(2) 1,043 1,151
Earningsbeforeprovisionfortaxesonincome $19,803 19,196 $71,890 70,074 27.5% 27.4
(1) SeeNote18totheConsolidatedFinancialStatementsformoredetails.
(2) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
ConsumerSegment:In2016,theConsumersegmentincomebeforetaxasapercenttosaleswas18.3%,versus
13.2%in2015,primarilydrivenbyfavorableselling,marketingandadministrativeexpensesduetocostmanagementand
highergrossprofitmarginsfromcostimprovementprojectsandfavorablemix.Thiswaspartiallyoffsetbyhighergainsin
2015relatedtodivestitures,primarilythedivestitureoftheSPLENDA®brand.Additionally,operationsinVenezuela
negativelyimpactedtheConsumersegmentincomebeforetaxin2016ascomparedto2015.
In2015,theConsumersegmentincomebeforetaxasapercenttosaleswas13.2%,versus13.4%in2014,primarilydue
tolowerdivestituregainsin2015versus2014.In2015,theConsumersegmenttaxincludedagainof$0.3billionfrom
divestitures,primarilythedivestitureoftheSPLENDA®brand.In2014,theConsumersegmentincludedagain$0.5billion
fromdivestitures,primarilythedivestitureoftheK-Y®brand.
PharmaceuticalSegment:In2016,thePharmaceuticalsegmentincomebeforetaxasapercenttosaleswas38.3%
versus37.3%in2015.Theincreaseinincomebeforetaxwasprimarilyduetostrongsalesvolumegrowthandfavorable
selling,marketingandadministrativeexpensesduetocostmanagement.Additionally,thefiscalyear2015,hadhigher
gainsof$0.7billionrelatedtodivestiturespartiallyoffsetbyahigherIPR&Dchargeof$0.2billionascomparedto2016.
Thefiscalyearof2016includedthegainsfromthedivestituresofthecontrolledsubstancerawmaterialandAPIbusiness
andcertainanestheticproductsinEuropeversusthegainsrecordedin2015fromtheU.S.divestitureofNUCYNTA®.
In2015,thePharmaceuticalsegmentincomebeforetaxasapercenttosaleswas37.3%versus36.2%in2014.The
favorableincomebeforetaxwasprimarilyduetohighergainsrecognizedin2015partiallyoffsetbyasalesdeclineof
OLYSIO®/SOVRIAD®(simeprevir),increasedinvestmentspendingandnegativecurrencyimpactsascomparedto2014.
Includedin2015wasagainof$1.0billionontheU.S.divestitureofNUCYNTA®,aswellasreceiptofacontingent
paymentandapositiveadjustmenttopreviousreserveestimates,includingManagedMedicaidrebates.Additionally,the
Pharmaceuticalsegmentincomebeforetaxin2014wasnegativelyimpactedby$0.2billionforanadditionalyearofthe
BrandedPrescriptionDrugFeeandhigherintangibleassetamortizationexpenseof$0.3billionprimarilyrelatedtothe
write-downofINCIVO®(telaprevir).
MedicalDevicesSegment:In2016,theMedicalDevicessegmentincomebeforetaxasapercenttosaleswas22.2%
versus27.2%in2015.Thedecreaseintheincomebeforetaxasapercenttosaleswasprimarilyduetolowergainsof
$1.4billionrelatedtodivestitures,higherlitigationexpenseof$0.8billionandahigherrestructuringchargeof$0.1billion
ascomparedto2015.Thiswaspartiallyoffsetbyanintangibleassetwrite-downof$0.3billionrelatedtoAcclarentin
2015andfavorableselling,marketingandadministrativeexpensesin2016.
24 • Johnson&Johnson2016AnnualReportIn2015,theMedicalDevicessegmentincomebeforetaxasapercenttosaleswas27.2%versus28.9%in2014
primarilyduetoarestructuringchargeof$0.6billion,anintangibleassetwrite-downof$0.3billionrelatedtoAcclarent,
andlowergainsof$0.5billionondivestituresascomparedto2014.In2015,theMedicalDevicessegmentincluded
gainsof$1.4billion,primarilyforthedivestitureoftheCordisbusinessversusagainof$1.9billionrecordedin2014for
thedivestitureoftheOrtho-ClinicalDiagnosticsbusiness.The2015incomebeforetaxwasfavorablyimpactedbylower
netlitigationexpenseof$0.9billion,whichincludedagainfromthelitigationsettlementagreementof$0.6billionwith
Guidant,andlowerSynthesintegrationcostsof$0.6billionin2015ascomparedto2014.
Restructuring:TheCompanyannouncedrestructuringactionsinitsMedicalDevicessegmentthatareexpectedtoresult
inannualizedpre-taxcostsavingsof$800millionto$1.0billion,themajorityofwhichisexpectedtoberealizedbythe
endof2018.Approximately$250millioninsavingswererealizedin2016.ThesavingswillprovidetheCompanywith
addedflexibilityandresourcestofundinvestmentinnewgrowthopportunitiesandinnovativesolutionsforcustomersand
patients.TheCompanyestimatesthat,inconnectionwithitsplans,itwillrecordpre-taxrestructuringrelatedchargesof
approximately$2.0billionto$2.4billion,mostofwhichareexpectedtobeincurredbytheendof2017.In2016,the
Companyrecordedapre-taxchargeof$685million,ofwhich$45millionisincludedincostofproductssoldand
$149millionisincludedinother(income)expense.In2015,theCompanyrecordedapre-taxchargeof$590million,of
which$81millionwasincludedincostofproductssold.Restructuringchargesof$1.275billionhavebeenrecorded
sincetherestructuringwasannounced.SeeNote22totheConsolidatedFinancialStatementsforadditionaldetails
relatedtotherestructuring.
ProvisionforTaxesonIncome:Theworldwideeffectiveincometaxratewas16.5%in2016,19.7%in2015and
20.6%in2014.The2016effectivetaxratedecreasedby3.2%ascomparedto2015.AsdescribedinNote1tothe
ConsolidatedFinancialStatements,theCompanyadoptedanewaccountingstandardforthereportingofadditionaltax
benefitsonshare-basedcompensationthatvestedorwereexercisedduringthefiscalyear.Theadoptionofthisnew
standardreducedtheeffectivetaxrateforthefiscal2016by1.8%versus2015.Theremainderofthechangeinthe
effectivetaxratewasprimarilyrelatedtothelowerearningsbeforetaxesintheUnitedStatesandthesettlementofseveral
uncertaintaxpositionsin2016versus2015.
Thedecreaseinthe2015effectivetaxrate,ascomparedto2014wasprimarilyattributabletotheincreasesintaxable
incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictionsandataxbenefitresultingfromarestructuringof
internationalaffiliates.Additionally,the2014effectivetaxratewasaffectedbytheitemsmentionedbelow.
Theincreaseinthe2014effectivetaxrate,ascomparedto2013,wasattributabletothefollowing:thedivestitureofthe
Ortho-ClinicalDiagnosticsbusinessatanapproximate44%effectivetaxrate,litigationaccrualsatlowtaxrates,themixof
earningsintohighertaxjurisdictions,primarilytheU.S.,theaccrualofanadditionalyearoftheBrandedPrescriptionDrug
Fee,whichisnottaxdeductible,andadditionalU.S.taxexpenserelatedtoaplannedincreaseindividendsfromcurrent
yearforeignearningsascomparedtotheprioryear.Theseincreasestothe2014effectivetaxratewerepartiallyoffsetby
ataxbenefitof$0.4billionassociatedwiththeConorMedsystemsdivestiture.
The2014effectivetaxratewasalsoreducedastheCompanyadjusteditsunrecognizedtaxbenefitsasaresultof(i)the
federalappealscourt’sdecisioninOMJPharmaceuticals,Inc.’slitigationregardingcreditsunderformerSection936of
theInternalRevenueCodeand(ii)asettlementofsubstantiallyallissuesrelatedtotheCompany’sU.S.InternalRevenue
Serviceauditoftaxyears2006–2009.
Liquidity and Capital Resources
Liquidity&CashFlows
Cashandcashequivalentswere$19.0billionattheendof2016ascomparedto$13.7billionattheendof2015.The
primarysourcesandusesofcashthatcontributedtothe$5.3billionincreasewereapproximately$18.8billionofcash
generatedfromoperatingactivitiesoffsetby$4.8billionnetcashusedbyinvestingactivities,and$8.6billionnetcash
usedbyfinancingactivities,and$0.2billionduetotheeffectonexchangeratechangesoncashandcashequivalents.In
addition,theCompanyhad$22.9billioninmarketablesecuritiesattheendof2016and$24.6billionattheendof2015.
SeeNote1totheConsolidatedFinancialStatementsforadditionaldetailsoncash,cashequivalentsandmarketable
securities.
Cashflowfromoperationsof$18.8billionwastheresultof$16.5billionofnetearningsand$4.9billionofnon-cash
expensesandotheradjustmentsfordepreciationandamortization,stock-basedcompensationandassetswrite-downs,
reducedby$0.6billionfromnetgainsonsaleofassets/businesses,$0.3billionrelatedtodeferredtaxesand$2.4billion
Johnson&Johnson2016AnnualReport • 25relatedtoaccountsreceivable,inventoriesandothercurrentandnon-currentliabilities.Additionalsourcesofoperating
cashflowof$0.7billionresultedfromanincreaseinaccountspayableandaccruedliabilitiesandadecreaseinother
currentandnon-currentassets.
Investingactivitiesuseof$4.8billionwasprimarilyforacquisitions,netofcashacquiredof$4.5billionandadditionsto
property,plantandequipmentof$3.2billion.Thiswaspartiallyoffsetbyproceedsfromthenetsaleofinvestments
primarilymarketablesecuritiesof$1.8billionand$1.3billionofproceedsfromthedisposalofassets/businesses.
Financingactivitiesuseof$8.6billionwasprimarilyfordividendstoshareholdersof$8.6billionand$9.0billionforthe
repurchaseofcommonstock.Financingactivitiesalsoincludedasourceof$7.9billionfromnetproceedsofshortand
long-termdebtand$1.2billionofproceedsfromstockoptionsexercised/employeewithholdingtaxonstockawards,net.
In2016,theCompanyannouncedadefinitiveagreementtoacquireAbbottMedicalOpticsInc.forapproximately
$4.3billionandonJanuary26,2017,subsequenttoyearendtheCompanyannouncedadefinitivetransactionagreement
toacquireActelionLtd.forapproximately$30.0billion.AbbottMedicalOpticsclosedonFebruary27,2017.The
CompanywillusecashheldbytheCompany’sforeignsubsidiariestopayfortheseacquisitions.
OnOctober13,2015,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$10.0billionoftheCompany’ssharesofcommonstock.AsofJanuary1,
2017,$7.3billionhasbeenrepurchasedundertheprogram.Therepurchaseprogramhasnotimelimitandmaybe
delayedorsuspendedforperiodsordiscontinuedatanytime.Anysharesacquiredwillbeavailableforgeneralcorporate
purposes.TheCompanyintendstofinancethesharerepurchaseprogramthroughavailablecashandaccesstothe
capitalmarkets.TheprevioussharerepurchaseprogramapprovedonJuly21,2014,authorizingtheCompanytopurchase
upto$5.0billionoftheCompany’ssharesofcommonstock,wascompletedonApril28,2015.
In2016,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.TheCompanyhada
shelfregistrationwiththeU.S.SecuritiesandExchangeCommissionthatexpiredonFebruary26,2017.TheCompany
planstofileanewshelfregistrationonFebruary27,2017whichwillenableittoissuedebtsecuritiesonatimelybasis.
Foradditionaldetailsonborrowings,seeNote7totheConsolidatedFinancialStatements.
TheCompanyanticipatesthatoperatingcashflows,existingcreditfacilitiesandaccesstothecapitalmarketswillprovide
sufficientresourcestofundoperatingneedsin2017.
ConcentrationofCreditRisk
Globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge
numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimits.EconomicchallengesinItaly,
Spain,GreeceandPortugal(theSouthernEuropeanRegion)haveimpactedcertainpaymentpatterns,whichhave
historicallybeenlongerthanthoseexperiencedintheU.S.andotherinternationalmarkets.Thetotalnettradeaccounts
receivablebalanceintheSouthernEuropeanRegionwasapproximately$1.1billionasofJanuary1,2017and$1.3billion
asofJanuary3,2016.Approximately$0.7billionasofJanuary1,2017andapproximately$0.8billionasofJanuary3,
2016oftheSouthernEuropeanRegionnettradeaccountsreceivablebalancerelatedtotheCompany’sConsumer,
VisionCareandDiabetesCarebusinessesaswellascertainPharmaceuticalandMedicalDevicescustomerswhicharein
linewithhistoricalcollectionpatterns.
TheremainingbalanceofnettradeaccountsreceivableintheSouthernEuropeanRegionhasbeennegativelyimpacted
bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomers,aswellascertain
distributorsofthePharmaceuticalandMedicalDeviceslocalaffiliates.Thetotalnettradeaccountsreceivablebalancefor
thesecustomerswereapproximately$0.4billionatJanuary1,2017and$0.5billionatJanuary3,2016.TheCompany
continuestoreceivepaymentsfromthesecustomersand,insomecases,latepaymentswithinterest.Forcustomers
wherepaymentisexpectedoverperiodsoftimelongerthanoneyear,revenueandtradereceivableshavebeen
discountedovertheestimatedperiodoftimeforcollection.Allowancesfordoubtfulaccountshavebeenincreasedfor
thesecustomers,buthavebeenimmaterialtodate.TheCompanywillcontinuetoworkcloselywiththesecustomerson
paymentplans,monitortheeconomicsituationandtakeappropriateactionsasnecessary.
FinancingandMarketRisk
TheCompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows.
Accordingly,theCompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency
assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcosts.Gainsorlosses
onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactions.A10%appreciationoftheU.S.Dollar
26 • Johnson&Johnson2016AnnualReportfromtheJanuary1,2017marketrateswouldincreasetheunrealizedvalueoftheCompany’sforwardcontractsby
$23million.Conversely,a10%depreciationoftheU.S.DollarfromtheJanuary1,2017marketrateswoulddecreasethe
unrealizedvalueoftheCompany’sforwardcontractsby$28million.Ineitherscenario,thegainorlossontheforward
contractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhavenoimpactonfuture
anticipatedearningsandcashflows.
TheCompanyhedgestheexposuretofluctuationsincurrencyexchangerates,andtheeffectoncertainassetsand
liabilitiesinforeigncurrency,byenteringintocurrencyswapcontracts.A1%changeinthespreadbetweenU.S.and
foreigninterestratesontheCompany’sinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe
unrealizedvalueoftheCompany’sswapcontractsbyapproximately$82million.Ineitherscenario,atmaturity,thegainor
lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhaveno
impactonfutureanticipatedcashflows.
TheCompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposes.Further,theCompanyhasa
policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditrating.Thecounter-parties
tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone
counter-party.Managementbelievestheriskoflossisremote.
TheCompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate
risk.Thefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrates,whilefloating
ratesecuritiesmayproducelessincomethanpredictedifinterestratesfall.A1%(100basispoints)changeinspreadon
theCompany’sinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash
equivalentsandcurrentmarketablesecuritiesbyapproximately$336million.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2016,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember14,2017.Interestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementarenotmaterial.
Totalborrowingsattheendof2016and2015were$27.1billionand$19.9billion,respectively.Theincreasein
borrowingsbetween2016and2015wasaresultoffinancingfortheCompany’ssharerepurchaseprogramandgeneral
corporatepurposes.In2016,netcash(cashandcurrentmarketablesecurities,netofdebt)was$14.8billioncompared
tonetcashof$18.5billionin2015.Totaldebtrepresented27.8%oftotalcapital(shareholders’equityandtotaldebt)in
2016and21.8%oftotalcapitalin2015.Shareholders’equitypershareattheendof2016was$26.02comparedto
$25.82atyear-end2015,anincreaseof0.8%.
AsummaryofborrowingscanbefoundinNote7totheConsolidatedFinancialStatements.
ContractualObligationsandCommitments
TheCompany’scontractualobligationsareprimarilyforleases,debtandunfundedretirementplans.Therearenoother
significantobligations.Tosatisfytheseobligations,theCompanywillusecashfromoperations.Thefollowingtable
summarizestheCompany’scontractualobligationsandtheiraggregatematuritiesasofJanuary1,2017(seeNotes7,10
and16totheConsolidatedFinancialStatementsforfurtherdetails):
Intereston Unfunded
Debt Debt Retirement Operating
(DollarsinMillions) Obligations Obligations Plans Leases Total
2017 $1,704 799 83 216 2,802
2018 1,561 735 84 179 2,559
2019 2,538 680 89 134 3,441
2020 629 608 94 105 1,436
2021 1,795 574 100 88 2,557
After2021 15,919 6,956 610 100 23,585
Total $24,146 10,352 1,060 822 36,380
Fortaxmatters,seeNote8totheConsolidatedFinancialStatements.Forotherretirementplanandpost-employment
medicalbenefitinformation,seeNote10totheConsolidatedFinancialStatements.Thetabledoesnotincludeactivity
relatedtobusinesscombinations.
Johnson&Johnson2016AnnualReport • 27Dividends
TheCompanyincreaseditsdividendin2016forthe54thconsecutiveyear.Cashdividendspaidwere$3.15persharein
2016comparedwithdividendsof$2.95persharein2015,and$2.76persharein2014.Thedividendsweredistributed
asfollows:
2016 2015 2014
Firstquarter $0.75 0.70 0.66
Secondquarter 0.80 0.75 0.70
Thirdquarter 0.80 0.75 0.70
Fourthquarter 0.80 0.75 0.70
Total $3.15 2.95 2.76
OnJanuary3,2017,theBoardofDirectorsdeclaredaregularquarterlycashdividendof$0.80pershare,payableon
March14,2017,toshareholdersofrecordasofFebruary28,2017.TheCompanyexpectstocontinuethepracticeof
payingregularcashdividends.
Other Information
CriticalAccountingPoliciesandEstimates
Management’sdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedontheCompany’s
consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin
theU.S.(GAAP).Thepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand
assumptionsthataffecttheamountsreportedforrevenues,expenses,assets,liabilitiesandotherrelateddisclosures.
Actualresultsmayormaynotdifferfromtheseestimates.TheCompanybelievesthattheunderstandingofcertainkey
accountingpoliciesandestimatesareessentialinachievingmoreinsightintotheCompany’soperatingresultsand
financialcondition.Thesekeyaccountingpoliciesincluderevenuerecognition,incometaxes,legalandself-insurance
contingencies,valuationoflong-livedassets,assumptionsusedtodeterminetheamountsrecordedforpensionsandother
employeebenefitplansandaccountingforstockbasedawards.
RevenueRecognition:TheCompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordelivered,and
titleandriskoflosspasstothecustomer.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,
productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsales
arerecorded.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingpriceschargedbycompetitors.Rebates,whichincludetheMedicaidrebateprovision,
areestimatedbasedoncontractualterms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarket
conditionsinthevariousmarketsserved.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproducts
primarilythroughtheanalysisofwholesalerandotherthird-partysell-throughandmarketresearchdata,aswellas
internallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa
percenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescreditto
customersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsfor
certainfranchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompanyinfrequently
exchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhasbeen
approximately1.0%ofannualnettradesalesduringthefiscalreportingyears2016,2015and2014.
28 • Johnson&Johnson2016AnnualReportPromotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
yearincurred.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentiveprograms.The
redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.Volume-based
incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold.
TheCompanyalsoearnsservicerevenueforco-promotionofcertainproducts.Forallyearspresented,servicerevenues
were1%orlessofthetotalrevenuesandareincludedinsalestocustomers.Thesearrangementsareevaluatedto
determinetheappropriateamountstobedeferredorrecordedasareductionofrevenue.
Inaddition,theCompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities.
Amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered,
basedontherelativesellingprice.Upfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover
theperformanceperiod.SeeNote1totheConsolidatedFinancialStatementsforadditionaldisclosuresoncollaborations.
Reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebates,returnsandpromotionsarenot
anticipatedtohaveamaterialeffectonthefinancialstatements.TheCompanycurrentlydisclosestheimpactofchanges
toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact.
Belowaretablesthatshowtheprogressionofaccruedrebates,returns,promotions,reservefordoubtfulaccountsand
reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedJanuary1,2017andJanuary3,2016.
ConsumerSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2016
Accruedrebates(1) $139 615 (618) 136
Accruedreturns 54 111 (100) 65
Accruedpromotions 412 1,908 (1,962) 358
Subtotal $605 2,634 (2,680) 559
Reservefordoubtfulaccounts 18 12 (6) 24
Reserveforcashdiscounts 17 209 (201) 25
Total $640 2,855 (2,887) 608
2015
Accruedrebates(1) $122 581 (564) 139
Accruedreturns 77 84 (107) 54
Accruedpromotions 241 1,846 (1,675) 412
Subtotal $440 2,511 (2,346) 605
Reservefordoubtfulaccounts 18 5 (5) 18
Reserveforcashdiscounts 22 206 (211) 17
Total $480 2,722 (2,562) 640
(1) Includesreserveforcustomerrebatesof$37millionatJanuary1,2017and$31millionatJanuary3,2016,recordedasacontra
asset.
Johnson&Johnson2016AnnualReport • 29Pharmaceutical Segment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits(2) Period
2016
Accruedrebates(1) $3,451 12,306 (12,337) 3,420
Accruedreturns 404 140 (210) 334
Accruedpromotions 11 10 (21) —
Subtotal $3,866 12,456 (12,568) 3,754
Reservefordoubtfulaccounts 46 2 (10) 38
Reserveforcashdiscounts 63 613 (618) 58
Total $3,975 13,071 (13,196) 3,850
2015
Accruedrebates(1) $2,717 10,449 (9,715) 3,451
Accruedreturns 422 52 (70) 404
Accruedpromotions 34 127 (150) 11
Subtotal $3,173 10,628 (9,935) 3,866
Reservefordoubtfulaccounts 41 30 (25) 46
Reserveforcashdiscounts 51 625 (613) 63
Total $3,265 11,283 (10,573) 3,975
(1) Includesreserveforcustomerrebatesof$102millionatJanuary1,2017and$64millionatJanuary3,2016,recordedasacontra
asset.
(2) Includesadjustments
MedicalDevicesSegment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2016
Accruedrebates(1) $1,189 5,700 (5,389) 1,500
Accruedreturns 239 518 (630) 127
Accruedpromotions 47 78 (93) 32
Subtotal $1,475 6,296 (6,112) 1,659
Reservefordoubtfulaccounts 204 21 (35) 190
Reserveforcashdiscounts 20 430 (434) 16
Total $1,699 6,747 (6,581) 1,865
2015
Accruedrebates(1) $844 5,216 (4,871) 1,189
Accruedreturns 188 556 (505) 239
Accruedpromotions 53 95 (101) 47
Subtotal $1,085 5,867 (5,477) 1,475
Reservefordoubtfulaccounts 216 13 (25) 204
Reserveforcashdiscounts 16 877 (873) 20
Total $1,317 6,757 (6,375) 1,699
(1) Includesreserveforcustomerrebatesof$430millionatJanuary1,2017and$411millionatJanuary3,2016,recordedasacontra
asset.
30 • Johnson&Johnson2016AnnualReportIncomeTaxes:Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe
resultsofanydifferencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.
TheCompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesin
taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAP,which
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
AtJanuary1,2017andJanuary3,2016,thecumulativeamountsofundistributedinternationalearningswere
approximately$66.2billionand$58.0billion,respectively.AtJanuary1,2017andJanuary3,2016,theCompany’s
foreignsubsidiariesheldbalancesofcash,cashequivalentsandmarketablesecuritiesintheamountsof$41.3billionand
$38.2billion,respectively.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertain
internationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.TheCompanyintendsto
continuetoreinvesttheseearningsininternationaloperations.IftheCompanydecidedatalaterdatetorepatriatethese
earningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectsontheseamounts.TheCompany
doesnotdeterminethedeferredtaxliabilityassociatedwiththeseundistributedearnings,assuchdeterminationisnot
practical.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
LegalandSelfInsuranceContingencies:TheCompanyrecordsaccrualsforvariouscontingencies,includinglegal
proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusiness.Theaccrualsarebasedon
management’sjudgmentastotheprobabilityoflossesand,whereapplicable,actuariallydeterminedestimates.The
Companyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.Additionally,theCompanyrecordsinsurancereceivableamountsfromthird-partyinsurerswhen
recoveryisprobable.Asappropriate,reservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynot
becollectedfromthird-partyinsurers.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
SeeNotes1and21totheConsolidatedFinancialStatementsforfurtherinformationregardingproductliabilityandlegal
proceedings.
Long-LivedandIntangibleAssets:TheCompanyassesseschangesineconomicconditionsandmakesassumptions
regardingestimatedfuturecashflowsinevaluatingthevalueoftheCompany’sproperty,plantandequipment,goodwill
andintangibleassets.Astheseassumptionsandestimatesmaychangeovertime,itmayormaynotbenecessaryforthe
Companytorecordimpairmentcharges.
EmployeeBenefitPlans:TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,
definedcontributionandterminationindemnityplans,whichcovermostemployeesworldwide.Theseplansarebasedon
assumptionsforthediscountrate,expectedreturnonplanassets,mortalityrates,expectedsalaryincreases,healthcare
costtrendratesandattritionrates.SeeNote10totheConsolidatedFinancialStatementsforfurtherdetailsontheserates
andtheeffectaratechangetothehealthcarecosttrendwouldhaveontheCompany’sresultsofoperations.
StockBasedCompensation:TheCompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity
instrumentstoemployeesfortheirservices.Basedonthetypeofequityinstrument,thefairvalueisestimatedonthedate
ofgrantusingeithertheBlack-ScholesoptionvaluationmodeloracombinationofboththeBlack-Scholesoption
valuationmodelandMonteCarlovaluationmodel,andisexpensedinthefinancialstatementsovertheserviceperiod.The
inputassumptionsusedindeterminingfairvaluearetheexpectedlife,expectedvolatility,risk-freerateandexpected
dividendyield.Forperformanceshareunitsthefairmarketvalueiscalculatedforeachofthethreecomponentgoalsatthe
dateofgrant.Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedon
thedateofgrantusingthefairmarketvalueofthesharesatthetimeoftheaward,discountedfordividends,whicharenot
paidontheperformanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalof
eachperformanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.SeeNote17to
theConsolidatedFinancialStatementsforadditionalinformation.
Johnson&Johnson2016AnnualReport • 31NewAccountingPronouncements
RefertoNote1totheConsolidatedFinancialStatementsforrecentlyadoptedaccountingpronouncementsandrecently
issuedaccountingpronouncementsnotyetadoptedasofJanuary1,2017.
EconomicandMarketFactors
TheCompanyisawarethatitsproductsareusedinanenvironmentwhere,formorethanadecade,policymakers,
consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcare.Inresponsetotheseconcerns,
theCompanyhasalong-standingpolicyofpricingproductsresponsibly.Fortheperiod2006–2016,intheUnited
States,theweightedaveragecompoundannualgrowthrateoftheCompany’snetpriceincreasesforhealthcareproducts
(prescriptionandover-the-counterdrugs,hospitalandprofessionalproducts)wasbelowtheU.S.ConsumerPriceIndex
(CPI).
TheCompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallenges.The
Companycontinuestomonitorthesesituationsandtakeappropriateactions.Inflationratescontinuetohaveaneffecton
worldwideeconomiesand,consequently,onthewaycompaniesoperate.TheCompanyhasaccountedforoperationsin
Venezuelaashighlyinflationary,asthepriorthree-yearcumulativeinflationratesurpassed100%.Inthefaceofincreasing
costs,theCompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms,productivityimprovementsand
periodicpriceincreases.
TheVenezuelangovernmenthasestablishedalternativesystemsandofferingsofvariousforeigncurrencyexchanges.
Throughthefourthquarterof2015,thenumberoftheCompany’stransactionsconductedattheofficialratedeclinedfrom
priorquarters.Asaresult,theCompanydeterminedthatitwasnolongerlikelythatalloutstandingnetmonetaryassets
wouldbesettledattheofficialgovernmentrateof6.3BolivaresFuertestooneU.S.Dollar.Thereforein2015,the
Companyrecordedachargeof$161milliontorevalueitsnetmonetaryassetsinVenezuelaatoneofthegovernment’s
alternativeexchangerates(SIMADI)andimpairitsnon-monetaryassets.Aftertherevaluation,asofJanuary3,2016,the
Company’sVenezuelansubsidiariesrepresentedlessthan0.1%oftheCompany’sconsolidatedassetsandliabilities.
WhiletheCompanycontinuestodobusinessinGreece,theCompanycloselymonitorstheeconomicsituation.Asof
January1,2017,theCompany’sGreeksubsidiariesrepresented0.3%and0.4%oftheCompany’sconsolidatedassets
andrevenues,respectively.
OnJune23,2016,theUnitedKingdom(U.K.)heldareferenduminwhichvotersapprovedanexitfromtheEuropean
Union(E.U.),commonlyreferredtoas“Brexit.”Giventhelackofcomparableprecedent,itisunclearwhatfinancial,trade,
regulatoryandlegalimplicationsthewithdrawaloftheU.K.fromtheE.U.willhave.Brexitcreatesglobalpoliticaland
economicuncertainty,whichmaycause,amongotherconsequences,volatilityinexchangeratesandinterestrates,
additionalcostcontainmentbythird-partypayorsandchangesinregulations.However,theCompanycurrentlydoesnot
believethattheseandotherrelatedeffectswillhaveamaterialimpactontheCompany’sconsolidatedfinancialpositionor
operatingresults.AsofJanuary1,2017,thebusinessoftheCompany’sU.K.subsidiariesrepresentedlessthan3%of
boththeCompany’sconsolidatedassetsandfiscaltwelvemonthsrevenues.
TheCompanyisexposedtofluctuationsincurrencyexchangerates.A1%changeinthevalueoftheU.S.Dollaras
comparedtoallforeigncurrenciesinwhichtheCompanyhadsales,incomeorexpensein2016wouldhaveincreasedor
decreasedthetranslationofforeignsalesbyapproximately$330millionandincomeby$105million.
Governmentsaroundtheworld,includingintheUnitedStates,considervariousproposalstomakechangestotaxlaws,
whichmayincludeincreasingordecreasingexistingstatutorytaxrates.Achangeinstatutorytaxrateinanycountrywould
resultintherevaluationoftheCompany’sdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictioninthe
periodinwhichthenewtaxlawisenacted.ThischangewouldresultinanexpenseorbenefitrecordedtotheCompany’s
ConsolidatedStatementofEarnings.TheCompanycloselymonitorstheseproposalsastheyariseinthecountrieswhere
itoperates.Changestothestatutorytaxratemayoccuratanytime,andanyrelatedexpenseorbenefitrecordedmaybe
materialtothefiscalquarterandyearinwhichthelawchangeisenacted.
TheBelgiangovernmentiscurrentlyconsideringaproposedchangetoitscorporatetaxcode,includingaproposalto
loweritsstatutorytaxrate.Ifenacted,theproposedchangewouldresultinrevaluationoftheCompany’sdeferredtax
assets,withacorrespondingchargetotaxexpensethatmayhaveamaterialeffectontheCompany’sresultsofoperations
fortheperiod.BasedonthedeferredtaxassetbalancesasofJanuary1,2017,theCompanyestimatesforevery1%that
thestatutorytaxisloweredtherewillbeadditionalone-timetaxexpenseofapproximately$60-75million.Asignificant
portionofthedeferredtaxassetdescribedas“InternationalR&Dcapitalizedfortax”inNote8totheConsolidated
FinancialStatementsisrelatedtotheCompany’soperationsinBelgium.
32 • Johnson&Johnson2016AnnualReportTheU.S.governmentiscurrentlyconsideringvariousproposalstochangesinitscorporatetaxcode.Theseproposals
includebutarenotlimitedtoloweringthestatutorytaxrateandtherulesonhowinternationalincomeearnedbythe
CompanyistaxedintheU.S.TheimpactoftheseproposalsmayhaveamaterialeffectontheCompany’sresultsof
operationsfortheperiodandonfutureperiods.
AstheBelgianorU.S.governmentsarestillconsideringtheseproposals,itisnotcertainwhenoriftheywillbeenacted.
TheCompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude
healthcarecostcontainmentandgovernmentlegislationrelatingtosales,promotionsandreimbursementofhealthcare
products.
Changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservices,includingdelaying
medicalprocedures,rationingprescriptionmedications,reducingthefrequencyofphysicianvisitsandforegoinghealth
careinsurancecoverage,asaresultofthecurrentglobaleconomicdownturn,maycontinuetoimpacttheCompany’s
businesses.
TheCompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrights.Firmshavefiled
AbbreviatedNewDrugApplicationsorBiosimilarBiologicalProductApplicationswiththeFDAorotherwisechallenged
thecoverageand/orvalidityoftheCompany’spatents,seekingtomarketgenericorbiosimilarformsofmanyofthe
Company’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Intheevent
theCompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuits,genericorbiosimilar
versionsoftheproductsatissuewillbeintroducedtothemarket,resultinginthepotentialforsubstantialmarketshareand
revenuelossesforthoseproducts,andwhichmayresultinanon-cashimpairmentchargeinanyassociatedintangible
asset.Thereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue
followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace.Forfurtherinformation,seethe
discussionon“REMICADE®RelatedCases”and“LitigationAgainstFilersofAbbreviatedNewDrugApplications”in
Note21totheConsolidatedFinancialStatements.
LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseofbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.TheCompanyhasaccruedforcertain
litigationmattersandcontinuestomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther
developmentsinaccordancewithAccountingStandardsCodification(ASC)450-20-25.Fortheseandotherlitigation
andregulatorymatterscurrentlydisclosedforwhichalossisprobableorreasonablypossible,theCompanyisunableto
estimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.Amountsaccruedforlegalcontingencies
oftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyonestimatesand
assumptions.Theabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactors,includingwhether
damagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnot
commencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;therearesignificant
factsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
SeeNote21totheConsolidatedFinancialStatementsforfurtherinformationregardinglegalproceedings.
Johnson&Johnson2016AnnualReport • 33CommonStockMarketPrices
TheCompany’sCommonStockislistedontheNewYorkStockExchangeunderthesymbolJNJ.AsofFebruary17,
2017,therewere156,073recordholdersofCommonStockoftheCompany.Thecompositemarketpricerangesfor
Johnson&JohnsonCommonStockduring2016and2015were:
2016 2015
High Low High Low
Firstquarter $109.56 94.28 $106.50 97.15
Secondquarter 121.54 107.88 104.48 97.01
Thirdquarter 126.07 117.04 101.36 81.79
Fourthquarter 122.50 109.32 105.49 89.90
Year-endclose $115.21 $102.72
34 • Johnson&Johnson2016AnnualReportItem 7A. Quantitative and Qualitative Disclosures about Market Risk
Theinformationcalledforbythisitemisincorporatedhereinbyreferenceto“Item7.Management’sDiscussionand
AnalysisofResultsofOperationsandFinancialCondition–LiquidityandCapitalResources–FinancingandMarketRisk”
ofthisReport;andNote1“SummaryofSignificantAccountingPolicies–FinancialInstruments”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 8. Financial Statements and Supplementary Data
IndextoAuditedConsolidatedFinancialStatements
36 ConsolidatedBalanceSheets
37 ConsolidatedStatementsofEarnings
38 ConsolidatedStatementsofComprehensiveIncome
39 ConsolidatedStatementsofEquity
40 ConsolidatedStatementsofCashFlows
41 NotestoConsolidatedFinancialStatements
86 ReportofIndependentRegisteredPublicAccountingFirm
87 Management’sReportonInternalControlOverFinancialReporting
Johnson&Johnson2016AnnualReport • 35Johnson & Johnson and Subsidiaries
Consolidated Balance Sheets
AtJanuary1,2017andJanuary3,2016
(DollarsinMillionsExceptShareandPerShareAmounts)(Note1)
2016 2015
Assets
Currentassets
Cashandcashequivalents(Notes1and2) $18,972 13,732
Marketablesecurities(Notes1and2) 22,935 24,644
Accountsreceivabletrade,lessallowancesfordoubtfulaccounts$252(2015,$268) 11,699 10,734
Inventories(Notes1and3) 8,144 8,053
Prepaidexpensesandotherreceivables 3,282 3,047
Totalcurrentassets 65,032 60,210
Property,plantandequipment,net(Notes1and4) 15,912 15,905
Intangibleassets,net(Notes1and5) 26,876 25,764
Goodwill(Notes1and5) 22,805 21,629
Deferredtaxesonincome(Note8) 6,148 5,490
Otherassets 4,435 4,413
Totalassets $141,208 133,411
LiabilitiesandShareholders’Equity
Currentliabilities
Loansandnotespayable(Note7) $4,684 7,004
Accountspayable 6,918 6,668
Accruedliabilities 5,635 5,411
Accruedrebates,returnsandpromotions 5,403 5,440
Accruedcompensationandemployeerelatedobligations 2,676 2,474
Accruedtaxesonincome(Note8) 971 750
Totalcurrentliabilities 26,287 27,747
Long-termdebt(Note7) 22,442 12,857
Deferredtaxesonincome(Note8) 2,910 2,562
Employeerelatedobligations(Notes9and10) 9,615 8,854
Otherliabilities 9,536 10,241
Totalliabilities 70,790 62,261
Shareholders’equity
Preferredstock–withoutparvalue(authorizedandunissued2,000,000shares) – –
Commonstock–parvalue$1.00pershare(Note12)(authorized4,320,000,000shares;issued
3,119,843,000shares) 3,120 3,120
Accumulatedothercomprehensiveincome(Note13) (14,901) (13,165)
Retainedearnings 110,551 103,879
98,770 93,834
Less:commonstockheldintreasury,atcost(Note12)(413,332,000sharesand364,681,000shares) 28,352 22,684
Totalshareholders’equity 70,418 71,150
Totalliabilitiesandshareholders’equity $141,208 133,411
SeeNotestoConsolidatedFinancialStatements
36 • Johnson&Johnson2016AnnualReportJohnson & Johnson and Subsidiaries
Consolidated Statements of Earnings
(DollarsandSharesinMillionsExceptPerShareAmounts)(Note1)
2016 2015 2014
Salestocustomers $71,890 70,074 74,331
Costofproductssold 21,685 21,536 22,746
Grossprofit 50,205 48,538 51,585
Selling,marketingandadministrativeexpenses 19,945 21,203 21,954
Researchanddevelopmentexpense 9,095 9,046 8,494
In-processresearchanddevelopment 29 224 178
Interestincome (368) (128) (67)
Interestexpense,netofportioncapitalized(Note4) 726 552 533
Other(income)expense,net 484 (2,064) (70)
Restructuring(Note22) 491 509 –
Earningsbeforeprovisionfortaxesonincome 19,803 19,196 20,563
Provisionfortaxesonincome(Note8) 3,263 3,787 4,240
Netearnings $16,540 15,409 16,323
Netearningspershare(Notes1and15)
Basic $6.04 5.56 5.80
Diluted $5.93 5.48 5.70
Cashdividendspershare $3.15 2.95 2.76
Averagesharesoutstanding(Notes1and15)
Basic 2,737.3 2,771.8 2,815.2
Diluted 2,788.9 2,812.9 2,863.9
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2016AnnualReport • 37Johnson & Johnson and Subsidiaries
Consolidated Statements of Comprehensive Income
(DollarsinMillions)(Note1)
2016 2015 2014
Netearnings $16,540 15,409 16,323
Othercomprehensiveincome(loss),netoftax
Foreigncurrencytranslation (612) (3,632) (4,601)
Securities:
Unrealizedholdinggain(loss)arisingduringperiod (52) 471 156
Reclassificationstoearnings (141) (124) (5)
Netchange (193) 347 151
Employeebenefitplans:
Priorservicecredit(cost),netofamortization 21 (60) 193
Gain(loss),netofamortization (862) 931 (3,698)
Effectofexchangerates 159 148 197
Netchange (682) 1,019 (3,308)
Derivatives&hedges:
Unrealizedgain(loss)arisingduringperiod (359) (115) 92
Reclassificationstoearnings 110 (62) (196)
Netchange (249) (177) (104)
Othercomprehensiveincome(loss) (1,736) (2,443) (7,862)
Comprehensiveincome $14,804 12,966 8,461
Thetaxeffectsinothercomprehensiveincomeforthefiscalyearsended2016,2015and2014respectively:Securities;
$104million,$187millionand$81million,EmployeeBenefitPlans;$346million,$519millionand$1,556million,
Derivatives&Hedges;$134million,$95millionand$56million.
SeeNotestoConsolidatedFinancialStatements
38 • Johnson&Johnson2016AnnualReportJohnson & Johnson and Subsidiaries
Consolidated Statements of Equity
(DollarsinMillions)(Note1)
Accumulated Common
Other Stock Treasury
Retained Comprehensive Issued Stock
Total Earnings Income Amount Amount
Balance,December29,2013 $74,053 89,493 (2,860) 3,120 (15,700)
Netearnings 16,323 16,323
Cashdividendspaid (7,768) (7,768)
Employeecompensationandstockoptionplans 2,164 (769) 2,933
Repurchaseofcommonstock (7,124) (7,124)
Other (34) (34)
Othercomprehensiveincome(loss),netoftax (7,862) (7,862)
Balance,December28,2014 69,752 97,245 (10,722) 3,120 (19,891)
Netearnings 15,409 15,409
Cashdividendspaid (8,173) (8,173)
Employeecompensationandstockoptionplans 1,920 (577) 2,497
Repurchaseofcommonstock (5,290) (5,290)
Other (25) (25)
Othercomprehensiveincome(loss),netoftax (2,443) (2,443)
Balance,January3,2016 71,150 103,879 (13,165) 3,120 (22,684)
Netearnings 16,540 16,540
Cashdividendspaid (8,621) (8,621)
Employeecompensationandstockoptionplans 2,130 (1,181) 3,311
Repurchaseofcommonstock (8,979) (8,979)
Other (66) (66)
Othercomprehensiveincome(loss),netoftax (1,736) (1,736)
Balance,January1,2017 $70,418 110,551 (14,901) 3,120 (28,352)
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2016AnnualReport • 39Johnson & Johnson and Subsidiaries
Consolidated Statements of Cash Flows
(DollarsinMillions)(Note1)
2016 2015 2014
Cashflowsfromoperatingactivities
Netearnings $16,540 15,409 16,323
Adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities:
Depreciationandamortizationofpropertyandintangibles 3,754 3,746 3,895
Stockbasedcompensation 878 874 792
Venezuelaadjustments – 122 87
Assetwrite-downs 283 624 410
Netgainonsaleofassets/businesses (563) (2,583) (2,383)
Deferredtaxprovision (341) (270) 441
Accountsreceivableallowances (11) 18 (28)
Changesinassetsandliabilities,netofeffectsfromacquisitionsanddivestitures:
Increaseinaccountsreceivable (1,065) (433) (247)
Increaseininventories (249) (449) (1,120)
Increaseinaccountspayableandaccruedliabilities 656 287 1,194
Decreaseinothercurrentandnon-currentassets 18 65 442
(Decrease)/Increaseinothercurrentandnon-currentliabilities (1,133) 2,159 (1,096)
Netcashflowsfromoperatingactivities 18,767 19,569 18,710
Cashflowsfrominvestingactivities
Additionstoproperty,plantandequipment (3,226) (3,463) (3,714)
Proceedsfromthedisposalofassets/businesses,net 1,267 3,464 4,631
Acquisitions,netofcashacquired(Note20) (4,509) (954) (2,129)
Purchasesofinvestments (33,950) (40,828) (34,913)
Salesofinvestments 35,780 34,149 24,119
Other(primarilyintangibles) (123) (103) (299)
Netcashusedbyinvestingactivities (4,761) (7,735) (12,305)
Cashflowsfromfinancingactivities
Dividendstoshareholders (8,621) (8,173) (7,768)
Repurchaseofcommonstock (8,979) (5,290) (7,124)
Proceedsfromshort-termdebt 111 2,416 1,863
Retirementofshort-termdebt (2,017) (1,044) (1,267)
Proceedsfromlong-termdebt 12,004 75 2,098
Retirementoflong-termdebt (2,223) (68) (1,844)
Proceedsfromtheexerciseofstockoptions/employeewithholdingtaxonstockawards,net 1,189 1,005 1,543
Other (15) (57) –
Netcashusedbyfinancingactivities (8,551) (11,136) (12,499)
Effectofexchangeratechangesoncashandcashequivalents (215) (1,489) (310)
Increase/(Decrease)incashandcashequivalents 5,240 (791) (6,404)
Cashandcashequivalents,beginningofyear(Note1) 13,732 14,523 20,927
Cashandcashequivalents,endofyear(Note1) $18,972 13,732 14,523
Supplementalcashflowdata
Cashpaidduringtheyearfor:
Interest $730 617 603
Interest,netofamountcapitalized 628 515 488
Incometaxes 2,843 2,865 3,536
Supplementalscheduleofnon-cashinvestingandfinancingactivities
Treasurystockissuedforemployeecompensationandstockoptionplans,netofcashproceeds/employee
withholdingtaxonstockawards 2,043 1,486 1,409
Conversionofdebt 35 16 17
Acquisitions
Fairvalueofassetsacquired $4,586 1,174 2,167
Fairvalueofliabilitiesassumedandnoncontrollinginterests (77) (220) (38)
Netcashpaidforacquisitions $4,509 954 2,129
SeeNotestoConsolidatedFinancialStatements
40 • Johnson&Johnson2016AnnualReportNOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
PrinciplesofConsolidation
TheconsolidatedfinancialstatementsincludetheaccountsofJohnson&Johnsonanditssubsidiaries(theCompany).
Intercompanyaccountsandtransactionsareeliminated.
DescriptionoftheCompanyandBusinessSegments
TheCompanyhasapproximately126,400employeesworldwideengagedintheresearchanddevelopment,manufacture
andsaleofabroadrangeofproductsinthehealthcarefield.TheCompanyconductsbusinessinvirtuallyallcountriesof
theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwell-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices.The
Consumersegmentincludesabroadrangeofproductsusedinthebabycare,oralcare,beauty(previouslyreferredtoas
skincare),over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.Theseproductsaremarketedto
thegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworld.ThePharmaceuticalsegmentis
focusedonfivetherapeuticareas,includingimmunology,infectiousdiseases,neuroscience,oncology,andcardiovascular
andmetabolicdiseases.Productsinthissegmentaredistributeddirectlytoretailers,wholesalers,hospitalsandhealth
careprofessionalsforprescriptionuse.TheMedicalDevicessegmentincludesabroadrangeofproductsusedinthe
orthopaedic,surgery,cardiovascular,diabetescareandvisioncarefields,whicharedistributedtowholesalers,hospitals
andretailers,andusedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsand
clinics.
NewAccountingPronouncements
RecentlyAdoptedAccountingPronouncements
Duringthefiscalfirstquarterof2016,theFinancialAccountingStandardsBoard(FASB)issuedAccountingStandards
Update2016-09Compensation–StockCompensation:ImprovementstoEmployeeShareBasedPaymentAccounting.
TheamendmentsintheupdateareeffectiveforannualperiodsbeginningafterDecember15,2016andinterimperiods
withinthoseannualperiods.Earlyadoptionispermittedforanyentityinanyinterimorannualperiod.Duringthefiscal
secondquarterof2016,theCompanyelectedtoearlyadoptthisstandard.Theupdaterequiresthefollowingchangesto
presentationofthefinancialstatements:
• Allexcesstaxbenefitsanddeficienciestoberecognizedasareductionoranincreasetotheprovisionfortaxeson
income.Previously,theCompanyrecordedthesebenefitsdirectlytoRetainedEarnings.Thetaxbenefitforthe
Companywas$353millionforthefiscalyear2016.Thestandarddoesnotpermitretroactivepresentationofthis
benefittopriorfiscalyearsontheConsolidatedStatementofEarnings.
• Thetaxbenefitordeficiencyisrequiredtobeclassifiedandpresentedasacashflowto/fromoperatingactivities.Itwas
previouslyrequiredtobepresentedasacashflowto/fromfinancingactivitiesontheConsolidatedStatementofCash
Flows.Aspermittedinthestandard,theCompanyhaselectedtoadoptthisreclassificationonaprospectivebasisand
thereforepriorfiscalyearsfortheConsolidatedStatementofCashFlowshavenotbeenrecastforthisprovision.
• Clarifiesthatallcashpaymentsmadetotaxingauthoritiesonemployees’share-basedcompensationshouldbe
classifiedasacashoutflowfromfinancingactivities.Thisreclassificationisrequiredtoberecastretrospectively.Asa
result,forthefiscalyear2016,$269millionwasclassifiedasacashoutflowfromfinancingactivitiesand$290million
and$239million,ofcashoutflowwasreclassifiedfromanoperatingactivitytoafinancingactivity(Proceedsfromthe
exerciseofstockoptions/employeewithholdingtaxonstockawards,net)inthefiscalyears2015and2014,
respectively.
• Inthedilutednetearningspersharecalculation,whenapplyingthetreasurystockmethodforsharesthatcouldbe
repurchased,theassumedproceedsnolongerincludetheamountofexcesstaxbenefit.Thisdidnothaveamaterial
impactontheCompany’sdilutednetearningspersharecalculation.
Duringthefiscalsecondquarterof2015,theFASBissuedAccountingStandardsUpdate2015-03:Simplifyingthe
PresentationofDebtIssuanceCosts.Thisupdaterequirescapitalizeddebtissuancecoststobepresentedasareduction
Johnson&Johnson2016AnnualReport • 41tothecarryingvalueofdebtinsteadofbeingclassifiedasadeferredcharge.ThisupdateiseffectivefortheCompanyfor
allannualandinterimperiodsbeginningafterDecember15,2015andisrequiredtobeappliedretroactivelyforallperiods
presented.ThisupdatedidnothaveamaterialimpactonthepresentationoftheCompany’sfinancialposition.
Duringthefiscalthirdquarterof2015,theFASBissuedAccountingStandardsUpdate2015-16BusinessCombinations:
SimplifyingtheAccountingforMeasurement-PeriodAdjustments.Theamendmentsinthisupdaterequirethatanacquirer
recognizeadjustmentstoprovisionalamountsthatareidentifiedduringthemeasurementperiodinthereportingperiodin
whichtheadjustmentamountsaredetermined.ThisupdateiseffectivefortheCompanyforallannualandinterimperiods
beginningafterDecember15,2015.Theamendmentsinthisupdateshouldbeappliedprospectivelytoadjustmentsto
provisionalamountsthatoccuraftertheeffectivedateofthisupdatewithearlierapplicationpermittedforfinancial
statementsthathavenotbeenissued.ThisupdatedidnothaveamaterialimpactontheCompany’sconsolidatedfinancial
statements.
Duringthefiscalthirdquarterof2014,theFASBissuedAccountingStandardsUpdateNo.2014-15:Disclosureof
UncertaintiesaboutanEntity’sAbilitytoContinueasaGoingConcern.Thisstandardrequiresmanagementtoevaluate,
foreachannualandinterimreportingperiod,whetherthereareconditionsandevents,consideredintheaggregate,that
raisesubstantialdoubtaboutanentity’sabilitytocontinueasagoingconcernwithinoneyearafterthedatethefinancial
statementsareissuedorareavailabletobeissued.Ifsubstantialdoubtisraised,additionaldisclosuresaround
management’splantoalleviatethesedoubtsarerequired.Thisupdatebecomeseffectiveforallannualperiodsandinterim
reportingperiodsendingafterDecember15,2016.Theadoptionofthisstandarddidnothaveanyimpactonthe
Company’scurrentdisclosuresinthefinancialstatements.
RecentlyIssuedAccountingPronouncements
NotAdoptedasofJanuary1,2017
Duringthefiscalfirstquarterof2017,theFASBissuedAccountingStandardUpdate2017-01:ClarifyingtheDefinitionof
aBusiness.Thisupdatenarrowsthedefinitionofabusinessbyprovidingascreentodeterminewhenanintegratedsetof
assetsandactivitiesisnotabusiness.Thescreenspecifiesthatanintegratedsetofassetsandactivitiesisnotabusiness
ifsubstantiallyallofthefairvalueofthegrossassetsacquiredordisposedofisconcentratedinasingleoragroupof
similaridentifiableassets.ThisupdatewillbeeffectivefortheCompanyforannualperiodsbeginningafterDecember15,
2017,includinginterimperiodswithinthoseannualperiods.Earlyadoptionispermitted.Thisupdateshouldbeapplied
prospectively.TheCompanyiscurrentlyassessingtheimpactofthefutureadoptionofthisstandardonitsfinancial
statements.
Duringthefiscalfirstquarterof2017,theFASBissuedAccountingStandardUpdate2017-04:SimplifyingtheTestfor
GoodwillImpairment.Thisupdatesimplifieshowanentityisrequiredtotestgoodwillforimpairment.Agoodwill
impairmentwillnowbemeasuredbytheamountbywhichareportingunit’scarryingvalueexceedsitsfairvalue,notto
exceedthecarryingamountofgoodwill.ThisupdatewillbeeffectivefortheCompanyforitsannualoranyinterimgoodwill
impairmenttestsinfiscalyearsbeginningafterDecember15,2019.Earlyadoptionispermitted.Thisupdateshouldbe
appliedprospectively.TheCompanyiscurrentlyassessingtheimpactofthefutureadoptionofthisstandardonits
financialstatements.
Duringthefiscalfirstquarterof2017,theFASBissuedAccountingStandardUpdate2017-05:OtherIncome-Gainsand
LossesfromtheDerecognitionofNonfinancialAssets.Thisupdateclarifiesthescopeofassetderecognitionguidance,
addsguidanceforpartialsalesofnonfinancialassetsandclarifiesrecognizinggainsandlossesfromthetransferof
nonfinancialassetsincontractswithnoncustomers.ThisupdatewillbeeffectivefortheCompanyforitsannualandinterim
reportingperiodsbeginningafterDecember15,2017,thesametimeastheamendmentsinUpdate2014-09Revenue
fromContractswithCustomers.ThisupdateallowstheCompanytochooseeitherafullretrospectivemethodormodified
retrospectivemethoduponadoption.TheCompanyiscurrentlyassessingtheimpactofthefutureadoptionofthis
standardonitsfinancialstatements.
Duringthefiscalfirstquarterof2016,theFASBissuedAccountingStandardsUpdate2016-01FinancialInstruments:
RecognitionandMeasurementofFinancialAssetsandFinancialLiabilities.Theamendmentsinthisupdatesupersedethe
guidancetoclassifyequitysecuritieswithreadilydeterminablefairvaluesintodifferentcategories(thatis,tradingor
available-for-sale)andrequireequitysecuritiestobemeasuredatfairvaluewithchangesinthefairvaluerecognized
throughnetincome.Thestandardamendsfinancialreportingbyprovidingrelevantinformationaboutanentity’sequity
investmentsandreducingthenumberofitemsthatarerecognizedinothercomprehensiveincome.Thisupdatewillbe
effectivefortheCompanyforannualperiodsbeginningafterDecember15,2017,andinterimperiodswithinthoseannual
periods.TheCompanyisunabletoestimatetheimpactofthefutureadoptionofthisstandardonitsfinancialstatements
asitwilldependontheequityinvestmentsasoftheadoptiondate.
42 • Johnson&Johnson2016AnnualReportDuringthefiscalfirstquarterof2016,theFASBissuedAccountingStandardsUpdate2016-02Leases(Topic842).This
updaterequirestherecognitionofleaseassetsandleaseliabilitiesonthebalancesheetforallleaseobligationsand
disclosingkeyinformationaboutleasingarrangements.Thisupdaterequirestherecognitionofleaseassetsandlease
liabilitiesbylesseesforthoseleasesclassifiedasoperatingleasesundercurrentgenerallyacceptedaccountingprinciples.
ThisupdatewillbeeffectivefortheCompanyforallannualandinterimperiodsbeginningafterDecember15,2018,
includinginterimperiodswithinthosefiscalyears.Earlyapplicationispermitted.Theupdateisrequiredtobeadoptedusing
amodifiedretrospectiveapproach.TheCompanyanticipatesthatmostofitsoperatingleaseswillresultintherecognitionof
additionalassetsandthecorrespondingliabilitiesonitsConsolidatedBalanceSheets,howeverdoesnotexpecttohavea
materialimpactonthefinancialposition.TheactualimpactwilldependontheCompany’sleaseportfolioatthetimeof
adoption.TheCompanycontinuestoassessallimplicationsofthestandardandrelatedfinancialdisclosures.
Duringthefiscalfirstquarterof2016,theFASBissuedAccountingStandardsUpdate2016-07Investments–Equity
MethodandJointVentures(Topic323):SimplifyingtheTransitiontotheEquityMethodofAccounting.Theamendments
intheupdateeliminatetherequirementthatwhenaninvestmentqualifiesfortheuseoftheequitymethodasaresultofan
increaseinthelevelofownershipinterestordegreeofinfluence,aninvestormustadjusttheinvestment,resultsof
operations,andretainedearningsretroactivelyonastepbystepbasisasiftheequitymethodhadbeenineffectduringall
previousperiodsthattheinvestmenthadbeenheld.Theamendmentsinthisupdateareeffectiveforallentitiesforfiscal
years,andinterimperiodswithinthosefiscalyears,beginningafterDecember15,2016.Theamendmentsshouldbe
appliedprospectivelyupontheireffectivedatetoincreasesinthelevelofownershipinterestordegreeofinfluencethat
resultintheapplicationoftheequitymethod.Earlieradoptionispermittedforanyentityinanyinterimorannualperiod.
TheadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthepresentationoftheCompany’s
consolidatedfinancialstatements.
Duringthefiscalthirdquarterof2016,theFASBissuedAccountingStandardsUpdate2016-15StatementofCash
Flows(Topic230):ClassificationofCertainCashReceiptsandCashPayments.Thisupdateaddresseswhetherto
presentcertainspecificcashflowitemsasoperating,investingorfinancingactivities.Theamendmentsinthisupdateare
effectiveforpublicentitiesforfiscalyears,andinterimperiodswithinthosefiscalyears,beginningafterDecember15,
2017.Earlyadoptionispermitted,includingadoptioninaninterimperiod.TheCompanyiscurrentlyassessingtheimpact
ofthefutureadoptionofthisstandardonitsconsolidatedStatementsofCashFlows.
Duringthefiscalfourthquarterof2016,theFASBissuedAccountingStandardsUpdate2016-16IncomeTaxes(Topic
740):Intra-EntityTransfersofAssetsOtherThanInventory.ThisupdateremovesthecurrentexceptioninUSGAAP
prohibitingentitiesfromrecognizingcurrentanddeferredincometaxexpensesorbenefitsrelatedtotransferofassets,
otherthaninventory,withintheconsolidatedentity.Thecurrentexceptiontodefertherecognitionofanytaximpactonthe
transferofinventorywithintheconsolidatedentityuntilitissoldtoathirdpartyremainsunaffected.Theamendmentsin
thisupdateareeffectiveforpublicentitiesforannualreportingperiodsbeginningafterDecember15,2017.Earlyadoption
ispermittedandshouldbeinthefirstinterimperiodifanentityissuesinterimfinancialstatements.TheCompanyis
currentlyassessingtheimpactofthefutureadoptionofthisstandardonitsconsolidatedfinancialstatements.
Duringthefiscalsecondquarterof2015,theFASBissuedAccountingStandardsUpdate2015-11:Simplifyingthe
MeasurementofInventory.Thisupdaterequiresinventorytobemeasuredatthelowerofcostornetrealizablevalue.Net
realizablevalueistheestimatedsellingpricesintheordinarycourseofbusiness,lessreasonablypredictablecostsof
completion,disposalandtransportation.ThisupdatewillbeeffectivefortheCompanyforallannualandinterimperiods
beginningafterDecember15,2016.Theamendmentsinthisupdateshouldbeappliedprospectivelywithearlier
applicationpermittedasofthebeginningofaninterimorannualreportingperiod.Thisupdatewillnothaveamaterial
impactonthepresentationoftheCompany’sfinancialposition.
Duringthefiscalsecondquarterof2014,theFASBissuedAccountingStandardsUpdate2014-09:Revenuefrom
ContractswithCustomers,which,alongwithamendmentsissuedin2015and2016,willreplacesubstantiallyallcurrent
U.S.GAAPguidanceonthistopicandeliminateindustry-specificguidance.Earlyadoptionofthisstandardispermitted
butnotbeforetheoriginaleffectivedateforallannualperiodsandinterimreportingperiodsbeginningafterDecember15,
2017.Theguidancepermitstwomethodsofadoption:fullretrospectivemethod(retrospectiveapplicationtoeachprior
reportingperiodpresented)ormodifiedretrospectivemethod(retrospectiveapplicationwiththecumulativeeffectof
initiallyapplyingtheguidancerecognizedatthedateofinitialapplicationandprovidingcertainadditionaldisclosures).
WhiletheCompanycontinuestoevaluatetheeffectofthestandard,preliminarily,itdoesnotanticipateamaterialimpact
onitsfinancialstatements.Tocompletetheassessmentoftheimpactofthestandardtothefinancialstatements,the
Companycontinuestoassessallimplicationsofthestandard,methodofadoptionandrelatedfinancialdisclosures.
Additionally,theCompanycontinuestomonitormodifications,clarificationsandinterpretationsissuedbytheFASBthat
mayaffectcurrentconclusions.
Johnson&Johnson2016AnnualReport • 43CashEquivalents
TheCompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase
ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof
purchaseascurrentmarketablesecurities.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercial
institutionsthathaveatleastaninvestmentgradecreditrating.TheCompanyinvestsitscashprimarilyingovernment
securitiesandobligations,corporatedebtsecurities,moneymarketfundsandreverserepurchaseagreements(RRAs).
RRAsarecollateralizedbydepositsintheformofGovernmentSecuritiesandObligationsforanamountnotlessthan
102%oftheirvalue.TheCompanydoesnotrecordanassetorliabilityastheCompanyisnotpermittedtosellor
repledgetheassociatedcollateral.TheCompanyhasapolicythatthecollateralhasatleastanA(orequivalent)credit
rating.TheCompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis
maintainedat102%ofthevalueoftheRRAsonadailybasis.RRAswithstatedmaturitiesofgreaterthanthreemonths
fromthedateofpurchaseareclassifiedasmarketablesecurities.
Investments
Investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare
reportedinearnings.Investmentsclassifiedasavailable-for-salearecarriedatestimatedfairvaluewithunrealizedgains
andlossesrecordedasacomponentofaccumulatedothercomprehensiveincome.Available-for-salesecuritiesavailable
forcurrentoperationsareclassifiedascurrentassetsotherwise,theyareclassifiedaslongterm.Managementdetermines
theappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeofpurchaseandre-evaluatessuch
determinationateachbalancesheetdate.TheCompanyperiodicallyreviewsitsinvestmentsinequitysecuritiesfor
impairmentandadjuststheseinvestmentstotheirfairvaluewhenadeclineinmarketvalueisdeemedtobeotherthan
temporary.Iflossesonthesesecuritiesareconsideredtobeotherthantemporary,thelossisrecognizedinearnings.
Property,PlantandEquipmentandDepreciation
Property,plantandequipmentarestatedatcost.TheCompanyutilizesthestraight-linemethodofdepreciationoverthe
estimatedusefullivesoftheassets:
Buildingandbuildingequipment 20-30years
Landandleaseholdimprovements 10-20years
Machineryandequipment 2-13years
TheCompanycapitalizescertaincomputersoftwareanddevelopmentcosts,includedinmachineryandequipment,when
incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternaluse.Capitalizedsoftwarecostsare
amortizedovertheestimatedusefullivesofthesoftware,whichgenerallyrangefrom3to8years.
TheCompanyreviewslong-livedassetstoassessrecoverabilityusingundiscountedcashflows.Whencertaineventsor
changesinoperatingoreconomicconditionsoccur,animpairmentassessmentmaybeperformedontherecoverabilityof
thecarryingvalueoftheseassets.Iftheassetisdeterminedtobeimpaired,thelossismeasuredbasedonthedifference
betweentheasset’sfairvalueanditscarryingvalue.Ifquotedmarketpricesarenotavailable,theCompanywillestimate
fairvalueusingadiscountedvalueofestimatedfuturecashflows.
Revenue Recognition
TheCompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss
passtothecustomer.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,productreturnsand
discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorded.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingpriceschargedbycompetitors.Rebates,whichincludeMedicaid,areestimatedbased
oncontractualterms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevarious
marketsserved.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughthe
analysisofwholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternallygenerated
information.
Salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibit
unusualsalesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedand
analyzedaspartoftheaccountingforsalesreturnsaccruals.
44 • Johnson&Johnson2016AnnualReportSalesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa
percenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescreditto
customersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewithU.S.GAAP
guidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsalesvalue.Sales
returnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsforcertain
franchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompanyinfrequently
exchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhasbeen
approximately1.0%ofannualsalestocustomersduringthefiscalreportingyears2016,2015and2014.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
yearincurred.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentiveprograms.The
redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.Volume-based
incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare
sold.TheCompanyalsoearnsservicerevenueforco-promotionofcertainproductsandincludesitinsalestocustomers.
Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedasareductionof
revenue.
ShippingandHandling
Shippingandhandlingcostsincurredwere$974million,$996millionand$1,068millionin2016,2015and2014,
respectively,andareincludedinselling,marketingandadministrativeexpense.Theamountofrevenuereceivedfor
shippingandhandlingislessthan0.5%ofsalestocustomersforallperiodspresented.
Inventories
Inventoriesarestatedatthelowerofcostormarketdeterminedbythefirst-in,first-outmethod.
IntangibleAssetsandGoodwill
TheauthoritativeliteratureonU.S.GAAPrequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed
annuallyforimpairment.TheCompanycompletedtheannualimpairmenttestfor2016inthefiscalfourthquarter.Future
impairmenttestswillbeperformedannuallyinthefiscalfourthquarter,orsoonerifwarranted.Purchasedin-process
researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted,
atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleasset,orabandoned,atwhichpoint
theintangibleassetwillbewrittenofforpartiallyimpaired.
Intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullives,andarereviewedfor
impairmentwhenwarrantedbyeconomicconditions.SeeNote5forfurtherdetailsonIntangibleAssetsandGoodwill.
FinancialInstruments
AsrequiredbyU.S.GAAP,allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Fairvalueistheexit
pricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-basedmeasurement
determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.Theauthoritativeliterature
establishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue,withLevel1havingthehighest
priorityandLevel3havingthelowest.Changesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings
orothercomprehensiveincome,dependingonwhetherthederivativeisdesignatedaspartofahedgetransaction,andif
so,thetypeofhedgetransaction.
TheCompanydocumentsallrelationshipsbetweenhedgeditemsandderivatives.Theoverallriskmanagementstrategy
includesreasonsforundertakinghedgetransactionsandenteringintoderivatives.Theobjectivesofthisstrategyare:
(1)minimizeforeigncurrencyexposure’simpactontheCompany’sfinancialperformance;(2)protecttheCompany’scash
flowfromadversemovementsinforeignexchangerates;(3)ensuretheappropriatenessoffinancialinstruments;and
(4)managetheenterpriseriskassociatedwithfinancialinstitutions.SeeNote6foradditionalinformationonFinancial
Instruments.
Johnson&Johnson2016AnnualReport • 45ProductLiability
Accrualsforproductliabilityclaimsarerecorded,onanundiscountedbasis,whenitisprobablethataliabilityhasbeen
incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially
determinedestimateswhereapplicable.Theaccrualsareadjustedperiodicallyasadditionalinformationbecomes
available.TheCompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts
areprobableandcanbereasonablyestimated.
Asaresultofcostandavailabilityfactors,effectiveNovember1,2005,theCompanyceasedpurchasingthird-party
productliabilityinsurance.TheCompanyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.In
additiontoaccrualsintheselfinsuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesare
probableandamountscanbereasonablyestimated.Basedontheavailabilityofpriorcoverage,receivablesforinsurance
recoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscountedbasis,whenitisprobablethatarecoverywill
berealized.Asappropriate,reservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynotbe
collectedfromthird-partyinsurers.
ConcentrationofCreditRisk
Globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge
numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimits.EconomicchallengesinItaly,
Spain,GreeceandPortugal(theSouthernEuropeanRegion)haveimpactedcertainpaymentpatterns,whichhave
historicallybeenlongerthanthoseexperiencedintheU.S.andotherinternationalmarkets.Thetotalnettradeaccounts
receivablebalanceintheSouthernEuropeanRegionwasapproximately$1.1billionasofJanuary1,2017and
approximately$1.3billionasofJanuary3,2016.Approximately$0.7billionasofJanuary1,2017andapproximately
$0.8billionasofJanuary3,2016oftheSouthernEuropeanRegionnettradeaccountsreceivablebalancerelatedtothe
Company’sConsumer,VisionCareandDiabetesCarebusinessesaswellascertainPharmaceuticalandMedicalDevices
customerswhichareinlinewithhistoricalcollectionpatterns.
TheremainingbalanceofnettradeaccountsreceivableintheSouthernEuropeanRegionhasbeennegativelyimpacted
bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomers,aswellascertain
distributorsofthePharmaceuticalandMedicalDeviceslocalaffiliates.Thetotalnettradeaccountsreceivablebalancefor
thesecustomerswereapproximately$0.4billionatJanuary1,2017and$0.5billionatJanuary3,2016.TheCompany
continuestoreceivepaymentsfromthesecustomersand,insomecases,latepaymentswithinterest.Forcustomers
wherepaymentisexpectedoverperiodsoftimelongerthanoneyear,revenueandtradereceivableshavebeen
discountedovertheestimatedperiodoftimeforcollection.Allowancesfordoubtfulaccountshavebeenincreasedfor
thesecustomers,buthavebeenimmaterialtodate.TheCompanywillcontinuetoworkcloselywiththesecustomerson
paymentplans,monitortheeconomicsituationandtakeappropriateactionsasnecessary.
ResearchandDevelopment
Researchanddevelopmentexpensesareexpensedasincurred.Upfrontandmilestonepaymentsmadetothirdpartiesin
connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval.
Paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful
lifeoftherelatedproduct.Amountscapitalizedforsuchpaymentsareincludedinotherintangibles,netofaccumulated
amortization.
TheCompanyentersintocollaborativearrangements,typicallywithotherpharmaceuticalorbiotechnologycompanies,to
developandcommercializedrugcandidatesorintellectualproperty.Thesearrangementstypicallyinvolvetwo(ormore)
partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe
commercialsuccessoftheactivities.Thesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties,
includingresearchanddevelopment,marketingandsellinganddistribution.Often,thesecollaborationsrequireupfront,
milestoneandroyaltyorprofitsharepayments,contingentupontheoccurrenceofcertainfutureeventslinkedtothe
successoftheassetindevelopment.Amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare
generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract
46 • Johnson&Johnson2016AnnualReportdevelopmentservicesisnotcentraltotheCompany’soperations.Ingeneral,theincomestatementpresentationforthese
collaborationsisasfollows:
Nature/TypeofCollaboration StatementofEarningsPresentation
Third-partysaleofproduct Salestocustomers
Royalties/milestonespaidtocollaborativepartner Costofproductssold
(post-regulatoryapproval)*
Royaltiesreceivedfromcollaborativepartner Otherincome(expense),net
Upfrontpayments&milestonespaidtocollaborativepartner Researchanddevelopmentexpense
(pre-regulatoryapproval)
Researchanddevelopmentpaymentstocollaborative Researchanddevelopmentexpense
partner
Researchanddevelopmentpaymentsreceivedfrom ReductionofResearchanddevelopmentexpense
collaborativepartner
* Milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife.
Forallyearspresented,therewasnoindividualprojectthatrepresentedgreaterthan5%ofthetotalannualconsolidated
researchanddevelopmentexpense.
TheCompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding
XARELTO®,co-developedwithBayerHealthCareAGandIMBRUVICA®,developedincollaborationandco-marketed
withPharmacyclicsLLC,anAbbViecompany.
Advertising
Costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinselling,marketingand
administrativeexpenses.Advertisingexpensesworldwide,whichcomprisedtelevision,radio,printmediaandInternet
advertising,were$2.4billion,$2.5billionand$2.6billionin2016,2015and2014,respectively.
IncomeTaxes
Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany
differencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.TheCompany
estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesintaxlawsand
ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
AtJanuary1,2017andJanuary3,2016,thecumulativeamountsofundistributedinternationalearningswere
approximately$66.2billionand$58.0billion,respectively.AtJanuary1,2017andJanuary3,2016,theCompany’s
foreignsubsidiariesheldbalancesofcash,cashequivalentsandmarketablesecuritiesintheamountsof$41.3billionand
$38.2billion,respectively.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertain
internationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.TheCompanyintendsto
continuetoreinvesttheseearningsininternationaloperations.IftheCompanydecidedatalaterdatetorepatriatethese
earningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectsontheseamounts.TheCompany
doesnotdeterminethedeferredtaxliabilityassociatedwiththeseundistributedearnings,assuchdeterminationisnot
practical.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
NetEarningsPerShare
Basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage
numberofcommonsharesoutstandingfortheperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcould
occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod.
Johnson&Johnson2016AnnualReport • 47UseofEstimates
Thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe
U.S.requiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreported.Estimatesareusedwhen
accountingforsalesdiscounts,rebates,allowancesandincentives,productliabilities,incometaxes,depreciation,
amortization,employeebenefits,contingenciesandintangibleassetandliabilityvaluations.Actualresultsmayormaynot
differfromthoseestimates.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
AnnualClosingDate
TheCompanyfollowstheconceptofafiscalyear,whichendsontheSundaynearesttotheendofthemonthof
December.Normallyeachfiscalyearconsistsof52weeks,buteveryfiveorsixyearsthefiscalyearconsistsof53weeks,
andthereforeincludesadditionalshippingdays,aswasthecasein2015,andwillbethecaseagainin2020.
Reclassification
Certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
2. Cash, Cash Equivalents and Current Marketable Securities
Attheendof2016and2015,cash,cashequivalentsandcurrentmarketablesecuritieswerecomprisedof:
2016
Cash& Current
Carrying Unrecognized Unrecognized Estimated Cash Marketable
(DollarsinMillions) Amount Gain Loss FairValue Equivalents Securities
Cash $1,979 – – 1,979 $1,979 –
U.S.Gov’tSecurities(1) 10,832 – (1) 10,831 2,249 8,583
OtherSovereignSecurities(1) 1,299 – – 1,299 120 1,179
U.S.Reverserepurchase
agreements 6,103 – – 6,103 6,103 –
OtherReverserepurchase
agreements 240 – – 240 240 –
Corporatedebtsecurities(1) 754 – – 754 – 754
Moneymarketfunds 7,187 – – 7,187 7,187 –
Timedeposits(1) 1,094 – – 1,094 1,094 –
Subtotal $29,488 – (1) 29,487 18,972 10,516
Unrealized Unrealized
Gain Loss
Gov’tSecurities $10,277 5 (51) 10,231 – 10,231
OtherSovereignSecurities 90 – – 90 90
Corporatedebtsecurities 1,777 1 (12) 1,766 – 1,766
Equityinvestments 34 298 332 332
Subtotalavailablefor
sale(2) $12,178 304 (63) 12,419 – 12,419
Totalcash,cashequivalents
andcurrentmarketable
securities $18,972 22,935
48 • Johnson&Johnson2016AnnualReport2015
Current
Carrying Unrecognized Unrecognized Estimated Cash Marketable
(DollarsinMillions) Amount Gain Loss FairValue Equivalents Securities
Cash $1,832 — — 1,832 1,832 —
U.S.Gov’tSecurities(1) 14,641 1 (2) 14,640 650 13,991
OtherSovereignSecurities(1) 2,122 — — 2,122 933 1,189
U.S.Reverserepurchase
agreements 1,579 — — 1,579 1,579 —
OtherReverserepurchase
agreements 2,200 — — 2,200 2,200 —
Corporatedebtsecurities(1) 2,941 — — 2,941 1,793 1,148
Moneymarketfunds 3,855 — — 3,855 3,855 —
Timedeposits(1) 890 — — 890 890 —
Subtotal $30,060 1 (2) 30,059 13,732 16,328
Unrealized Unrealized
Gain Loss
Gov’tSecurities $7,307 1 (34) 7,274 — 7,274
OtherSovereignSecurities — — — — —
Corporatedebtsecurities 1,046 1 (5) 1,042 — 1,042
Subtotalavailablefor
sale(2) $8,353 2 (39) 8,316 — 8,316
Totalcash,cashequivalents
andcurrentmarketable
securities $13,732 24,644
(1) Heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings.
(2) Availableforsalesecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinothercomprehensive
income.
Fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker
pricesandsignificantotherobservableinputs.
ThecontractualmaturitiesoftheavailableforsaledebtsecuritiesatJanuary1,2017areasfollows:
Cost Fair
(DollarsinMillions) Basis Value
Duewithinoneyear $474 474
Dueafteroneyearthroughfiveyears 11,430 11,381
Dueafterfiveyearsthroughtenyears 240 232
Totaldebtsecurities $12,144 12,087
TheCompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhigh-quality
moneymarketinstruments.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat
leastaninvestmentgradecreditrating.
3. Inventories
Attheendof2016and2015,inventorieswerecomprisedof:
(DollarsinMillions) 2016 2015
Rawmaterialsandsupplies $952 936
Goodsinprocess 2,185 2,241
Finishedgoods 5,007 4,876
Totalinventories $8,144 8,053
Johnson&Johnson2016AnnualReport • 494. Property, Plant and Equipment
Attheendof2016and2015,property,plantandequipmentatcostandaccumulateddepreciationwere:
(DollarsinMillions) 2016 2015
Landandlandimprovements $753 780
Buildingsandbuildingequipment 10,112 9,829
Machineryandequipment 23,554 22,511
Constructioninprogress 3,354 3,528
Totalproperty,plantandequipment,gross $37,773 36,648
Lessaccumulateddepreciation 21,861 20,743
Totalproperty,plantandequipment,net $15,912 15,905
TheCompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipment.Interestexpense
capitalizedin2016,2015and2014was$102million,$102millionand$115million,respectively.
Depreciationexpense,includingtheamortizationofcapitalizedinterestwas$2.5billionin2016,2015and2014.
Uponretirementorotherdisposalofproperty,plantandequipment,thecostsandrelatedamountsofaccumulated
depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccounts,respectively.The
difference,ifany,betweenthenetassetvalueandtheproceedsarerecordedinearnings.
5. Intangible Assets and Goodwill
Attheendof2016and2015,thegrossandnetamountsofintangibleassetswere:
(DollarsinMillions) 2016 2015
Intangibleassetswithdefinitelives:
Patentsandtrademarks–gross $10,521 8,299
Lessaccumulatedamortization 5,076 4,745
Patentsandtrademarks–net $5,445 3,554
Customerrelationshipsandotherintangibles–gross $17,615 17,583
Lessaccumulatedamortization 6,515 5,816
Customerrelationshipsandotherintangibles–net $11,100 11,767
Intangibleassetswithindefinitelives:
Trademarks $6,888 7,023
Purchasedin-processresearchanddevelopment 3,443 3,420
Totalintangibleassetswithindefinitelives $10,331 10,443
Totalintangibleassets–net $26,876 25,764
GoodwillasofJanuary1,2017andJanuary3,2016,asallocatedbysegmentofbusiness,wasasfollows:
(DollarsinMillions) Consumer Pharmaceutical MedDevices Total
GoodwillatDecember28,2014 $7,675 2,626 11,531 21,832
Goodwill,relatedtoacquisitions 110 366 34 510
Goodwill,relatedtodivestitures (119) (17) (57) (193)
Currencytranslation/other (426) (86) (8) (520)
GoodwillatJanuary3,2016 $7,240 2,889 11,500 21,629
Goodwill,relatedtoacquisitions 1,362 – 210 1,572
Goodwill,relatedtodivestitures (63) (12) – (75)
Currencytranslation/other (276) (37) (8) (321)
GoodwillatJanuary1,2017 $8,263 2,840 11,702 22,805
50 • Johnson&Johnson2016AnnualReportTheweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible
assetsare19yearsand24years,respectively.Theamortizationexpenseofamortizableassetsincludedincostof
productssoldwas$1.2billion,$1.2billionand$1.4billionbeforetax,forthefiscalyearsendedJanuary1,2017,
January3,2016andDecember28,2014,respectively.Theestimatedamortizationexpense,includingAbbottMedical
Optics(AMO),forthefivesucceedingyearsapproximates$1.5billionbeforetax,peryear.Intangibleassetwrite-downs
areincludedinOther(income)expense,net.
SeeNote20totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures.
6. Fair Value Measurements
TheCompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflows,primarily
relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthird-partypurchasesofmaterials
denominatedinaforeigncurrency.TheCompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk
primarilyrelatedtoborrowings.TheCompanyalsousesequitycollarcontractstomanageexposuretomarketrisk
associatedwithcertainequityinvestments.Allthreetypesofderivativesaredesignatedascashflowhedges.
Additionally,theCompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate
borrowings.Thesederivativesaretreatedasfairvaluehedges.TheCompanyusesforwardforeignexchangecontracts
designatedasnetinvestmenthedges.Additionally,theCompanyusesforwardforeignexchangecontractstooffsetits
exposuretocertainforeigncurrencyassetsandliabilities.Theseforwardforeignexchangecontractsarenotdesignatedas
hedgesandtherefore,changesinthefairvaluesofthesederivativesarerecognizedinearnings,therebyoffsettingthe
currentearningseffectoftherelatedforeigncurrencyassetsandliabilities.
TheCompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposes,orthatcontaincredit
riskrelatedcontingentfeaturesorrequirementstopostcollateral(excludingequitycollarcontract)byeithertheCompany
orthecounter-party.Forequitycollarcontracts,theCompanypledgedtheunderlyinghedgedmarketableequitysecurities
tothecounter-partyascollateral.Onanongoingbasis,theCompanymonitorscounterpartycreditratings.TheCompany
considerscreditnon-performancerisktobelow,becausetheCompanyprimarilyentersintoagreementswithcommercial
institutionsthathaveatleastaninvestmentgradecreditrating.Refertothetableonsignificantfinancialassetsand
liabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercialinstitutions.
AsofJanuary1,2017,theCompanyhadnotionalamountsoutstandingforforwardforeignexchangecontracts,cross
currencyinterestrateswaps,interestrateswapsandequitycollarcontractsof$36.0billion,$2.3billion,$1.8billionand
$0.3billionrespectively.
Allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Changesinthefairvalueofderivativesare
recordedeachperiodincurrentearningsorothercomprehensiveincome,dependingonwhetherthederivativeis
designatedaspartofahedgetransaction,andifso,thetypeofhedgetransaction.
Thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontract.Atinception,allderivatives
areexpectedtobehighlyeffective.Changesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis
highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings,
andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransaction.Gainsandlossesassociatedwith
interestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesininterestratesarerecordedto
interestexpenseintheperiodinwhichtheyoccur.Gainsandlossesonnetinvestmenthedgesareaccountedforthrough
thecurrencytranslationaccount.Onanongoingbasis,theCompanyassesseswhethereachderivativecontinuestobe
highlyeffectiveinoffsettingchangesofhedgeditems.Ifandwhenaderivativeisnolongerexpectedtobehighlyeffective,
hedgeaccountingisdiscontinued.Hedgeineffectiveness,ifany,isincludedincurrentperiodearningsinOther(income)
expense,netforforwardforeignexchangecontracts,crosscurrencyinterestrateswaps,netinvestmenthedgesandequity
collarcontracts.Forinterestrateswapsdesignatedasfairvaluehedges,hedgeineffectiveness,ifany,isincludedin
currentperiodearningswithininterestexpense.Forthecurrentreportingperiod,hedgeineffectivenessassociatedwith
interestrateswapswasnotmaterial.
Duringthefiscalsecondquarterof2016,theCompanydesignateditsEurodenominatednotesissuedinMay2016with
duedatesrangingfrom2022to2035asanetinvestmenthedgeoftheCompany’sinvestmentsincertainofits
internationalsubsidiariesthatusetheEuroastheirfunctionalcurrencyinordertoreducethevolatilitycausedbychanges
inexchangerates.During2016,thechangeinthecarryingvalueduetoremeasurementoftheseEuronotesresultedina
$375millionpretaxgainreflectedinforeigncurrencytranslationadjustment,withintheConsolidatedStatementsof
ComprehensiveIncome.
Johnson&Johnson2016AnnualReport • 51AsofJanuary1,2017,thebalanceofdeferrednetlossesonderivativesincludedinaccumulatedothercomprehensive
incomewas$285millionafter-tax.Foradditionalinformation,seetheConsolidatedStatementsofComprehensiveIncome
andNote13.TheCompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill
bereclassifiedintoearningsoverthenext12monthsasaresultoftransactionsthatareexpectedtooccuroverthat
period.ThemaximumlengthoftimeoverwhichtheCompanyishedgingtransactionexposureis18months,excluding
interestratecontracts,netinvestmenthedgesandequitycollarcontracts.Theamountultimatelyrealizedinearningsmay
differasforeignexchangerateschange.Realizedgainsandlossesareultimatelydeterminedbyactualexchangeratesat
maturityofthederivative.
Thefollowingtableisasummaryoftheactivityrelatedtoderivativesdesignatedascashflowhedgesforthefiscalyears
endedJanuary1,2017andJanuary3,2016:
Gain/(Loss) Gain/(Loss)
Gain/(Loss) ReclassifiedFrom RecognizedIn
RecognizedIn AccumulatedOCI Other
(DollarsinMillions) AccumulatedOCI(1) IntoIncome(1) Income/Expense(2)
CashFlowHedgesbyIncomeStatementCaption 2016 2015 2016 2015 2016 2015
Salestocustomers(3) $(65) (83) (47) (126) (1) (5)
Costofproductssold(3) (212) (22) (3) 122 (15) 14
Researchanddevelopmentexpense(3) (76) (3) (90) 6 — 1
Interest(income)/Interestexpense,net(4) 66 (40) 37 — — —
Other(income)expense,net(3)(5) (72) 33 (7) 60 2 1
Total $(359) (115) (110) 62 (14) 11
Allamountsshowninthetableabovearenetoftax.
(1) Effectiveportion
(2) Ineffectiveportion
(3) Forwardforeignexchangecontracts
(4) Crosscurrencyinterestrateswaps
(5) Includesequitycollarcontracts
ForthefiscalyearsendedJanuary1,2017andJanuary3,2016,alossof$56millionandalossof$34million,
respectively,wasrecognizedinOther(income)expense,net,relatingtoforwardforeignexchangecontractsnot
designatedashedginginstruments.
Fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-based
measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.The
authoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedbelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Thefairvalueofaderivativefinancialinstrument(i.e.forwardforeignexchangecontracts,interestratecontracts)isthe
aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand
subsequentlyconvertedtotheU.S.Dollaratthecurrentspotforeignexchangerate.TheCompanydoesnotbelievethat
fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor
maturity,orthatthechangesinfairvaluewillhaveamaterialeffectontheCompany’sresultsofoperations,cashflowsor
financialposition.TheCompanyalsoholdsequityinvestmentswhichareclassifiedasLevel1anddebtsecuritieswhich
areclassifiedasLevel2.TheCompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequire
revisedvaluationsunderthisstandardthatarerecognizedatfairvalue.
Thefollowingthreelevelsofinputsareusedtomeasurefairvalue:
Level1—Quotedpricesinactivemarketsforidenticalassetsandliabilities.
Level2—Significantotherobservableinputs.
Level3—Significantunobservableinputs.
52 • Johnson&Johnson2016AnnualReportTheCompany’ssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofJanuary1,2017andJanuary3,2016
wereasfollows:
2016 2015
(DollarsinMillions) Level1 Level2 Level3 Total Total(1)
Derivativesdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts(7) $ – 747 – 747 452
Interestratecontracts(2)(4)(7) – 31 – 31 28
Total – 778 – 778 480
Liabilities:
Forwardforeignexchangecontracts(8) – 723 – 723 358
Interestratecontracts(3)(4)(8) – 382 – 382 241
Equitycollarcontracts(8) – 57 – 57 –
Total – 1,162 – 1,162 599
Derivativesnotdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts(7) – 34 – 34 33
Liabilities:
Forwardforeignexchangecontracts(8) – 57 – 57 41
AvailableForSaleOtherInvestments:
Equityinvestments(5) 1,209 – – 1,209 1,494
Debtsecurities(6) $ – 12,087 – 12,087 8,316
(1) 2015assetsandliabilitiesareallclassifiedasLevel2withtheexceptionofequityinvestmentsof$1,494million,whichareclassified
asLevel1.
(2) Includes$23millionand$20millionofnon-currentassetsforthefiscalyearsendingJanuary1,2017andJanuary3,2016,
respectively.
(3) Includes$382millionand$239millionofnon-currentliabilitiesforthefiscalyearsendingJanuary1,2017andJanuary3,2016,
respectively.
(4) Includescrosscurrencyinterestrateswapsandinterestrateswaps.
(5) Classifiedasnon-currentotherassetswiththeexceptionof$332millionofcurrentassetsforJanuary1,2017.Thecarryingamount
oftheequityinvestmentswere$520millionand$528millionasofJanuary1,2017andJanuary3,2016,respectively.Theunrealized
gainswere$757millionand$979millionasofJanuary1,2017andJanuary3,2016,respectively.Theunrealizedlosseswere$68
millionand$13millionasofJanuary1,2017andJanuary3,2016,respectively.
(6) Classifiedascurrentmarketablesecurities.
(7) Classifiedasothercurrentassets.
(8) Classifiedasaccountspayable.
SeeNotes2and7forfinancialassetsandliabilitiesheldatcarryingamountontheConsolidatedBalanceSheet.
Johnson&Johnson2016AnnualReport • 537. Borrowings
Thecomponentsoflong-termdebtareasfollows:
Effective Effective
(DollarsinMillions) 2016 Rate% 2015 Rate%
2.15%Notesdue2016 $— — 900 2.22
3monthLIBOR+0.07%FRNdue2016 — — 800 0.48
0.70%Notesdue2016 — — 398 0.74
5.55%Debenturesdue2017 1,000 5.55 1,000 5.55
1.125%Notesdue2017 699 1.15 700 1.15
5.15%Debenturesdue2018 899 5.18 899 5.15
1.65%Notesdue2018 600 1.70 602 1.70
4.75%Notesdue2019(1BEuro1.0449)(2)/(1BEuro1.0882)(3) 1,041(2) 5.83 1,085(3) 5.83
1.875%Notesdue2019 499 1.93 502 1.93
0.89%Notesdue2019 299 1.20 — —
1.125%Notesdue2019 699 1.13 — —
3%ZeroCouponConvertibleSubordinatedDebenturesdue2020 84 3.00 137 3.00
2.95%Debenturesdue2020 546 3.15 545 3.15
3.55%Notesdue2021 447 3.67 448 3.67
2.45%Notesdue2021 348 2.48 349 2.48
1.65%Notesdue2021 997 1.65 — —
0.250%Notesdue2022(1BEuro1.0449)(2) 1,041(2) 0.26 — —
6.73%Debenturesdue2023 249 6.73 250 6.73
3.375%Notesdue2023 807 3.17 811 3.17
2.05%Notesdue2023 497 2.09 — —
0.650%Notesdue2024(750MMEuro1.0449)(2) 779(2) 0.68 — —
5.50%Notesdue2024(500MMGBP1.2237)(2)/(500MMGBP1.4818)(3) 605(2) 6.75 737(3) 6.75
2.45%Notesdue2026 1,989 2.47 — —
1.150%Notesdue2028(750MMEuro1.0449)(2) 775(2) 1.21 — —
6.95%Notesdue2029 296 7.14 297 7.14
4.95%Debenturesdue2033 497 4.95 500 4.95
4.375%Notesdue2033 857 4.24 864 4.24
1.650%Notesdue2035(1.5BEuro1.0449)(2) 1,549(2) 1.68 — —
3.55%Notesdue2036 987 3.59 — —
5.95%Notesdue2037 990 5.99 996 5.99
5.85%Debenturesdue2038 695 5.85 700 5.86
4.50%Debenturesdue2040 537 4.63 540 4.63
4.85%Notesdue2041 296 4.89 298 4.89
4.50%Notesdue2043 495 4.52 499 4.52
3.70%Notesdue2046 1,970 3.74 — —
Other 77 — 104 —
Subtotal 24,146(4) 3.33%(1) 14,961(4) 4.06(1)
Lesscurrentportion 1,704 2,104
Totallong-termdebt $22,442 12,857
(1) Weightedaverageeffectiverate.
54 • Johnson&Johnson2016AnnualReport(2) TranslationrateatJanuary1,2017.
(3) TranslationrateatJanuary3,2016.
(4) Theexcessofthefairvalueoverthecarryingvalueofdebtwas$1.6billionin2016and$1.7billionin2015.
Fairvalueofthelong-termdebtwasestimatedusingmarketprices,whichwerecorroboratedbyquotedbrokerpricesand
significantotherobservableinputs.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2016,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember14,2017.Interestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementsarenotmaterial.
Throughout2016,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Short-term
borrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$4.7billionattheendof2016,ofwhich
$2.7billionwasborrowedundertheCommercialPaperProgram.Theremainderprincipallyrepresentslocalborrowingby
internationalsubsidiaries.
Throughout2015,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Short-term
borrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$7.0billionattheendof2015,ofwhich
$4.6billionwasborrowedundertheCommercialPaperProgram.Theremainderprincipallyrepresentslocalborrowingby
internationalsubsidiaries.
Aggregatematuritiesoflong-termobligationscommencingin2017are:
(DollarsinMillions)
After
2017 2018 2019 2020 2021 2021
$1,704 1,561 2,538 629 1,795 15,919
8. Income Taxes
Theprovisionfortaxesonincomeconsistsof:
(DollarsinMillions) 2016 2015 2014
Currentlypayable:
U.S.taxes $1,896 2,748 2,625
Internationaltaxes 1,708 1,309 1,174
Totalcurrentlypayable 3,604 4,057 3,799
Deferred:
U.S.taxes 294 37 (258)
Internationaltaxes (635) (307) 699
Totaldeferred (341) (270) 441
Provisionfortaxesonincome $3,263 3,787 4,240
Johnson&Johnson2016AnnualReport • 55AcomparisonofincometaxexpenseattheU.S.statutoryrateof35%in2016,2015and2014,totheCompany’s
effectivetaxrateisasfollows:
(DollarsinMillions) 2016 2015 2014
U.S. $7,457 8,179 8,001
International 12,346 11,017 12,562
Earningsbeforetaxesonincome: $19,803 19,196 20,563
Taxrates:
U.S.statutoryrate 35.0% 35.0 35.0
InternationaloperationsexcludingIreland (9.4) (6.7) (7.0)
IrelandandPuertoRicooperations(1) (7.8) (8.7) (6.9)
Researchandorphandrugtaxcredits (0.4) (0.2) (0.3)
U.S.stateandlocal (0.1) 0.4 1.0
U.S.manufacturingdeduction (0.6) (0.6) (0.6)
U.S.taxoninternationalincome 1.3 0.2 1.4
Additionaltaxbenefitsonsharebasedcompensation (1.8) – –
U.S.taxbenefitonasset/businessdisposals – – (1.9)
Allother 0.3 0.3 (0.1)
Effectivetaxrate 16.5% 19.7 20.6
(1) TheCompanyhassubsidiariesoperatinginPuertoRicoundervarioustaxincentives.
The2016effectivetaxratedecreasedby3.2%ascomparedto2015.AsdescribedinNote1,theCompanyadopteda
newaccountingstandardforthereportingofadditionaltaxbenefitsonshare-basedcompensationthatvestedorwere
exercisedduringthefiscalyear.Theadoptionofthisnewstandardreducedtheeffectivetaxrateoffiscal2016by1.8%
versus2015.
TheremainderofthechangeintheeffectivetaxratewasprimarilyrelatedtothelowerearningsbeforetaxesintheUnited
Statesandthesettlementofseveraluncertaintaxpositionsin2016versus2015.
Thedecreaseinthe2015effectivetaxrate,ascomparedto2014,wasprimarilyattributabletotheincreasesintaxable
incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictionsandataxbenefitresultingfromarestructuringof
internationalaffiliates.Additionally,the2014effectivetaxratewasaffectedbytheitemsmentionedbelow.
Theincreaseinthe2014effectivetaxrate,ascomparedto2013,wasattributabletothefollowing:thedivestitureofthe
Ortho-ClinicalDiagnosticsbusinessatanapproximate44%effectivetaxrate,litigationaccrualsatlowtaxrates,themixof
earningsintohighertaxjurisdictions,primarilytheU.S.,theaccrualofanadditionalyearoftheBrandedPrescriptionDrug
Fee,whichisnottaxdeductible,andadditionalU.S.taxexpenserelatedtoaplannedincreaseindividendsfromcurrent
yearforeignearningsascomparedtotheprioryear.Theseincreasestothe2014effectivetaxratewerepartiallyoffsetby
ataxbenefitof$0.4billionassociatedwiththeConorMedsystemsdivestiture.
The2014effectivetaxratewasalsoreducedastheCompanyadjusteditsunrecognizedtaxbenefitsasaresultof(i)the
federalappealscourt’sdecisioninOMJPharmaceuticals,Inc.’slitigationregardingcreditsunderformerSection936of
theInternalRevenueCodeand(ii)asettlementofsubstantiallyallissuesrelatedtotheCompany’sU.S.InternalRevenue
Serviceauditoftaxyears2006—2009.TheimpactofthesettlementisreflectedintheU.S.taxoninternationalincome
andtheAllotherlineitemswithintheabovereconciliation.
Theitemsnotedabovereflectthekeydriversoftheratereconciliation.
56 • Johnson&Johnson2016AnnualReportTemporarydifferencesandcarryforwardsfor2016and2015wereasfollows:
2016 2015
DeferredTax DeferredTax
(DollarsinMillions) Asset Liability Asset Liability
Employeerelatedobligations $2,958 2,863
Stockbasedcompensation 749 790
Depreciation (219) (247)
Non-deductibleintangibles (6,672) (6,663)
InternationalR&Dcapitalizedfortax 1,264 1,318
Reserves&liabilities 1,857 1,801
Incomereportedfortaxpurposes 1,309 960
Netoperatinglosscarryforwardinternational 717 997
Miscellaneousinternational 1,135 (15) 922(1) (249)
MiscellaneousU.S. 155 436
Totaldeferredincometaxes $10,144 (6,906) 10,087 (7,159)
(1) NetofavaluationallowancerelatedtoBelgiumof$196million.In2016,thisallowancewasreversedandtherelateddeferredtax
assetwasutilizedtoreducecurrenttaxexpense.
TheCompanyhaswholly-ownedinternationalsubsidiariesthathavecumulativenetlosses.TheCompanybelievesthatitis
morelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincomesufficienttoutilizethesedeferredtaxassets.
Thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits:
(DollarsinMillions) 2016 2015 2014
Beginningofyear $3,080 2,465 2,729
Increasesrelatedtocurrentyeartaxpositions 348 570 281
Increasesrelatedtopriorperiodtaxpositions 11 182 295
Decreasesrelatedtopriorperiodtaxpositions (338) (79) (288)
Settlements (37) (4) (477)
Lapseofstatuteoflimitations (23) (54) (75)
Endofyear $3,041 3,080 2,465
Theunrecognizedtaxbenefitsof$3.0billionatJanuary1,2017,ifrecognized,wouldaffecttheCompany’sannual
effectivetaxrate.TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits
inprogresswithanumberoftaxauthorities.TheIRShascompleteditsauditforthetaxyearsthrough2009andis
currentlyauditingthetaxyears2010-2012.InothermajorjurisdictionswheretheCompanyconductsbusiness,theyears
remainopengenerallybacktotheyear2004.TheCompanybelievesitispossiblethatauditsmaybecompletedbytax
authoritiesinsomejurisdictionsoverthenexttwelvemonths.However,theCompanyisnotabletoprovideareasonably
reliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxpositions.
TheCompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslong-termliabilities.
Interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpense.TheCompany
recognizedaftertaxinterestexpenseof$7million,$44millionand$12millionin2016,2015and2014,respectively.The
totalamountofaccruedinterestwas$344millionand$366millionin2016and2015,respectively.
Johnson&Johnson2016AnnualReport • 579. Employee Related Obligations
Attheendof2016and2015,employeerelatedobligationsrecordedontheConsolidatedBalanceSheetswere:
(DollarsinMillions) 2016 2015
Pensionbenefits $4,710 3,857
Postretirementbenefits 2,733 2,738
Postemploymentbenefits 2,050 2,092
Deferredcompensation 534 584
Totalemployeeobligations 10,027 9,271
Lesscurrentbenefitspayable 412 417
Employeerelatedobligations–non-current $9,615 8,854
Prepaidemployeerelatedobligationsof$227millionand$256millionfor2016and2015,respectively,areincludedin
OtherassetsontheConsolidatedBalanceSheets.
10. Pensions and Other Benefit Plans
TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,definedcontributionand
terminationindemnityplans,whichcovermostemployeesworldwide.TheCompanyalsoprovidespost-retirement
benefits,primarilyhealthcare,toalleligibleU.S.retiredemployeesandtheirdependents.
Manyinternationalemployeesarecoveredbygovernment-sponsoredprogramsandthecosttotheCompanyisnot
significant.
RetirementplanbenefitsforemployeeshiredbeforeJanuary1,2015areprimarilybasedontheemployee’scompensation
duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofservice.In2014,theCompanyannounced
thattheU.S.DefinedBenefitplanwasamendedtoadoptanewbenefitformula,effectiveforemployeeshiredonorafter
January1,2015.Thebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof
service.
Internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrustees,annuitiesarepurchasedundergroup
contracts,orreservesareprovided.
TheCompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture.
In2016and2015theCompanyusedDecember31,2016andDecember31,2015,respectively,asthemeasurement
dateforallU.S.andinternationalretirementandotherbenefitplans.
NetperiodicbenefitcostsfortheCompany’sdefinedbenefitretirementplansandotherbenefitplansfor2016,2015and
2014includethefollowingcomponents:
RetirementPlans OtherBenefitPlans
(DollarsinMillions) 2016 2015 2014 2016 2015 2014
Servicecost $949 1,037 882 224 257 211
Interestcost 927 988 1,018 158 186 197
Expectedreturnonplanassets (1,962) (1,809) (1,607) (6) (7) (7)
Amortizationofpriorservicecost(credit) 1 2 6 (34) (33) (34)
Amortizationofnettransitionobligation – – 1 – – –
Recognizedactuariallosses 496 745 460 135 201 136
Curtailmentsandsettlements 11 8 (17) – – –
Netperiodicbenefitcost $422 971 743 477 604 503
58 • Johnson&Johnson2016AnnualReportAmountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearfortheCompany’sdefinedbenefit
retirementplansandotherpost-retirementplans:
(DollarsinMillions)
Amortizationofnettransitionobligation $ –
Amortizationofnetactuariallosses 715
Amortizationofpriorservicecredit 28
UnrecognizedgainsandlossesfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceforeach
plan.Forplanswithnoactiveemployees,theyareamortizedovertheaveragelifeexpectancy.Theamortizationofgains
andlossesfortheotherU.S.benefitplansisdeterminedbyusinga10%corridorofthegreaterofthemarketvalueof
assetsortheaccumulatedpostretirementbenefitobligation.Totalunamortizedgainsandlossesinexcessofthecorridor
areamortizedovertheaverageremainingfutureservice.
Priorservicecosts/benefitsfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceofplan
participantsatthetimeoftheplanamendment.Priorservicecost/benefitfortheotherU.S.benefitplansisamortizedover
theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment.
Thefollowingtablerepresentstheweighted-averageactuarialassumptions:
RetirementPlans OtherBenefitPlans
WorldwideBenefitPlans 2016 2015 2014 2016 2015 2014
NetPeriodicBenefitCost
Servicecostdiscountrate 3.98% 3.78 4.78 4.77 4.31 5.25
Interestcostdiscountrate 4.24% 3.78 4.78 4.10 4.31 5.25
Rateofincreaseincompensationlevels 4.02% 4.05 4.08 4.32 4.11 4.29
Expectedlong-termrateofreturnonplanassets 8.55% 8.53 8.46
BenefitObligation
Discountrate 3.78% 4.11 3.78 4.42 4.63 4.31
Rateofincreaseincompensationlevels 4.02% 4.01 4.05 4.29 4.28 4.11
TheCompany’sdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighquality,long-term
fixedincomeinstruments.Theresultingdiscountratesareconsistentwiththedurationofplanliabilities.Forthefiscalyear
2016,theCompanychangeditsmethodologyindeterminingserviceandinterestcostfromthesingleweightedaverage
discountrateapproachtodurationspecificspotratesalongthatyieldcurvetotheplans’liabilitycashflows,which
managementhasconcludedisamorepreciseestimate.Priortothischangeinmethodology,theCompanymeasured
serviceandinterestcostsutilizingasingleweighted-averagediscountratederivedfromtheyieldcurveusedtomeasure
theplanobligations.TheCompanyhasaccountedforthischangeasachangeinaccountingestimateand,accordingly,
hasaccountedforitonaprospectivebasis.Thischangedoesnotimpactthebenefitobligationanddidnothavea
materialimpacttothe2016fullyearresults.
TheexpectedratesofreturnonplanassetassumptionsrepresenttheCompany’sassessmentoflong-termreturnson
diversifiedinvestmentportfoliosglobally.Theassessmentisdeterminedusingprojectionsfromexternalfinancialsources,
long-termhistoricalaverages,actualreturnsbyassetclassandthevariousassetclassallocationsbymarket.
Thefollowingtabledisplaystheassumedhealthcarecosttrendrates,forallindividuals:
HealthCarePlans 2016 2015
Healthcarecosttrendrateassumedfornextyear 6.32% 6.60%
Ratetowhichthecosttrendrateisassumedtodecline(ultimatetrend) 4.50% 4.50%
Yeartheratereachestheultimatetrendrate 2038 2038
Johnson&Johnson2016AnnualReport • 59Aone-percentage-pointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect:
One-Percentage- One-Percentage-
(DollarsinMillions) PointIncrease PointDecrease
HealthCarePlans
Totalinterestandservicecost $30 (23)
Post-retirementbenefitobligation $401 (325)
Thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyear-end
2016and2015fortheCompany’sdefinedbenefitretirementplansandotherpost-retirementplans:
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2016 2015 2016 2015
ChangeinBenefitObligation
Projectedbenefitobligation–beginningofyear $25,855 26,889 4,669 5,081
Servicecost 949 1,037 224 257
Interestcost 927 988 158 186
Planparticipantcontributions 54 48 – –
Amendments (48) 60 – –
Actuarial(gains)losses 2,302 (1,578) (73) (400)
Divestitures&acquisitions (24) (5) – –
Curtailments,settlements&restructuring (25) (20) – (3)
Benefitspaidfromplan* (1,210) (773) (378) (420)
Effectofexchangerates (664) (791) 5 (32)
Projectedbenefitobligation–endofyear $28,116 25,855 4,605 4,669
ChangeinPlanAssets
Planassetsatfairvalue–beginningofyear $22,254 22,575 74 79
Actualreturnonplanassets 2,286 298 7 1
Companycontributions 838 752 372 414
Planparticipantcontributions 54 48 – –
Settlements (25) (20) – –
Divestitures&acquisitions (24) (5) – –
Benefitspaidfromplanassets* (1,210) (773) (378) (420)
Effectofexchangerates (540) (621) – –
Planassetsatfairvalue–endofyear $23,633 22,254 75 74
Fundedstatus–endofyear $(4,483) (3,601) (4,530) (4,595)
AmountsRecognizedintheCompany’sBalanceSheetconsistofthefollowing:
Non-currentassets $227 256 – –
Currentliabilities (86) (77) (315) (324)
Non-currentliabilities (4,624) (3,780) (4,215) (4,271)
Totalrecognizedintheconsolidatedbalancesheet–endofyear $(4,483) (3,601) (4,530) (4,595)
AmountsRecognizedinAccumulatedOtherComprehensiveIncomeconsistof
thefollowing:
Netactuarialloss $7,749 6,501 1,804 2,013
Priorservicecost(credit) (12) 34 (150) (185)
Unrecognizednettransitionobligation – – – –
Totalbeforetaxeffects $7,737 6,535 1,654 1,828
AccumulatedBenefitObligations–endofyear $25,319 23,262
* In2016,theCompanyofferedavoluntarylump-sumpaymentoptionbelowapre-determinedthresholdforcertaineligibleformer
employeeswhoarevestedparticipantsoftheU.S.QualifiedDefinedBenefitPensionPlan.Thedistributionofthelump-sumswas
60 • Johnson&Johnson2016AnnualReportsubstantiallycompletedbytheendoffiscal2016.Theamountdistributedin2016wasapproximately$420million.Thesedistributions
fromtheplandidnothaveamaterialimpactontheCompany’sfinancialposition.
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2016 2015 2016 2015
AmountsRecognizedinNetPeriodicBenefitCostandOtherComprehensive
Income
Netperiodicbenefitcost $422 971 477 604
Netactuarial(gain)loss 1,965 (75) (72) (389)
Amortizationofnetactuarialloss (496) (745) (135) (201)
Priorservicecost(credit) (48) 60 – –
Amortizationofpriorservice(cost)credit (1) (2) 34 33
Effectofexchangerates (218) (218) (1) (1)
Totalrecognizedinothercomprehensiveincome,beforetax $1,202 (980) (174) (558)
Totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome $1,624 (9) 303 46
TheCompanyplanstocontinuetofunditsU.S.QualifiedPlanstocomplywiththePensionProtectionActof2006.
InternationalPlansarefundedinaccordancewithlocalregulations.Additionaldiscretionarycontributionsaremadewhen
deemedappropriatetomeetthelong-termobligationsoftheplans.Forcertainplans,fundingisnotacommonpractice,as
fundingprovidesnoeconomicbenefit.Consequently,theCompanyhasseveralpensionplansthatarenotfunded.
In2016,theCompanycontributed$501millionand$337milliontoitsU.S.andinternationalpensionplans,respectively.
ThefollowingtabledisplaysthefundedstatusoftheCompany’sU.S.Qualified&Non-Qualifiedpensionplansand
internationalfundedandunfundedpensionplansatDecember31,2016andDecember31,2015,respectively:
U.S.Plans InternationalPlans
QualifiedPlans Non-QualifiedPlans FundedPlans UnfundedPlans
(DollarsinMillions) 2016 2015 2016 2015 2016 2015 2016 2015
PlanAssets $16,057 15,113 – – 7,576 7,141 – –
ProjectedBenefitObligation 16,336 15,280 1,905 1,675 9,502 8,542 373 358
AccumulatedBenefitObligation 14,759 13,876 1,568 1,411 8,663 7,661 329 314
Over(Under)FundedStatus
ProjectedBenefitObligation $(279) (167) (1,905) (1,675) (1,926) (1,401) (373) (358)
AccumulatedBenefitObligation 1,298 1,237 (1,568) (1,411) (1,087) (520) (329) (314)
Planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligation,projected
benefitobligationandplanassetsof$8.8billion,$9.9billionand$5.6billion,respectively,attheendof2016,and
$4.5billion,$5.3billionand$1.9billion,respectively,attheendof2015.
ThefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromtheCompany’sretirementandotherbenefitplans:
(DollarsinMillions) 2017 2018 2019 2020 2021 2022-2026
Projectedfuturebenefitpayments
Retirementplans $897 908 958 1,010 1,081 6,416
Otherbenefitplans $325 315 311 307 304 1,465
Thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplans.Theseamounts
donotincludeanydiscretionarycontributionsthattheCompanymayelecttomakeinthefuture.
(DollarsinMillions) 2017 2018 2019 2020 2021 2022-2026
Projectedfuturecontributions $83 84 89 94 100 610
Johnson&Johnson2016AnnualReport • 61Eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand
investmentofthepensionplans.Indetermininginvestmentpolicies,strategiesandgoals,eachcommitteeorboard
considersfactorsincluding,localpensionrulesandregulations;localtaxregulations;availabilityofinvestmentvehicles
(separateaccounts,commingledaccounts,insurancefunds,etc.);fundedstatusoftheplans;ratioofactivestoretirees;
durationofliabilities;andotherrelevantfactorsincluding:diversification,liquidityoflocalmarketsandliquidityofbase
currency.AmajorityoftheCompany’spensionfundsareopentonewentrantsandareexpectedtobeon-goingplans.
Permittedinvestmentsareprimarilyliquidand/orlisted,withlittlerelianceonilliquidandnon-traditionalinvestmentssuch
ashedgefunds.
TheCompany’sretirementplanassetallocationattheendof2016and2015andtargetallocationsfor2017areas
follows:
Percentof Target
PlanAssets Allocation
2016 2015 2017
WorldwideRetirementPlans
Equitysecurities 75% 79% 73%
Debtsecurities 25 21 27
Totalplanassets 100% 100% 100%
DeterminationofFairValueofPlanAssets
ThePlanhasanestablishedandwell-documentedprocessfordeterminingfairvalues.Fairvalueisbaseduponquoted
marketprices,whereavailable.Iflistedpricesorquotesarenotavailable,fairvalueisbaseduponmodelsthatprimarily
use,asinputs,market-basedorindependentlysourcedmarketparameters,includingyieldcurves,interestrates,volatilities,
equityordebtprices,foreignexchangeratesandcreditcurves.
WhilethePlanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipants,theuseof
differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent
estimateoffairvalueatthereportingdate.
ValuationHierarchy
Theauthoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedinthetablebelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Afinancialinstrument’scategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis
significanttothefairvaluemeasurement.
Followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue.
• Short-terminvestments–Cashandquotedshort-terminstrumentsarevaluedattheclosingpriceortheamountheld
ondepositbythecustodianbank.OtherinvestmentsarethroughinvestmentvehiclesvaluedusingtheNetAssetValue
(NAV)providedbytheadministratorofthefund.TheNAVisbasedonthevalueoftheunderlyingassetsownedbythe
fund,minusitsliabilities,andthendividedbythenumberofsharesoutstanding.TheNAVisaquotedpriceinamarket
thatisnotactiveandclassifiedasLevel2.
• Governmentandagencysecurities–Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon
themajormarketonwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,
theinvestmentsareclassifiedwithinLevel1ofthevaluationhierarchy.Ifquotedmarketpricesarenotavailableforthe
specificsecurity,thenfairvaluesareestimatedbyusingpricingmodels,quotedpricesofsecuritieswithsimilar
characteristicsordiscountedcashflows.Whenquotedmarketpricesforasecurityarenotavailableinanactivemarket,
theyareclassifiedasLevel2.
• Debtinstruments–Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket
onwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,theinvestmentsare
classifiedasLevel1.Ifquotedmarketpricesarenotavailableforthespecificsecurity,thenfairvaluesareestimatedby
usingpricingmodels,quotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified
asLevel2.Level3debtinstrumentsarepricedbasedonunobservableinputs.
62 • Johnson&Johnson2016AnnualReport• Equitysecurities–Commonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual
securitiesaretraded.SubstantiallyallcommonstockisclassifiedwithinLevel1ofthevaluationhierarchy.
• Commingledfunds–TheseinvestmentvehiclesarevaluedusingtheNAVprovidedbythefundadministrator.TheNAV
isbasedonthevalueoftheunderlyingassetsownedbythefund,minusitsliabilities,andthendividedbythenumberof
sharesoutstanding.AssetsintheLevel2categoryhaveaquotedmarketprice.
• Insurancecontracts–Theinstrumentsareissuedbyinsurancecompanies.Thefairvalueisbasedonnegotiatedvalue
andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe
issuer.Theunderlyinginvestmentsaregovernment,asset-backedandfixedincomesecurities.Ingeneral,insurance
contractsareclassifiedasLevel3astherearenoquotedpricesnorotherobservableinputsforpricing.
• Otherassets–Otherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestments,aswellas
commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebt.Otherassetsthatareexchange
listedandactivelytradedareclassifiedasLevel1,whileinactivelytradedassetsareclassifiedasLevel2.
ThefollowingtablesetsforththeRetirementPlans’investmentsmeasuredatfairvalueasofDecember31,2016and
December31,2015:
QuotedPrices Significant
inActive Other Significant Investments
Marketsfor Observable Unobservable Measuredat
IdenticalAssets Inputs Inputs(a) NetAsset
(Level1) (Level2) (Level3) Value(b) TotalAssets
(DollarsinMillions) 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015
Short-terminvestmentfunds $145 184 652 312 – – – – 797 496
Governmentandagencysecurities – – 2,655 1,767 – – – – 2,655 1,767
Debtinstruments – – 1,237 1,050 – 1 – – 1,237 1,051
Equitysecurities 11,433 11,317 12 11 – – – – 11,445 11,328
Commingledfunds – – 1,316 1,100 – – 5,767 6,122 7,083 7,222
Insurancecontracts – – – – 24 23 – – 24 23
Otherassets – – – 107 – – 392 260 392 367
Investmentsatfairvalue $11,578 11,501 5,872 4,347 24 24 6,159 6,382 23,633 22,254
(a) TheactivityfortheLevel3assetsisnotsignificantforallyearspresented.
(b) PeradoptionofASU2015-07,certaininvestmentsthataremeasuredatfairvalueusingthenetassetvaluepershare(orits
equivalent)practicalexpedienthavenotbeenclassifiedinthefairvaluehierarchy.AsperASU2015-7prioryearamountshavebeen
reclassifiedtoconformtothecurrentyearpresentation.Thefairvalueamountspresentedinthistableareintendedtopermit
reconciliationofthefairvaluehierarchytothetotalretirementplanassets.
TheCompany’sOtherBenefitPlansareunfundedexceptforU.S.commingledfunds(Level2)of$75millionand$74
millionatDecember31,2016andDecember31,2015,respectively.
ThefairvalueofJohnson&JohnsonCommonStockdirectlyheldinplanassetswas$847million(3.6%oftotalplan
assets)atDecember31,2016and$751million(3.4%oftotalplanassets)atDecember31,2015.
11. Savings Plan
TheCompanyhasvoluntary401(k)savingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible
employees.TheCompanymatchesapercentageofeachemployee’scontributionsconsistentwiththeprovisionsofthe
planforwhichhe/sheiseligible.TotalCompanymatchingcontributionstotheplanswere$191million,$187millionand
$172millionin2016,2015and2014,respectively.
Johnson&Johnson2016AnnualReport • 6312. Capital and Treasury Stock
Changesintreasurystockwere:
TreasuryStock
(AmountsinMillionsExceptTreasuryStockSharesinThousands) Shares Amount
BalanceatDecember29,2013 299,215 $15,700
Employeecompensationandstockoptionplans (32,302) (2,933)
Repurchaseofcommonstock 69,707 7,124
BalanceatDecember28,2014 336,620 19,891
Employeecompensationandstockoptionplans (24,413) (2,497)
Repurchaseofcommonstock 52,474 5,290
BalanceatJanuary3,2016 364,681 22,684
Employeecompensationandstockoptionplans (30,839) (3,311)
Repurchaseofcommonstock 79,490 8,979
BalanceatJanuary1,2017 413,332 $28,352
Aggregatesharesofcommonstockissuedwereapproximately3,119,843,000sharesattheendof2016,2015and
2014.
Cashdividendspaidwere$3.15persharein2016,comparedwithdividendsof$2.95persharein2015,and$2.76per
sharein2014.
OnOctober13,2015,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$10.0billionoftheCompany’ssharesofcommonstock.Therepurchase
programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime.Anysharesacquiredwillbe
availableforgeneralcorporatepurposes.TheCompanyintendstofinancethesharerepurchaseprogramthroughavailable
cashandaccesstothecapitalmarkets.AsofJanuary1,2017,$7.3billionhasbeenrepurchasedundertheprogram.
OnJuly21,2014,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.Thissharerepurchase
programwascompletedonApril28,2015.
13. Accumulated Other Comprehensive Income
Componentsofothercomprehensiveincome(loss)consistofthefollowing:
Gain/ Total
Gain/ (Loss) Accumulated
Foreign (Loss) Employee On Other
Currency On Benefit Derivatives Comprehensive
(DollarsinMillions) Translation Securities Plans &Hedges Income(Loss)
December29,2013 $(202) 106 (3,009) 245 (2,860)
Net2014changes (4,601) 151 (3,308) (104) (7,862)
December28,2014 (4,803) 257 (6,317) 141 (10,722)
Net2015changes (3,632) 347 1,019 (177) (2,443)
January3,2016 (8,435) 604 (5,298) (36) (13,165)
Net2016changes (612) (193) (682) (249) (1,736)
January1,2017 $(9,047) 411 (5,980) (285) (14,901)
Amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpact.Foreigncurrency
translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiaries.For
additionaldetailsoncomprehensiveincomeseetheConsolidatedStatementsofComprehensiveIncome.
64 • Johnson&Johnson2016AnnualReportDetailsonreclassificationsoutofAccumulatedOtherComprehensiveIncome:
Gain/(Loss)OnSecurities–reclassificationsreleasedtoOther(income)expense,net.
EmployeeBenefitPlans–reclassificationsareincludedinnetperiodicbenefitcost.SeeNote10foradditional
details.
Gain/(Loss)OnDerivatives&Hedges–reclassificationstoearningsarerecordedinthesameaccountasthe
hedgedtransaction.SeeNote6foradditionaldetails.
14. International Currency Translation
Fortranslationofitssubsidiariesoperatinginnon-U.S.Dollarcurrencies,theCompanyhasdeterminedthatthelocal
currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomies,which
aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationof100%ormoreduringthepastthreeyears,
orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency.
Inconsolidatinginternationalsubsidiaries,balancesheetcurrencyeffectsarerecordedasacomponentofaccumulated
othercomprehensiveincome.Thisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand
liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalrates,exceptforthoselocatedinhighlyinflationary
economies.Thetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperatingresults.
Arollforwardofthechangesduring2016,2015and2014forforeigncurrencytranslationadjustmentsisincludedin
Note13.
NetcurrencytransactiongainsandlossesincludedinOther(income)expensewerelossesof$289million,$104million
and$156millionin2016,2015and2014,respectively.
15. Earnings Per Share
Thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended
January1,2017,January3,2016andDecember28,2014:
(InMillionsExceptPerShareAmounts) 2016 2015 2014
Basicnetearningspershare $6.04 5.56 5.80
Averagesharesoutstanding–basic 2,737.3 2,771.8 2,815.2
Potentialsharesexercisableunderstockoptionplans 142.4 141.5 142.6
Less:sharesrepurchasedundertreasurystockmethod (92.1) (102.6) (96.5)
Convertibledebtshares 1.3 2.2 2.6
Adjustedaveragesharesoutstanding–diluted 2,788.9 2,812.9 2,863.9
Dilutednetearningspershare $5.93 5.48 5.70
Thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelated
reductionininterestexpenseof$2millionafter-taxforyear2016,and$3millionforyears2015and2014.
Thedilutednetearningspersharecalculationfor2016,2015and2014includedallsharesrelatedtostockoptions,as
theexercisepriceofalloptionswaslessthantheaveragemarketvalueoftheCompany’sstock.
16. Rental Expense and Lease Commitments
Rentalsofspace,vehicles,manufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases
wereapproximately$330million,$316millionand$341millionin2016,2015and2014,respectively.
Johnson&Johnson2016AnnualReport • 65Theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnon-cancelable
leasetermsinexcessofoneyearatJanuary1,2017are:
(DollarsinMillions)
After
2017 2018 2019 2020 2021 2021 Total
$216 179 134 105 88 100 822
Commitmentsundercapitalleasesarenotsignificant.
17. Common Stock, Stock Option Plans and Stock Compensation Agreements
AtJanuary1,2017,theCompanyhad2stock-basedcompensationplans.Thesharesoutstandingareforcontractsunder
theCompany’s2005Long-TermIncentivePlanandthe2012Long-TermIncentivePlan.The2005Long-TermIncentive
PlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthe2012Long-
TermIncentivePlan.Underthe2012Long-TermIncentivePlan,theCompanymayissueupto650millionsharesof
commonstock,plusanysharescanceled,expired,forfeited,ornotissuedfromthe2005Long-TermIncentivePlan
subsequenttoApril26,2012.Sharesavailableforfuturegrantsunderthe2012Long-TermIncentivePlanwere
439millionattheendof2016.
Thecompensationcostthathasbeenchargedagainstincomefortheseplanswas$878million,$874millionand
$792millionfor2016,2015and2014,respectively.Thetotalincometaxbenefitrecognizedintheincomestatementfor
share-basedcompensationcostswas$256million,$253millionand$259millionfor2016,2015and2014,
respectively.Anadditionaltaxbenefitof$353millionwasrecognizedin2016duetotheadoptionofanewaccounting
standardforthereportingofadditionaltaxbenefitsonshare-basedcompensationasdescribedinNote1.Thetotal
unrecognizedcompensationcostwas$749million,$744millionand$722millionfor2016,2015and2014,respectively.
Theweightedaverageperiodforthiscosttoberecognizedwas1.09years,0.98yearsand1.18yearsfor2016,2015,
and2014,respectively.Share-basedcompensationcostscapitalizedaspartofinventorywereinsignificantinallperiods.
TheCompanysettlesemployeebenefitequityissuanceswithtreasuryshares.Treasurysharesarereplenishedthroughout
theyearforthenumberofsharesusedtosettleemployeebenefitequityissuances.
StockOptions
Stockoptionsexpire10yearsfromthedateofgrantandvestoverserviceperiodsthatrangefrom6monthsto4years.All
optionsaregrantedattheaverageofthehighandlowpricesoftheCompany’sCommonStockontheNewYorkStock
Exchangeonthedateofgrant.
ThefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheBlack-Scholesoptionvaluationmodel
thatusestheassumptionsnotedinthefollowingtable.For2014grants,expectedvolatilityrepresentsablendedrateof
4-yeardailyhistoricalaveragevolatilityrate,anda5-weekaverageimpliedvolatilityratebasedonat-the-moneytraded
Johnson&Johnsonoptionswithalifeof2years.For2016and2015grants,expectedvolatilityrepresentsablendedrate
of10-yearweeklyhistoricaloverallvolatilityrate,anda5-weekaverageimpliedvolatilityratebasedonat-the-money
tradedJohnson&Johnsonoptionswithalifeof2years.Forallgrants,historicaldataisusedtodeterminetheexpectedlife
oftheoption.Therisk-freeratewasbasedontheU.S.Treasuryyieldcurveineffectatthetimeofgrant.
Theaveragefairvalueofoptionsgrantedwas$10.01,$10.68and$8.42,in2016,2015and2014,respectively.Thefair
valuewasestimatedbasedontheweightedaverageassumptionsof:
2016 2015 2014
Risk-freerate 1.51% 1.77% 1.87%
Expectedvolatility 15.76% 15.48% 14.60%
Expectedlife(inyears) 7.0 7.0 6.0
Expecteddividendyield 3.10% 2.90% 3.10%
66 • Johnson&Johnson2016AnnualReportAsummaryofoptionactivityunderthePlanasofJanuary1,2017,January3,2016andDecember28,2014,and
changesduringtheyearsendingonthosedatesispresentedbelow:
Aggregate
Intrinsic
Weighted Value
Outstanding Average (Dollarsin
(SharesinThousands) Shares ExercisePrice Millions)
SharesatDecember29,2013 119,556 $64.70 $3,306
Optionsgranted 24,356 90.44
Optionsexercised (25,319) 62.31
Optionscanceled/forfeited (2,881) 75.48
SharesatDecember28,2014 115,712 70.37 4,014
Optionsgranted 20,484 100.06
Optionsexercised (16,683) 62.53
Optionscanceled/forfeited (2,996) 82.22
SharesatJanuary3,2016 116,517 76.41 3,065
Optionsgranted 22,491 101.87
Optionsexercised (22,547) 65.66
Optionscanceled/forfeited (3,006) 92.83
SharesatJanuary1,2017 113,455 $83.16 $3,636
Thetotalintrinsicvalueofoptionsexercisedwas$980million,$644millionand$954millionin2016,2015and2014,
respectively.
ThefollowingtablesummarizesstockoptionsoutstandingandexercisableatJanuary1,2017:
(SharesinThousands) Outstanding Exercisable
Average Average
Average Exercise Exercise
ExercisePriceRange Options Life(1) Price Options Price
$52.13-$58.33 7,361 2.1 $58.32 7,361 $58.32
$58.34-$62.20 11,297 2.4 $61.95 11,297 $61.95
$62.62-$65.62 14,380 3.1 $64.24 14,380 $64.24
$66.07-$72.54 18,127 6.0 $72.52 17,241 $72.52
$90.44-$101.87 62,290 8.1 $97.40 135 $93.73
113,455 6.2 $83.16 50,414 $65.77
(1) Averagecontractualliferemaininginyears.
StockoptionsoutstandingatJanuary3,2016andDecember28,2014were116,517andanaveragelifeof5.9yearsand
115,712andanaveragelifeof5.7years,respectively.StockoptionsexercisableatJanuary3,2016andDecember28,
2014were48,345atanaveragepriceof$62.26and57,846atanaveragepriceof$61.94,respectively.
RestrictedShareUnitsandPerformance ShareUnits
TheCompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrom6monthsto3years.The
Companyalsograntsperformanceshareunits,whicharepaidinsharesofJohnson&JohnsonCommonStockafterthe
endofathree-yearperformanceperiod.Whetheranyperformanceshareunitsvest,andtheamountthatdoesvest,istied
tothecompletionofserviceperiodsthatrangefrom6monthsto3yearsandtheachievement,overathree-yearperiod,of
threeequally-weightedgoalsthatdirectlyalignwithorhelpdrivelong-termtotalshareholderreturn:operationalsales,
adjustedoperationalearningspershare,andrelativetotalshareholderreturn.Thenumberofsharesactuallyearnedatthe
endofthethree-yearperiodwillvary,basedonlyonactualperformance,from0%to200%ofthetargetnumberof
performanceshareunitsgranted.
Johnson&Johnson2016AnnualReport • 67AsummaryoftherestrictedshareunitsandperformanceshareunitsactivityunderthePlansasofJanuary1,2017is
presentedbelow:
Outstanding Outstanding
Restricted Performance
(SharesinThousands) ShareUnits ShareUnits
SharesatDecember29,2013 30,617 1,535
Granted 8,487 1,113
Issued (9,685) (19)
Canceled/forfeited (1,726) (98)
SharesatDecember28,2014 27,693 2,531
Granted 7,637 931
Issued (10,164) (285)
Canceled/forfeited (1,281) (99)
SharesatJanuary3,2016 23,885 3,078
Granted 7,173 958
Issued (8,913) (1,437)
Canceled/forfeited (1,084) (184)
SharesatJanuary1,2017 21,061 2,415
Theaveragefairvalueoftherestrictedshareunitsgrantedwas$92.45,$91.65and$83.01in2016,2015and2014,
respectively,usingthefairmarketvalueatthedateofgrant.Thefairvalueofrestrictedshareunitswasdiscountedfor
dividends,whicharenotpaidontherestrictedshareunitsduringthevestingperiod.Thefairvalueofrestrictedshareunits
issuedwas$587.7million,$597.6millionand$541.0millionin2016,2015and2014,respectively.
Theweightedaveragefairvalueoftheperformanceshareunitsgrantedwas$105.30,$93.54and$85.94in2016,2015and
2014,calculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthedateofgrant.
Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof
grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividends,whicharenotpaidonthe
performanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeach
performanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.Thefairvalueof
performanceshareunitsissuedwas$127.7million,$16.7millionand$1.4millionin2016,2015and2014,respectively.
18. Segments of Business and Geographic Areas
SalestoCustomers
(DollarsinMillions) 2016 2015 2014
Consumer–
UnitedStates $5,420 5,222 5,096
International 7,887 8,285 9,400
Total 13,307 13,507 14,496
Pharmaceutical–
UnitedStates 20,125 18,333 17,432
International 13,339 13,097 14,881
Total 33,464 31,430 32,313
MedicalDevices–
UnitedStates 12,266 12,132 12,254
International 12,853 13,005 15,268
Total 25,119 25,137 27,522
Worldwidetotal $71,890 70,074 74,331
68 • Johnson&Johnson2016AnnualReportIncomeBeforeTax IdentifiableAssets
(DollarsinMillions) 2016(3) 2015(4) 2014(5) 2016 2015
Consumer $2,441 1,787 1,941 $23,971 20,772
Pharmaceutical 12,827 11,734 11,696 27,477 26,144
MedicalDevices 5,578 6,826 7,953 39,773 40,979
Total 20,846 20,347 21,590 91,221 87,895
Less:Expensenotallocatedtosegments(1) 1,043 1,151 1,027
Generalcorporate(2) 49,987 45,516
Worldwidetotal $19,803 19,196 20,563 $141,208 133,411
AdditionstoProperty, Depreciationand
Plant&Equipment Amortization
(DollarsinMillions) 2016 2015 2014 2016 2015 2014
Consumer $486 544 581 $608 559 577
Pharmaceutical 927 1,063 977 886 929 1,053
MedicalDevices 1,472 1,631 1,807 1,928 1,945 1,974
Segmentstotal 2,885 3,238 3,365 3,422 3,433 3,604
Generalcorporate 341 225 349 332 313 291
Worldwidetotal $3,226 3,463 3,714 $3,754 3,746 3,895
SalestoCustomers Long-LivedAssets(6)
(DollarsinMillions) 2016 2015 2014 2016 2015
UnitedStates $37,811 35,687 34,782 $36,934 36,609
Europe 15,770 15,995 18,947 21,996 20,167
WesternHemisphereexcludingU.S. 5,734 6,045 7,160 2,961 2,881
Asia-Pacific,Africa 12,575 12,347 13,442 2,512 2,493
Segmentstotal 71,890 70,074 74,331 64,403 62,150
Generalcorporate 1,190 1,148
Othernonlong-livedassets 75,615 70,113
Worldwidetotal $71,890 70,074 74,331 $141,208 133,411
SeeNote1foradescriptionofthesegmentsinwhichtheCompanyoperates.
Exportsalesarenotsignificant.In2016,theCompanyhadtwowholesalersdistributingproductsforallthreesegments
thatrepresentedapproximately13.5%and10.7%ofthetotalconsolidatedrevenues.In2015and2014,theCompany
hadonewholesalerdistributingproductsforallthreesegmentsthatrepresentedapproximately12.5%and11.0%,
respectively,ofthetotalconsolidatedrevenues.
(1) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
(2) Generalcorporateincludescash,cashequivalentsandmarketablesecurities.
(3) Includesnetlitigationexpenseof$806millionandarestructuringrelatedchargeof$685millionintheMedicalDevicessegment.
ThePharmaceuticalsegmentincludesapositiveadjustmentof$0.5billiontopreviousreserveestimates,anin-processresearchand
developmentexpenseof$29million,andgainsfromthedivestituresofthecontrolledsubstancerawmaterialandactive
pharmaceuticalingredient(API)businessandcertainanestheticproductsinEurope.
(4) TheMedicalDevicessegmentincludesarestructuringrelatedchargeof$590million,anintangibleassetwrite-downof$346million
relatedtoAcclarent,Synthesintegrationcostsof$196millionand$148millionexpenseforthecostassociatedwiththeDePuyASR
TMHipprogram.Includes$224millionofin-processresearchanddevelopmentexpense,comprisedof$214millionand$10million
inthePharmaceuticalandMedicalDevicessegments,respectively.Includesnetlitigationexpenseof$141millioncomprisedof
$136millioninthePharmaceuticalsegmentand$5millionintheMedicalDevicessegment,whichincludedthegainfromthe
litigationsettlementagreementwithGuidantfor$600million.TheMedicalDevicesSegmentincludesagainof$1.3billionfromthe
divestitureoftheCordisbusiness.ThePharmaceuticalsegmentincludesagainof$981millionfromtheU.S.divestitureof
NUCYNTA®andapositiveadjustmentof$0.5billiontopreviousreserveestimates,includingManagedMedicaidrebates.The
Consumersegmentincludesagainof$229millionfromthedivestitureofSPLENDA®brand.
Johnson&Johnson2016AnnualReport • 69(5) Includesnetlitigationexpenseof$1,253millioncomprisedof$907million,$259millionand$87millionintheMedicalDevices,
PharmaceuticalandConsumersegments,respectively.Includes$178millionofin-processresearchanddevelopmentexpense,
comprisedof$147millionand$31millioninthePharmaceuticalandMedicalDevicessegments,respectively.TheMedicalDevices
segmentincludesanetgainof$1,899millionfromthedivestitureoftheOrtho-ClinicalDiagnosticsbusiness,Synthesintegration
costsof$754millionand$126millionexpenseforthecostassociatedwiththeDePuyASRTMHipprogram.ThePharmaceutical
segmentincludesanadditionalyearoftheBrandedPrescriptionDrugFeeof$220millionandapositiveadjustmentof$0.1billionto
previousreserveestimates.
(6) Long-livedassetsincludeproperty,plantandequipment,netfor2016,and2015of$15,912and$15,905,respectively,and
intangibleassetsandgoodwill,netfor2016and2015of$49,681and$47,393,respectively.
19. Selected Quarterly Financial Data (unaudited)
Selectedunauditedquarterlyfinancialdatafortheyears2016and2015aresummarizedbelow:
2016 2015
(DollarsinMillionsExceptPerShare First Second Third Fourth First Second Third Fourth
Data) Quarter(1) Quarter(2) Quarter(3) Quarter(4) Quarter(5) Quarter(6) Quarter(7) Quarter(8)
Segmentsalestocustomers
Consumer $3,195 3,419 3,261 3,432 3,390 3,483 3,314 3,320
Pharmaceutical 8,178 8,654 8,400 8,232 7,726 7,946 7,694 8,064
MedicalDevices 6,109 6,409 6,159 6,442 6,258 6,358 6,094 6,427
Totalsales 17,482 18,482 17,820 18,106 17,374 17,787 17,102 17,811
Grossprofit 12,153 13,146 12,334 12,572 12,092 12,430 11,878 12,138
Earningsbeforeprovisionfortaxeson
income 5,294 4,904 5,281 4,324 5,575 5,741 4,122 3,758
Netearnings 4,457 3,997 4,272 3,814 4,320 4,516 3,358 3,215
Basicnetearningspershare $1.62 1.46 1.56 1.41 1.55 1.63 1.21 1.16
Dilutednetearningspershare $1.59 1.43 1.53 1.38 1.53 1.61 1.20 1.15
(1) ThefirstquarterhasbeenrecasttoreflecttheadoptionofASU2016-09.SeeNote1totheConsolidatedFinancialStatementsfor
moredetails.Thefirstquarterof2016includesarestructuringchargeof$120millionafter-tax($137millionbefore-tax)andnet
litigationexpenseof$56millionafter-tax($66millionbefore-tax).
(2) Thesecondquarterof2016includesarestructuringchargeof$97millionafter-tax($141millionbefore-tax)andnetlitigation
expenseof$493millionafter-tax($600millionbefore-tax).
(3) Thethirdquarterof2016includesarestructuringchargeof$76millionafter-tax($109millionbefore-tax)andnetlitigationexpense
of$46millionafter-tax($55millionbefore-tax).
(4) Thefourthquarterof2016includesarestructuringchargeof$251millionafter-tax($298millionbefore-tax)andnetlitigation
expenseof$80millionafter-tax($96millionbefore-tax).
(5) Thefirstquarterof2015includesanetlitigationgainof$253millionafter-tax($402millionbefore-tax)and$122millionafter-tax
($139millionbefore-tax)forcostsassociatedwiththeDePuyASRTMHipprogram.
(6) Thesecondquarterof2015includesnetlitigationexpenseof$23millionafter-tax($134millionbefore-tax).
(7) Thethirdquarterof2015includesnetlitigationexpenseof$348millionafter-tax($409millionbefore-tax).
(8) Thefourthquarterof2015includesarestructuringchargeof$415millionafter-tax($590millionbefore-tax),$156millionafter-tax
($214millionbefore-tax)fromimpairmentofin-processresearchanddevelopmentandSynthesintegrationcostsof$59millionafter-
tax($83millionbefore-tax).Additionally,thefourthquarterof2015includesthegainontheCordisdivestiture.
70 • Johnson&Johnson2016AnnualReport20. Business Combinations and Divestitures
Certainbusinesseswereacquiredfor$4,509millionincashand$77millionofliabilitiesassumedduring2016.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2016acquisitionsprimarilyincluded:VogueInternationalLLC,aprivately-heldcompanyfocusedonthemarketing,
developmentanddistributionofsalon-influencedandnatureinspiredhaircareandotherpersonalproducts;NeuWave
Medical,Inc.,aprivately-heldmedicaldevicecompanythatmanufacturesandmarketsminimallyinvasivesofttissue
microwaveablationsystems;NeoStrataCompany,Inc.,agloballeaderindermocosmetics,andtheglobalrightsforthe
commercializationofRHINOCORT®allergysprayoutsidetheUnitedStates.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$4,077millionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
ThenetpurchasepriceforVogueInternationalLLCof$3.3billionwasprimarilyrecordedasamortizableintangibleassets
for$2.3billionandgoodwillfor$1.1billion.Theweightedaveragelifeforthe$2.3billionoftotalamortizableintangiblesis
approximately22years.Thetrademarkassetvaluesweredeterminedtohavedefinitelivesrangingfrom10to22years,
withthemajoritybeing22years.Thegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness
acquisitionandisexpectedtobedeductiblefortaxpurposes.TheassetsacquiredwererecordedintheConsumer
segment.
Duringthefiscalthirdquarterof2016,theCompanyannouncedadefinitiveagreementtoacquireAbbottMedicalOptics
(AMO),awholly-ownedsubsidiaryofAbbottLaboratories,for$4.325billionincash.Theacquisitionwillinclude
ophthalmicproductsrelatedto:cataractsurgery,laserrefractivesurgeryandconsumereyehealth.Thetransactionclosed
onFebruary27,2017.Thepurchasepriceallocationisinprogressandisexpectedtoresultinanallocationofsignificant
valuetotheamortizableintangibleassetswithanyresidualrecordedasgoodwill.
OnJanuary26,2017,subsequenttoyearend,theCompanyannouncedadefinitivetransactionagreementunderwhich
thecompanywilllaunchanall-cashtenderofferinSwitzerlandtoacquirealloftheoutstandingsharesofActelionLtd.for
$280pershare,payableinU.S.dollars,forapproximately$30.0billion.Aspartofthetransaction,immediatelypriortothe
completionoftheacquisition,Actelionwillspinoutitsdrugdiscoveryoperationsandearly-stageclinicaldevelopment
assetsintoanewlycreatedSwissbiopharmaceuticalcompany(“R&DNewCo”).ThesharesofR&DNewCo,whichwillbe
listedontheSIXSwissExchange(SIX),willbedistributedtoActelion’sshareholdersasastockdividenduponclosingof
thetender.TheCompanywillinitiallyhold16%ofthesharesofR&DNewCoandhaverightstoanadditional16%ofR&D
NewCoequitythroughaconvertiblenote.Actelionhasestablishedaleadingfranchiseofdifferentiated,innovative
productsforpulmonaryarterialhypertension(PAH)thatishighlycomplementarytotheexistingportfoliooftheCompany.
TheadditionofActelion’sspecialtyin-marketmedicinesandlate-stageproductsisconsistentwiththeCompany’sefforts
togrowinattractiveandcomplementarytherapeuticareasandservepatientswithseriousillnessesandsignificantunmet
medicalneed.Theclosingissubjecttothedemerger,antitrustclearanceandothercustomaryclosingconditions.
OnFebruary15,2017,subsequenttoyearend,theCompanyreceivedabindingofferfromIntegraLifeSciencesHoldings
CorporationtopurchasetheCodmanNeurosurgerybusinessforapproximately$1.0billion.
Subsequenttoyearend,theCompanyannounceditisengaginginaprocesstoevaluatepotentialstrategicoptionsfor
theJohnson&JohnsonDiabetesCareCompanies,specificallyLifeScan,Inc.,AnimasCorporation,andCalibraMedical,
Inc.Strategicoptionsmayincludetheformationofoperatingpartnerships,jointventuresorstrategicalliances,asaleof
thebusinesses,orotheralternativeseitherseparatelyortogether.Alloptionswillbeevaluatedtodeterminethebest
opportunitytodrivefuturegrowthandmaximizeshareholdervalue.Therecanbenoassurancethatthisprocesswillresult
inanytransactionorotherstrategicalternativeofanykindtherefore,therewerenoassetsheldforsaleasofJanuary1,
2017relatedtotheannouncement.
Certainbusinesseswereacquiredfor$954millionincashand$220millionofliabilitiesassumedduring2015.The
assumedliabilitiesprimarilyrepresentthefairvalueofthecontingentconsiderationof$210million.Theseacquisitions
wereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincludedinthe
financialstatementsfromtheirrespectivedatesofacquisition.
The2015acquisitionsprimarilyincluded:XO1Limited,aprivately-heldbiopharmaceuticalcompanydevelopingananti-
thrombinantibodyandNoviraTherapeutics,Inc.,aprivatelyheldclinical-stagebiopharmaceuticalcompanydeveloping
innovativetherapiesforcurativetreatmentofchronichepatitisBvirusinfection.
Johnson&Johnson2016AnnualReport • 71Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$1,173millionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately$839
millionhasbeenidentifiedasthevalueofIPR&DprimarilyassociatedwiththeacquisitionsofXO1LimitedandNovira
Therapeutics,Inc.ThevalueoftheIPR&Dwascalculatedusingcashflowprojectionsdiscountedfortheinherentriskin
theprojects.
TheIPR&DrelatedtotheacquisitionofXO1Limitedof$360millionisassociatedwitharecombinanthumanantibody
developedtomimictheactivityofahumanantibodywhichappearstoproduceananticoagulatedstatewithout
predispositiontobleeding.Aprobabilityofsuccessfactorof36.0%wasusedtoreflectinherentclinicalandregulatory
risk.Thediscountrateappliedwas11.75%.
TheIPR&DrelatedtotheacquisitionofNoviraTherapeutics,Inc.of$396millionisassociatedwithitsleadcandidateNVR
3-778whichisaninvestigationalsmallmolecule,direct-actingantiviral,fororaladministrationinpatientswithHBVthat
inhibitstheHBVcoreorcapsidprotein.Aprobabilityofsuccessfactorof51.0%wasusedtoreflectinherentclinicaland
regulatoryrisk.Thediscountrateappliedwas16.0%.
Certainbusinesseswereacquiredfor$2,129millionincashand$38millionofliabilitiesassumedduring2014.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2014acquisitionsincluded:CovagenAG,aprivately-held,biopharmaceuticalcompanyspecializinginthe
developmentofmultispecificproteintherapeuticsthroughtheFynomAb®technologyplatform;AliosBioPharma,Inc.,a
privately-held,clinicalstagebiopharmaceuticalcompanyfocusedondevelopingtherapiesforviraldiseases;andthe
ORSLTMelectrolyteready-to-drinkbrandfromJagdaleIndustriesLtd.Theexcessofpurchasepriceovertheestimatedfair
valueoftangibleassetsacquiredamountedto$2,069millionandhasbeenassignedtoidentifiableintangibleassets,with
anyresidualrecordedtogoodwill.Ofthisamount,approximately$1,913millionhasbeenidentifiedasthevalueofIPR&D
associatedwiththeacquisitionsofCovagenAGandAliosBioPharma,Inc.ThevalueoftheIPR&Dwascalculatedusing
cashflowprojectionsdiscountedfortheinherentriskintheprojects.
TheIPR&DrelatedtotheacquisitionofAliosBioPharma,Inc.of$1,688millionisassociatedwithAlios’leadcompound
AL-8176,anorallyadministeredantiviraltherapyfortreatmentofinfantswithrespiratorysyncytialvirus(RSV).Aprobability
ofsuccessfactorof60.0%wasusedtoreflectinherentclinicalandregulatoryrisk.Thediscountrateappliedwas11.4%.
TheIPR&DrelatedtotheacquisitionofCovagenAGof$225millionisassociatedwithCovagen’sleadcompound
COVA-322,currentlyinPhase1bstudyforpsoriasisandholdingpotentialasatreatmentforabroadrangeof
inflammatorydiseasesincludingrheumatoidarthritis.Aprobabilityofsuccessfactorof26.0%wasusedtoreflectinherent
clinicalandregulatoryrisk.Thediscountrateappliedwas12.5%.During2015,theCompanyrecordedachargeforthe
impairmentoftheIPR&DrelatedtotheacquisitionofCovagenAG.
In2012,theCompanycompletedtheacquisitionofSynthes,Inc.forapurchasepriceof$20.2billionincashandstock.
InconnectionwiththeacquisitionofSynthes,Inc.theCompanyenteredintotwoacceleratedsharerepurchase(ASR)
agreements.In2013,theCompanysettledtheremainingliabilitiesundertheASRagreements.WhiletheCompany
believesthatthetransactionsundereachASRagreementandaseriesofrelatedinternaltransactionswereconsummated
inataxefficientmannerinaccordancewithapplicablelaw,itispossiblethattheInternalRevenueServicecouldassert
oneormorecontrarypositionstochallengethetransactionsfromataxperspective.Ifchallenged,anamountuptothe
totalpurchasepricefortheSynthessharescouldbetreatedassubjecttoapplicableU.S.taxatapproximatelythe
statutoryratetotheCompany,plusinterest.
Supplementalproformainformationfor2016,2015and2014inaccordancewithU.S.GAAPstandardsrelatedto
businesscombinations,andgoodwillandotherintangibleassets,isnotprovided,astheimpactoftheaforementioned
acquisitionsdidnothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
During2016,theCompanydivestituresincluded:thecontrolledsubstancerawmaterialandactivepharmaceutical
ingredient(API)business;certainanestheticproductsinEurope;andcertainnon-strategicConsumerbrands.In2016,the
pre-taxgainsonthedivestitureswereapproximately$0.6billion.
During2015,theCompanydivestituresincluded:theCordisbusinesstoCardinalHealth;theSPLENDA®brandto
HeartlandFoodProductsGroup;andtheU.S.licenserightstoNUCYNTA®(tapentadol),NUCYNTA®ER(tapentadol
extended-releasetablets),andNUCYNTA®(tapentadol)oralsolution.In2015,thepre-taxgainsonthedivestitureswere
approximately$2.6billion.
During2014,theCompanydivestituresincluded:theOrtho-ClinicalDiagnosticsbusinesstoTheCarlyleGroup;theK-Y®
brandtoReckittBenckiserGroupPLCintheU.S.andcertainothermarkets;andtheBENECOL®brandtoRaisioplc.
72 • Johnson&Johnson2016AnnualReportIn2014,thepre-taxgainsonthedivestitureswereapproximately$2.4billion.TheCompanycompletedthedivestitureof
itsOrtho-ClinicalDiagnosticsbusinesstoTheCarlyleGroupforapproximately$4.0billionandtheCompanyrecordeda
pre-taxgainofapproximately$1.9billion.Ortho-ClinicalDiagnostics’resultsareincludedintheCompany’sMedical
Devicessegment.
21. Legal Proceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseoftheirbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.AsofJanuary1,2017,theCompanyhas
determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.The
Companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight
bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Fortheseand
otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,theCompany
isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.Amountsaccruedforlegal
contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon
estimatesandassumptions.Theabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactors,
includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscovery
hasnotcommencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;thereare
significantfactsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
ProductLiability
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving
multipleproducts.Claimantsinthesecasesseeksubstantialcompensatoryand,whereavailable,punitivedamages.While
theCompanybelievesithassubstantialdefenses,itisnotfeasibletopredicttheultimateoutcomeoflitigation.The
CompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithASC450-20basedon
currentlyavailableinformation,whichinsomecasesmaybelimited.TheCompanyaccruesanestimateofthelegal
defensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonablyestimated.Forcertain
ofthesematters,theCompanyhasaccruedadditionalamountssuchasestimatedcostsassociatedwithsettlements,
damagesandotherlosses.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,theCompanydoes
notrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.Productliabilityaccruals
canrepresentprojectedproductliabilityforthousandsofclaimsaroundtheworld,eachindifferentlitigationenvironments
andwithdifferentfactpatterns.Changestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes
available.
ThemostsignificantofthesecasesincludetheDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacing
System,thePINNACLE®AcetabularCupSystem,pelvicmeshes,RISPERDAL®,XARELTO®andJOHNSON’S®Baby
Powder.AsofJanuary1,2017,intheU.S.therewereapproximately2,000plaintiffswithdirectclaimsinpendinglawsuits
regardinginjuriesallegedlyduetotheDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacingSystem,
9,400withrespecttothePINNACLE®AcetabularCupSystem,54,800withrespecttopelvicmeshes,18,500with
respecttoRISPERDAL®,16,900withrespecttoXARELTO®and3,100withrespecttoJOHNSON’S®BabyPowder.
InAugust2010,DePuyOrthopaedics,Inc.(DePuy)announcedaworldwidevoluntaryrecallofitsASR™XLAcetabular
SystemandDePuyASR™HipResurfacingSystemusedinhipreplacementsurgery.Claimsforpersonalinjuryhavebeen
madeagainstDePuyandJohnson&Johnson.Thenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits
aresettledordismissedandadditionallawsuitsarefiled.CasesfiledinfederalcourtsintheUnitedStateshavebeen
organizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheNorthernDistrictofOhio.Litigationhas
alsobeenfiledincountriesoutsideoftheUnitedStates,primarilyintheUnitedKingdom,Canada,Australia,Ireland,
Johnson&Johnson2016AnnualReport • 73GermanyandItaly.InNovember2013,DePuyreachedanagreementwithaCourt-appointedcommitteeoflawyers
representingASRHipSystemplaintiffstoestablishaprogramtosettleclaimswitheligibleASRHippatientsintheUnited
StateswhohadsurgerytoreplacetheirASRHips,knownasrevisionsurgery,asofAugust31,2013.Thissettlement
coveredapproximately8,000patients.InFebruary2015,DePuyreachedanadditionalagreement,whicheffectively
extendstheexistingsettlementprogramtoASRHippatientswhohadrevisionsurgeriesafterAugust31,2013andprior
toFebruary1,2015.Thissecondagreementisestimatedtocoverapproximately1,800additionalpatients.Theestimated
costoftheseagreementsiscoveredbyexistingaccruals.Thissettlementprogramisexpectedtobringtoaclose
significantASRHiplitigationactivityintheUnitedStates.However,manylawsuitsintheUnitedStateswillremain,andthe
settlementprogramdoesnotaddresslitigationoutsideoftheUnitedStates.InAustralia,asettlementwasreachedwith
representativesofaclassactionlawsuitpendingintheFederalCourtofNewSouthWalesthatresolvestheclaimsofthe
majorityofASRHippatientsinthatcountry.TheCompanycontinuestoreceiveinformationwithrespecttopotentialcosts
associatedwiththisrecallonaworldwidebasis.TheCompanyhasestablishedaccrualsforthecostsassociatedwiththe
DePuyASR™Hipprogramandrelatedproductliabilitylitigation.Changestotheseaccrualsmayberequiredinthefuture
asadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavealsobeenmadeagainstDePuyandJohnson&JohnsonrelatingtothePINNACLE®
AcetabularCupSystemusedinhipreplacementsurgery.Thenumberofpendingproductliabilitylawsuitscontinuesto
increase,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof
cases.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationintheUnited
StatesDistrictCourtfortheNorthernDistrictofTexas.LitigationhasalsobeenfiledincountriesoutsideoftheUnited
States,primarilyintheUnitedKingdom.TheCompanyhasestablishedanaccrualfordefensecostsinconnectionwith
productliabilitylitigationassociatedwiththePINNACLE®AcetabularCupSystem.Changestothisaccrualmaybe
requiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andJohnson&JohnsonarisingoutofEthicon’s
pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapse.Thenumberofpendingproduct
liabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcosts
andtheanticipatednumberofcases.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-
districtlitigationintheUnitedStatesDistrictCourtfortheSouthernDistrictofWestVirginia.Inaddition,classactionsand
individualpersonalinjurycasesorclaimshavebeencommencedinvariouscountriesoutsideoftheUnitedStates,
includingclaimsandcasesintheUnitedKingdom,theNetherlands,Belgium,ItalyandVenezuela,andclassactionsin
Israel,AustraliaandCanada,seekingdamagesforallegedinjuryresultingfromEthicon’spelvicmeshdevices.The
CompanyhasestablishedanaccrualwithrespecttoproductliabilitylitigationassociatedwithEthicon’spelvicmesh
products.Changestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstJanssenPharmaceuticals,Inc.andJohnson&Johnsonarisingoutofthe
useofRISPERDAL®,indicatedforthetreatmentofschizophrenia,acutemanicormixedepisodesassociatedwithbipolarI
disorderandirritabilityassociatedwithautism,andrelatedcompounds.Lawsuitshavebeenprimarilyfiledinstatecourtsin
Pennsylvania,California,andMissouri.OtheractionsarependinginvariouscourtsintheUnitedStatesandCanada.The
numberofpendingproductliabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwith
respecttopotentialcostsandtheanticipatednumberofcases.TheCompanyhasestablishedanaccrualwithrespectto
productliabilitylitigationassociatedwithRISPERDAL®.Changestothisaccrualmayberequiredinthefutureas
additionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstJanssenPharmaceuticals,Inc.andJohnson&Johnsonarisingoutofthe
useofXARELTO®,anoralanticoagulant.Thenumberofpendingproductliabilitylawsuitscontinuestoincrease,andthe
Companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcases.Cases
filedinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationintheUnitedStatesDistrict
CourtfortheEasternDistrictofLouisiana.Inaddition,caseshavebeenfiledinstatecourtsacrosstheUnitedStates.
ManyofthesecaseshavebeenconsolidatedintoastatemasstortlitigationinPhiladelphia,Pennsylvania;andthereare
coordinatedproceedingsinDelaware,CaliforniaandMissouri.ClassactionlawsuitsalsohavebeenfiledinCanada.The
Companyhasestablishedanaccrualfordefensecostsinconnectionwithproductliabilitylitigationassociatedwith
XARELTO®.Changestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstJohnson&JohnsonConsumerInc.andJohnson&Johnsonarisingout
oftheuseofJOHNSON’S®BabyPowder.Thenumberofpendingproductliabilitylawsuitscontinuestoincrease,andthe
Companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcases.Lawsuits
havebeenprimarilyfiledinstatecourtsinMissouri,NewJerseyandCalifornia.Inaddition,afederalmulti-districtlitigation
proceedinghasbeencreatedforthislitigationintheDistrictCourtofNewJersey.TheCompanyhasestablishedan
74 • Johnson&Johnson2016AnnualReportaccrualfordefensecostsinconnectionwithproductliabilitylitigationassociatedwithJOHNSON’S®Baby
Powder.Changestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable.
IntellectualProperty
CertainsubsidiariesofJohnson&Johnsonaresubject,fromtimetotime,tolegalproceedingsandclaimsrelatedto
patent,trademarkandotherintellectualpropertymattersarisingoutoftheirbusinesses.Manyofthesemattersinvolve
challengestothecoverageand/orvalidityofthepatentsonvariousproductsandallegationsthatcertainoftheCompany’s
productsinfringethepatentsofthirdparties.Althoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto
thesechallengesandallegationswithrespecttoallsignificantpatents,therecanbenoassuranceastotheoutcomeof
thesematters.Alossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts,
resultinlossofsalesduetolossofmarketexclusivity,requirethepaymentofpastdamagesandfutureroyalties,andmay
resultinanon-cashimpairmentchargeforanyassociatedintangibleasset.Themostsignificantofthesemattersare
describedbelow.
MedicalDevices
InJune2009,RembrandtVisionTechnologies,L.P.(Rembrandt)filedapatentinfringementlawsuitagainstJohnson&
JohnsonVisionCare,Inc.(JJVCI)intheUnitedStatesDistrictCourtfortheEasternDistrictofTexasallegingthatJJVCI’s
manufactureandsaleofitsACUVUE®ADVANCEandACUVUEOASYS®HydrogelContactLensesinfringetheirU.S.
PatentNo.5,712,327(the‘327patent).Rembrandtisseekingmonetaryrelief.ThecasewastransferredtotheUnited
StatesDistrictCourtfortheMiddleDistrictofFlorida.InMay2012,thejuryreturnedaverdictholdingthatneitherofthe
accusedlensesinfringesthe‘327patent.Rembrandtappealed,andinAugust2013,theUnitedStatesCourtofAppeals
fortheFederalCircuitaffirmedtheDistrictCourt’sjudgment.RembrandtaskedtheDistrictCourttograntitanewtrial
basedonallegednewevidence,andinJuly2014,theDistrictCourtdeniedRembrandt’smotion.Rembrandtappealed
andtheCourtofAppealsoverturnedthatrulinginApril2016andremandedthecasetotheDistrictCourtforanewtrial.
JJVCI’smotiontoreconsiderandpetitionforreviewwiththeUnitedStatesSupremeCourtwerebothdenied.Anewtrial
isscheduledforAugust2017.
InDecember2009,theStateofIsraelfiledalawsuitintheDistrictCourtinTelAvivJaffaagainstOmrix
Biopharmaceuticals,Inc.andvariousaffiliates(Omrix).Inthelawsuit,theStateclaimedthatanemployeeofagovernment-
ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe
wasagovernmentemployee.TheStateclaimedthathehadnorighttotransferanyintellectualpropertytoOmrixbecause
itbelongstotheState.TheStatesoughtdamagesplusroyaltiesonQUIXIL™andEVICEL®products,oralternatively,
transferofthepatentstotheState.ThecasewassettledinDecember2016.
LifeScanfiledapatentinfringementlawsuitagainstUniStripTechnologies,LLC(UniStrip)intheUnitedStatesDistrict
CourtfortheDistrictofNorthCarolinainMay2014,allegingthatthemakingandmarketingofUniStrip’sstripsforusein
LifeScan’sbloodglucosemonitorsinfringeU.S.PatentNos.6,241,862(the‘862patent)and7,250,105(the‘105
patent).InAugust2014,theUnitedStatesPatentandTrademarkOffice(USPTO)determinedthatthe‘105patentis
invalid.InJanuary2016,theinvaliditydecisionwasupheldonappeal.LifeScanfiledamotionforrehearing,whichwas
denied.InJuly2014,UniStripbroughtalawsuitagainstLifeScanintheUnitedStatesDistrictCourtfortheEasternDistrict
ofPennsylvania,allegingantitrustviolationsrelatingtomarketingpracticesforLifeScanstrips.
InMarch2013,MedinolLtd.(Medinol)filedapatentinfringementlawsuitagainstCordisCorporation(Cordis)and
Johnson&JohnsonintheUnitedStatesDistrictCourtfortheSouthernDistrictofNewYorkallegingthatallofCordis’s
salesoftheCYPHER™andCYPHERSELECT™StentsmadeintheUnitedStatessince2005willfullyinfringedfourof
Medinol’spatentsdirectedtothegeometryofarticulatedstents.Medinolisseekingdamagesandattorneys’fees.After
trialinJanuary2014,theDistrictCourtdismissedthecase,findingMedinolunreasonablydelayedbringingitsclaims,and
Medinoldidnotappealthedecision.InSeptember2014,theDistrictCourtdeniedamotionbyMedinoltovacatethe
judgmentandgrantitanewtrial.Medinol’sappealofthisdecisionhasbeendismissed.Medinolhasfiledapetitionfor
reviewwiththeUnitedStatesSupremeCourt.Cordiswasdivestedin2015andtheCompanyretainedanyliabilitythat
mayresultfromthiscase.
InNovember2016,MedIdea,L.L.C.(MedIdea)filedapatentinfringementlawsuitagainstDePuyOrthopaedics,Inc.inthe
UnitedStatesDistrictCourtfortheNorthernDistrictofIllinoisalleginginfringementbytheATTUNE®KneeSystemoftwo
patentsrelatingtoposteriorstabilizedkneesystems.Specifically,MedIdeaallegesthattheSOFCAMTMContactfeatureof
theATTUNE®posteriorstabilizedkneeproductsinfringesthepatents-in-suit.MedIdeaisseekingmonetarydamagesand
injunctiverelief.
Johnson&Johnson2016AnnualReport • 75InDecember2016,EthiconEndo-Surgery,Inc.andEthiconEndo-Surgery,LLC(nowknownasEthiconLLC)sued
Covidien,Inc.intheU.S.DistrictCourtfortheDistrictofMassachusettsseekingadeclarationthatCovidien’sU.S.Patent
Nos.6,585,735;7,118,587;7,473,253;8,070,748;and8,241,284areeitherinvalidornotinfringedbyEthicon’s
ENSEAL®X1LargeJawTissueSealerproduct(ENSEALX1).TheENSEALX1productisscheduledtolaunchinthe
UnitedStatesandEuropeinthefirstquarterof2017.
Pharmaceutical
InApril2016,MorphoSysAG,aGermanbiotechcompany,filedapatentinfringementlawsuitagainstJanssenBiotech,
Inc.(JBI),GenmabU.S.Inc.andGenmabA/S(collectively,Genmab)intheUnitedStatesDistrictCourtfortheDistrictof
Delaware,allegingthatJBI’smanufactureandsaleofDARZALEX®(daratumumab)willfullyinfringesMorphoSys’U.S.
PatentNo.8,263,746.MorphoSysisseekingmoneydamages.JBIlicensespatentsandthecommercialrightsto
DARZALEX®fromGenmab.InJune2016,JBIfiledamotiontodismissthelawsuit.InNovember2016,MorphoSys
soughtleavetoaddanotherpatenttothecase(U.S.PatentNo.9,200,061),andinFebruary2017,theCourtgrantedthe
request.TrialinthecaseiscurrentlyscheduledtocommenceinAugust2018.
InAugust2016,SandozLtdandHexalAG(collectively,Sandoz)filedalawsuitintheEnglishHighCourtagainstG.D.
SearleLLC(aPfizercompany)andJanssenSciencesIrelandUC(JSI)allegingthatSearle’ssupplementaryprotection
certificateSPC/GB07/038(SPC),whichisexclusivelylicensedtoJSI,isinvalidandshouldberevoked.Janssen-Cilag
LimitedsellsPREZISTA®(darunavir)intheUKpursuanttothislicense.InOctober2016,SearleandJSIcounterclaimed
againstSandozforthreatenedinfringementoftheSPCbasedonstatementsofitsplanstolaunchgenericdarunavirinthe
UK.TrialofthecasehasbeenscheduledtobegininlateApril/earlyMay2017.
REMICADE®RelatedCases
U.S.Proceedings
InSeptember2013,JanssenBiotech,Inc.(JBI)andNYULangoneMedicalCenter(NYU)receivedanOfficeActionfrom
theUnitedStatesPatentandTrademarkOffice(USPTO)rejectingtheclaimsinU.S.PatentNo.6,284,471relatingto
REMICADE®(infliximab)(the‘471patent)inareexaminationproceedinginstitutedbyathirdparty.The‘471patentisco-
ownedbyJBIandNYU,andNYUgrantedJBIanexclusivelicensetoNYU’srightsunderthepatent.The‘471patent
expiresinSeptember2018.Followingseveralofficeactionsbythepatentexaminer,includingtwofurtherrejections,and
responsesbyJBI,theUSPTOissuedafurtheractionmaintainingitsrejectionofthe‘471patent.JBIfiledanoticeof
appealtotheUSPTO’sPatentTrialandAppealBoard.InNovember2016,thePatentTrialandAppealBoardissueda
decisionupholdingtheexaminer’srejection.JBIhasfiledanappealtotheU.S.CourtofAppealsfortheFederalCircuit.
InAugust2014,CelltrionHealthcareCo.Ltd.andCelltrionInc.(together,Celltrion)filedanapplicationwiththeU.S.Food
andDrugAdministration(FDA)forapprovaltomakeandsellitsowninfliximabbiosimilar.InMarch2015,JBIfiledalawsuit
intheUnitedStatesDistrictCourtfortheDistrictofMassachusettsagainstCelltrionandHospiraHealthcareCorporation
(Hospira),whichhasexclusiveU.S.marketingrightsforCelltrion’sinfliximabbiosimilar,seeking,amongotherthings,a
declaratoryjudgmentthattheirbiosimilarproductinfringesorpotentiallyinfringesseveralJBIpatents,includingthe
‘471patentandU.S.PatentNo.7,598,083(the‘083patent).InAugust2016,theDistrictCourtgrantedbothCelltrion’s
andHospira’smotionsforsummaryjudgmentofinvalidityofthe‘471patent.JBIhasappealedthosedecisionstotheU.S.
CourtofAppealsfortheFederalCircuit.Thiscaseandtheappealofthereexaminationofthe‘471patenthavebeen
designatedcompanioncasesandwillbeheardbythesamepanelofjudgesintheFederalCircuit.
InJune2016,JBIfiledtwoadditionalpatentinfringementlawsuitsassertingthe‘083patent,oneagainstCelltrioninthe
UnitedStatesDistrictCourtfortheDistrictofMassachusettsandtheotheragainstHyCloneLaboratories,Inc.,the
manufacturerofthecellculturemediathatCelltrionusestomakeitsbiosimilarproduct,intheUnitedStatesDistrictCourt
fortheDistrictofUtah.Althoughthe‘083patentisalreadyassertedintheexistinglawsuitagainstCelltrion,theadditional
lawsuitexpandstheclaimstoincludeanyuseofthecellculturemediamadeintheUnitedStatestomanufacture
Celltrion’sbiosimilar.ThisadditionallawsuitagainstCelltrionhasbeenconsolidatedwiththeexistinglawsuitdiscussed
above.Hospirahasmovedtodismissallcountsofthelawsuitrelatedtothe‘083patentastoit.Celltrionhasmovedto
dismissallcountsofthelawsuitrelatedtothe‘083patentwithoutprejudiceforfailuretojoinalltheco-ownersofthe‘083
patentasplaintiffs.Thetrialhasbeenpostponedpendingresolutionofthesemotions.
TheFDAapprovedCelltrion’sinfliximabbiosimilarforsaleintheUnitedStatesinApril2016,andthe180-dayperiodfor
noticeoflaunchofabiosimilarproductundertheBiologicsPriceCompetitionandInnovationActhaspassed.
76 • Johnson&Johnson2016AnnualReportHospira’sparentcompany,PfizerInc.,beganshipmentofCelltrion’sinfliximabbiosimilartowholesalersintheUnited
StatesinlateNovember2016.IntroductiontotheU.S.marketofthebiosimilarwillresultinareductioninU.S.salesof
REMICADE®.
CanadianProceedings
InMarch2013,HospirafiledanimpeachmentproceedingagainstTheKennedyInstituteofRheumatology(Kennedy)
challengingthevalidityofaCanadianpatentrelatedtoREMICADE®(aFeldmanpatent),whichisexclusivelylicensedto
JBI.InOctober2013,Kennedy,alongwithJBI,JanssenInc.(Janssen)andCilagGmbHInternational(bothaffiliatesofJBI),
filedacounterclaimforinfringementagainstCelltrionandHospira.Thecounterclaimallegesthattheproductsdescribedin
Celltrion’sandHospira’smarketingapplicationstoHealthCanadafortheirsubsequententrybiologics(SEB)to
REMICADE®wouldinfringetheFeldmanpatentsownedbyKennedy.AtrialinthispatentactionconcludedinOctober
2016,andclosingargumentstookplaceinJanuary2017.Thepartiesareawaitingadecision.
InJanuary2014,HealthCanadaapprovedCelltrion’sSEBtoREMICADE®,allowingCelltriontomarketitsinfliximab
biosimilarinCanada,regardlessofthependingpatentaction.InJune2014,HealthCanadaapprovedHospira’sSEBto
REMICADE®.InJuly2014,JanssenfiledalawsuittocompeltheCanadianMinisterofHealthtowithdrawtheNoticeof
ComplianceforHospira’sSEBbecauseHospiradidnotserveaNoticeofAllegationonJanssentoaddressthepatent
listedbyJanssenonthePatentRegister.InMarch2015,thepartiesenteredintoasettlementagreementwherebyHealth
CanadaagreedtoaConsentJudgmentsettingasideHospira’sNoticeofCompliance,subjecttoHealthCanada’sappeal,
whichwasfiledinJune2015.Nevertheless,Hospirabeganmarketinganinfliximabbiosimilarasadistributorunder
Celltrion’sNoticeofCompliance.InOctober2016,theappealscourtreversedtheConsentJudgment.Janssenhasfiled
anapplicationforleavetoappealwiththeSupremeCourtofCanada.HospiracontinuestomarketandsellCelltrion’s
infliximabbiosimilarinCanada.
InCanada,iftheREMICADE®patentdiscussedaboveisfoundtobeinvalidfollowingallappeals,itcouldnotberelied
upontopreventthefurtherintroductionofinfliximabbiosimilarspriortotheAugust1,2017expirydateofthepatent.
LitigationAgainstFilersofAbbreviatedNewDrugApplications(ANDAs)
ThefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledAbbreviatedNewDrugApplications
(ANDAs)withtheFDA,orundertakensimilarregulatoryprocessesoutsideoftheUnitedStates,seekingtomarketgeneric
formsofproductssoldbyvarioussubsidiariesofJohnson&Johnsonpriortoexpirationoftheapplicablepatentscovering
thoseproducts.TheseANDAstypicallyincludeallegationsofnon-infringement,invalidityandunenforceabilityofthe
applicablepatents.Intheeventthesubsidiariesarenotsuccessfulintheseactions,orthestatutory30-monthstaysofthe
ANDAsexpirebeforetheUnitedStatesDistrictCourtrulingsareobtained,thethird-partycompaniesinvolvedwillhavethe
ability,uponapprovaloftheFDA,tointroducegenericversionsoftheproductsatissuetothemarket,resultinginthe
potentialforsubstantialmarketshareandrevenuelossesforthoseproducts,andwhichmayresultinanon-cash
impairmentchargeinanyassociatedintangibleasset.Inaddition,fromtimetotime,subsidiariesmaysettletheseactions
andsuchsettlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarketpriortothe
expirationoftherelevantpatents.Theinterpartesreview(IPR)processwiththeUnitedStatesPatentandTrademark
Office(USPTO),createdunderthe2011AmericaInventsAct,isalsobeingusedbygenericcompaniesinconjunction
withtheseANDAsandlawsuitstochallengepatentsheldbytheCompany’ssubsidiaries.
CONCERTA®
InDecember2014,JanssenInc.andALZACorporationfiledaNoticeofApplicationagainstActavisPharmaCompany
(Actavis)inresponsetoActavis’NoticeofAllegationseekingapprovaltomarketagenericversionofCONCERTA®before
theexpirationofCanadianPatentNo.2,264,852(the‘852patent).InDecember2016,theCanadianFederalCourt
allowedtheApplicationandissuedanorderpreventingActavisfromobtainingmarketingapproval(aNoticeof
Compliance)foritsgenericversionofCONCERTA®untiltheexpirationofthe‘852patent.Actavisdidnotcommencean
appealpriortothedeadlinefordoingsoandthus,ispreventedfromobtainingaNoticeofComplianceforageneric
versionofCONCERTA®untiltheexpirationofthe‘852patent.
InOctober2016,ALZACorporationandJanssenPharmaceuticals,Inc.filedapatentinfringementlawsuitintheU.S.
DistrictCourtfortheDistrictofDelawareagainstAmnealPharmaceuticalsofNewYork,LLCandAmnealPharmaceuticals
LLCinresponsetoAmneal’sANDAseekingapprovaltomarketagenericversionofCONCERTA®beforetheexpirationof
UnitedStatesPatentNos.8,163,798and9,144,549.InNovember2016,Amnealfiledamotionforjudgmentonthe
pleadings,arguingthatcertainclaimsofthepatentsareinvalidandothersarenotinfringed.Janssenhasopposedthe
motion.
Johnson&Johnson2016AnnualReport • 77ZYTIGA®
InJuneandJuly2015,JanssenBiotech,Inc.(JBI)receivednoticesofparagraphIVcertificationfromseveralcompanies
advisingoftheirrespectiveANDAsseekingapprovalforagenericversionofZYTIGA®beforetheexpirationofoneor
morepatentsrelatingtoZYTIGA®.InJuly2015,JBI,JanssenOncology,Inc.(JanssenOncology)andJanssenResearch&
Development,LLC(collectively,Janssen)andBTGInternationalLtd.(BTG)filedapatentinfringementlawsuitintheUnited
StatesDistrictCourtfortheDistrictofNewJerseyagainstseveralgenericANDAapplicants(andcertainoftheiraffiliates
and/orsuppliers)inresponsetotheirrespectiveANDAsseekingapprovaltomarketagenericversionofZYTIGA®before
theexpirationofUnitedStatesPatentNos.5,604,213(the‘213patent)and/or8,822,438(the‘438patent).Thegeneric
companiesincludeActavisLaboratories,FL,Inc.(Actavis);AmnealPharmaceuticals,LLCandAmnealPharmaceuticalsof
NewYork,LLC(collectively,Amneal);ApotexInc.andApotexCorp.(collectively,Apotex);CitronPharmaLLC(Citron);
Dr.Reddy’sLaboratories,Ltd.andDr.Reddy’sLaboratories,Inc.(collectively,Dr.Reddy’s);MylanPharmaceuticalsInc.
andMylanInc.(collectively,Mylan);ParPharmaceuticals,Inc.andParPharmaceuticalCompanies,Inc.(collectively,Par);
SunPharmaceuticalIndustriesLtd.andSunPharmaceuticalsIndustries,Inc.(collectively,Sun);TevaPharmaceuticals
USA,Inc.(Teva);WockhardtBioA.G.;WockhardtUSALLCandWockhardtLtd.(collectively,Wockhardt);West-Ward
PharmaceuticalCorp.(West-Ward);andHikmaPharmaceuticals,LLC(Hikma).TheCourtenteredastayofthelawsuit
againstParandCitron,aseachagreedtobeboundbythedecisionagainsttheotherdefendantsintheaction.The‘213
patentexpiredinDecember2016andthustheinfringementactionsconcernonlythe‘438patent.InFebruary2016,the
CourtsetatrialdateofOctober2017.
InAugust2015,JanssenandBTGfiledanadditionaljurisdictionalprotectivelawsuitagainsttheMylandefendantsinthe
UnitedStatesDistrictCourtfortheNorthernDistrictofWestVirginia,whichhasbeenstayed.
InAugust2015,JanssenreceivedanoticeofparagraphIVcertificationfromHeteroUSAInc.,theU.S.RegulatoryAgent
forHeteroLabsLimitedUnit-V,adivisionofHeteroLabsLimited(collectively,Hetero)advisingofHetero’sANDAseeking
approvalforagenericversionofZYTIGA®beforeexpirationofthe‘438patent.InSeptember2015,JanssenandBTG
filedanamendedcomplaintintheNewJerseylawsuittoaddallegedinfringementofthe‘438patentbyHetero.
InMarch2016,JanssenfiledamotionintheNewJerseylawsuittocorrectinventorshipofthe‘438patenttoaddan
inventorand,ifgranted,forleavetoamendthecomplaintaccordingly.InJanuary2017,theCourtgrantedJanssen’s
motion,andJanssenfiledasecondamendedcomplaintaddingBTGasaco-ownerofthe‘438patentandaco-plaintiff
regardingthe‘438patentinfringementclaims.
InMarch2016,JanssenreceivedanoticefromAmerigenPharmaceuticalsLimited(Amerigen)advisingofAmerigen’s
ANDAseekingapprovalforagenericversionofZYTIGA®beforeexpirationofthe‘438patent.Inresponse,Janssenand
BTGfiledaseparatepatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainst
AmerigeninMay2016.
InMay2016,JanssenreceivedanoticeofparagraphIVcertificationfromGlenmarkPharmaceuticalsInc.,onbehalfof
GlenmarkPharmaceuticalsSA,awhollyownedsubsidiaryofGlenmarkPharmaceuticalsLtd.(collectively,Glenmark)
advisingofGlenmark’sANDAseekingapprovalforagenericversionofZYTIGA®beforeexpirationofthe‘438patent.In
response,inJune2016,JanssenandBTGfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofNewJerseyagainstGlenmark.ThepartieshavestipulatedtoadismissalofGlenmarkPharmaceuticalsLtd.
Thefilingoftheabove-referencedlawsuitstriggeredastayuntilOctober2018duringwhichtimetheFDAwillnotgrant
finalapprovalofthegenerics’ANDAsunlessthereisanearlierDistrictCourtdecisionfindingthepatents-in-suitinvalidor
notinfringed.
Ineachoftheabovelawsuits,Janssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversions
ofZYTIGA®beforetheexpirationoftherelevantpatents.
InDecember2015,AmerigenfiledapetitionforaninterpartesreviewintheUSPTOseekingtoinvalidatethe‘438patent.
InMay2016,theUSPTOgrantedtheinterpartesreview,andadecisionastothevalidityofthe‘438patentisexpected
byMay2017.InJune2016,ArgentumPharmaceuticalsLLCandMylanPharmaceuticalsInc.filedpetitionsforinterpartes
reviewintheUSPTOseekingtoinvalidatethe‘438patentandmovedtojointheinterpartesreviewfiledbyAmerigen.The
USPTOinstitutedArgentum’spetitionandgrantedArgentum’smotionforjoinderand,inJanuary2017,grantedMylan’s
petitionforinterpartesreviewbutdeniedMylan’smotionforjoinder.InAugust2016,WockhardtBioAGfiledapetition
forinterpartesreviewintheUSPTOseekingtoinvalidatethe‘438patent,whichtheUSPTOgrantedinJanuary2017.In
February2017,Actavis,Amneal,Dr.Reddy’s,Sun,Teva,West-WardandHikmafiledajointpetitionforinterpartesreview
intheUSPTOseekingtoinvalidatethe‘438patentandmovedtojointheinterpartesreviewfiledbyMylan.
78 • Johnson&Johnson2016AnnualReportCOMPLERA®
InAugustandSeptember2015,JanssenPharmaceuticaNVandJanssenSciencesIrelandUC(collectively,Janssen)and
GileadSciences,Inc.andGileadSciencesIrelandUC(collectively,Gilead)filedpatentinfringementlawsuitsintheUnited
StatesDistrictCourtsfortheDistrictofDelawareandtheDistrictofWestVirginia,respectively,againstMylan,Inc.and
MylanPharmaceuticals,Inc.(collectively,Mylan)inresponsetoMylan’sANDAseekingapprovaltomarketageneric
versionofCOMPLERA®beforetheexpirationofUnitedStatesPatentNos.8,841,310(the‘310patent),7,125,879(the
‘879patent)and8,101,629(the‘629patent).
IntheWestVirginiaaction,inSeptember2015,Mylanfiledananswerandcounterclaimsassertinginvalidityandnon-
infringementofthe‘310patent,‘879patent,and‘629patent,aswellasUnitedStatesPatentNo.8,080,551(the
‘551patent).InMarch2016,theDistrictofWestVirginiaCourtstayedthelawsuitandscheduledaconditionaltrialdatein
February2018,inaccordancewiththescheduleinthefirst-filedDelawarelawsuitdescribedbelow.
IntheDelawareaction,inJanuaryandMarch2016,JanssenandGileadamendedtheircomplainttoaddclaimsforpatent
infringementwithrespecttothe‘551patentandUnitedStatesPatentNos.7,399,856(the‘856patent),7,563,922(the
‘922patent),8,101,752(the‘752patent)and8,618,291(the‘291patent).Mylanfiledamotiontodismissthesuitfor
lackofpersonaljurisdictionandamotiontodismiss,strikeorsevertheinfringementclaimsregardingthe‘752and
‘291patents.InSeptember2016,theDelawareDistrictCourtdeniedbothofMylan’smotions.AtrialintheDelaware
actionhasbeenscheduledforFebruary2018.
Ineachoftheselawsuits,Janssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof
COMPLERA®beforetheexpirationoftherelevantpatents.
XARELTO®
AnumberofgenericcompanieshavefiledANDAsseekingapprovaltomarketgenericversionsofXARELTO®.InOctober
2015,JanssenPharmaceuticals,Inc.(JPI)andBayerPharmaAGandBayerIntellectualPropertyGmbH(collectively,
Bayer)filedpatentinfringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstAurobindo
PharmaLimited,AurobindoPharmaUSA,Inc.,BreckenridgePharmaceutical,Inc.,MicroLabsUSAInc.andMicroLabs
Ltd.(collectively,Micro),MylanPharmaceuticalsInc.,MylanInc.(Mylan),PrinstonPharmaceutical,Inc.,Sigmapharm
Laboratories,LLC,TorrentPharmaceuticals,LimitedandTorrentPharmaInc.,inresponsetothoseparties’respective
ANDAsseekingapprovaltomarketgenericversionsofXARELTO®beforetheexpirationofBayer’sUnitedStatesPatent
Nos.7,157,456(the‘456patent),7,585,860(the‘860patent)and7,592,339(the‘339patent)relatingtoXARELTO®.
JPIistheexclusivelicenseeoftheassertedpatents.
InNovember2015,Mylanmovedtodismisstheaction.InDecember2015,JPI,Bayer,andMylanstipulatedandagreedto
dismisstheclaimsagainstMylan,andsuspendfurtherbriefingandargumentonMylan’smotiontodismiss,pending
appealsrelatingtopersonaljurisdictionoverMylanPharmaceuticalsInc.intheDistrictofDelaware.InFebruary2016,a
similarpatentinfringementactionbyJPIandBayeragainstInvagenPharmaceuticalsInc.(Invagen),inresponseto
Invagen’snoticeofparagraphIVcertificationadvisingofitsANDAseekingFDAapprovalforagenericXARELTO®
productbeforeexpirationoftherelevantpatents,wasconsolidatedwiththeoriginalcase.TheDistrictCourthassetatrial
dateofMarch2018.
InApril2016,JPIandBayerfiledaseparatepatentinfringementactionintheDistrictofDelawareagainstMicro,in
responsetotheirnoticeofparagraphIVcertificationadvisingoftheirANDAseekingFDAapprovalforageneric
XARELTO®productbeforeexpirationofthe‘860and‘339patents.InMay2016,thisactionwasconsolidatedwiththe
originalaction.
InJuly2016,JPIandBayerfiledaseparatepatentinfringementactionintheDistrictofDelawareagainstBreckenridge
Pharmaceutical,Inc.,inresponsetoitsnoticeofparagraphIVcertificationadvisingofitsANDAseekingFDAapprovalfor
agenericXARELTO®productbeforeexpirationofthe‘456and‘339patents.Thisactionhasbeenconsolidatedwiththe
originalaction.
Ineachoftheselawsuits,JPIisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof
XARELTO®beforetheexpirationoftherelevantpatents.
InOctober2016,MylanfiledpetitionsforinterpartesreviewintheUSPTOseekingtoinvalidatethe‘339,‘456and‘860
patents.
Johnson&Johnson2016AnnualReport • 79GovernmentProceedings
Likeothercompaniesinthepharmaceuticalandmedicaldevicesindustries,Johnson&Johnsonandcertainofits
subsidiariesaresubjecttoextensiveregulationbynational,stateandlocalgovernmentagenciesintheUnitedStatesand
othercountriesinwhichtheyoperate.Asaresult,interactionwithgovernmentagenciesisongoing.Themostsignificant
litigationbroughtby,andinvestigationsconductedby,governmentagenciesarelistedbelow.Itispossiblethatcriminal
chargesandsubstantialfinesand/orcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation.
AverageWholesalePrice(AWP)Litigation
Johnson&Johnsonandseveralofitspharmaceuticalsubsidiaries(theJ&JAWPDefendants),alongwithnumerousother
pharmaceuticalcompanies,aredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe
pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct
because,amongotherthings,thecompaniesallegedlyreportedaninflatedAverageWholesalePrice(AWP)forthedrugs
atissue.PayorsallegedthattheyusedthoseAWPsincalculatingproviderreimbursementlevels.Manyofthesecases,
bothfederalactionsandstateactionsremovedtofederalcourt,wereconsolidatedforpre-trialpurposesinaMulti-District
Litigation(MDL)intheUnitedStatesDistrictCourtfortheDistrictofMassachusetts.Theplaintiffsinthesecasesincluded
threeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseofthedrugsatissuebasedonAWP,
andstategovernmententitiesthatmadeMedicaidpaymentsforthedrugsatissuebasedonAWP.InJune2007,aftera
trialonthemerits,theMDLCourtdismissedtheclaimsoftwooftheplaintiffclassesagainsttheJ&JAWPDefendants.In
March2011,theCourtdismissedtheclaimsofthethirdclassagainsttheJ&JAWPDefendantswithoutprejudice.
AWPcasesbroughtbyvariousAttorneysGeneralhaveproceededtotrialagainstothermanufacturers.Severalstate
casesagainstcertainJohnson&Johnsonsubsidiarieshavebeensettled,includingthecaseinWisconsin,whichsettledin
February2016.CasesarestillpendinginIllinois,NewJersey,andUtah.ThecasesinIllinoisandNewJerseyhavenotyet
proceededtotrial.InUtah,theclaimsbroughtbytheAttorneyGeneralweredismissedbytheCourtin2013,buttheState
mayappealthedismissalaftertheconclusionofsimilarpendingmattersagainstotherdefendants.IntheAWPcase
againsttheJ&JAWPDefendantsbroughtbytheCommonwealthofPennsylvania,followingatrialin2010,the
PennsylvaniaCommonwealthCourtfoundinfavoroftheCommonwealthwithregardtocertainofitsclaimsunderthe
PennsylvaniaUnfairTradePracticesandConsumerProtectionLaw,andinfavoroftheJ&JAWPDefendantsonthe
Commonwealth’sremainingclaims.FollowinganappealtothePennsylvaniaSupremeCourtthatvacatedthatjudgment,
theCommonwealthCourtenteredasubsequentjudgmentinfavoroftheJ&JAWPDefendantsonallclaims.That
subsequentjudgmenthasbeenupheldbythePennsylvaniaSupremeCourtinasuccessiveappeal.
McNeilConsumerHealthcare
StartinginJune2010,McNeilConsumerHealthcareDivisionofMcNEIL-PPC,Inc.(nowJohnson&JohnsonConsumer
Inc.,McNeilConsumerHealthcareDivision)(McNeilConsumerHealthcare)andcertainaffiliates,includingJohnson&
Johnson(theCompanies),receivedgrandjurysubpoenasfromtheUnitedStatesAttorney’sOfficefortheEasternDistrict
ofPennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvariousproductsofMcNeilConsumerHealthcare,and
theFDAinspectionsoftheFortWashington,PennsylvaniaandLancaster,Pennsylvaniamanufacturingfacilities,aswellas
certaindocumentsrelatingtorecallsofasmallnumberofproductsofothersubsidiaries.Inaddition,inFebruary2011,the
governmentservedMcNEIL-PPC,Inc.(nowJohnson&JohnsonConsumerInc.)(JJCI)withaCivilInvestigativeDemand
seekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationoftheFederalFalseClaimsAct.InMarch
2015,McNEIL-PPC,Inc.(nowJJCI)enteredaguiltypleaintheUnitedStatesDistrictCourtfortheEasternDistrictof
PennsylvaniatoamisdemeanorviolationoftheU.S.Food,DrugandCosmeticAct.McNEIL-PPC,Inc.(nowJJCI)agreed
topaya$20millionfineanda$5millionforfeituretoresolvethematter.
TheCompanieshavealsoreceivedCivilInvestigativeDemandsfrommultipleStateAttorneysGeneralOfficesbroadly
relatingtotheMcNeilrecallissues.TheCompaniescontinuetocooperatewiththeseinquiries,whicharebeing
coordinatedthroughamulti-statecoalition.Ifaresolutioncannotbereachedwiththismulti-statecoalition,itispossible
thatindividualStateAttorneysGeneralOfficesmayfilecivilmonetaryclaimsagainsttheCompanies.
InJanuary2011,theOregonAttorneyGeneralfiledacivilcomplaintagainstJohnson&Johnson,McNEIL-PPC,Inc.(now
JJCI)andMcNeilHealthcareLLCinstatecourtallegingcivilviolationsoftheOregonUnlawfulTradePracticesActrelating
toanearlierrecallofaMcNeilOTCproduct.InNovember2012,thestatecourtgrantedamotionbytheCompaniesto
dismissOregon’scomplaintinitsentirety,withprejudice.InNovember2015,theStateCourtofAppealsreversedthetrial
courtandreinstatedOregon’sconsumerprotectionclaims.InFebruary2016,theOregonSupremeCourtdeniedthe
Companies’petitionforreview,andthecasewassentbacktothetrialcourt.
80 • Johnson&Johnson2016AnnualReportOpioidsLitigation
Asdescribedbelow,Johnson&Johnson(J&J)andJanssenPharmaceuticals,Inc.(JPI),alongwithotherpharmaceutical
companies,havebeennamedinfourlawsuitsallegingclaimsrelatedtomarketingofopioids,includingDURAGESIC®,
NUCYNTA®andNUCYNTA®ER,andhavebeensubpoenaedbytwootherstatesforinformationrelatedtoopioid
marketingpractices.
InMay2014,SantaClaraandOrangeCountiesinCaliforniafiledacomplaintinstatecourtinOrangeCounty,California
againstnumerouspharmaceuticalmanufacturers,includingJ&JandJPI,allegingclaimsrelatedtoopioidmarketing
practices,includingfalseadvertising,unfaircompetition,andpublicnuisance.Thecountiesseekinjunctiveandmonetary
relief.InFebruary2015,thedefendantsfiledmotionschallengingthesufficiencyofthecomplaint.InAugust2015,the
CourtstayedthecaseuntiltheFDAconcludesitsongoinginquiryintothesafetyandeffectivenessoflong-termopioid
treatment.Followingamotionbythecountiestoliftthestay,inOctober2016,theCourtkeptthestayinplaceinpart,
requestedthepartiestoconfer,andadjournedthematteruntilalaterdate.
InJune2014,theCityofChicagofiledacomplaintinCookCountyCircuitCourtagainstthesamegroupof
pharmaceuticalmanufacturers,includingJ&JandJPI,alleginganumberofclaimsrelatedtoopioidmarketingpractices,
includingconsumerfraudviolationsandfalseclaims,andseekinginjunctiveandmonetaryrelief.Thecasewaslater
removedtotheUnitedStatesDistrictCourtfortheNorthernDistrictofIllinois.InDecember2014,J&JandJPIfileda
motiontodismisstheCityofChicago’sfirstamendedcomplaint,whichwasgrantedwithleavetofileanamended
complaint.TheCityfiledasecondamendedcomplaint,andinNovember2015,J&JandJPIfiledamotiontodismissthe
secondamendedcomplaint.InSeptember2016,theCourtdismissedeightoftheCity’stencausesofactionandgranted
theCityonefinalopportunitytorepleadthedismissedclaims.TheCityfiledathirdamendedcomplaintinOctober2016,
and,inDecember2016,J&JandJPIfiledananswerastotwocausesofactionandamotiontodismisstheremaining
causesofaction.
InSeptember2014,theTennesseeAttorneyGeneralDivisionofConsumerAffairsissuedaRequestforInformationtoJPI
andotherpharmaceuticalcompaniesrelatedtoopioidsmarketingpractices.
InAugust2015,theNewHampshireAttorneyGeneral,ConsumerProtectionandAntitrustBureauissuedasubpoenato
JPIandotherpharmaceuticalcompaniesrelatedtoopioidsmarketingpractices.InOctober2015,theStatefiledamotion
intheStateofNewHampshireSuperiorCourttoenforcethesubpoena.JPIandtheotherpharmaceuticalcompanies
subsequentlyfiledajointmotionforinjunctivereliefandaprotectiveordertoprecludetheStatefromengagingprivate
contingentfeecounseltoparticipateintheState’sinvestigationoranysubsequentenforcementaction.InMarch2016,
theCourtgrantedtheprotectiveorderonthegroundsthattheStatehadnotobtainedrequisiteexecutiveandlegislative
approvalstoretainprivatecounsel,butrejectedthecontentionthatthecontingencyfeeagreementwasotherwise
unlawful.AllpartieshaveappealedtheMarch2016rulingtotheNewHampshireSupremeCourt.InAugust2016,the
Courtdeniedthepharmaceuticalcompanies’jointmotiontoenforcetheprotectiveorderonthegroundthattheunderlying
deficiency(legislativeapproval)hadbeencured.InSeptember2016,theStatestipulatedtostayenforcementofany
subpoenaspendingtheNewHampshireSupremeCourt’sconsiderationofthecompanies’appealoftheMarch2016
ruling.
InDecember2015,theStateofMississippifiledacomplaintintheChanceryCourtoftheFirstJudicialDistrictofHinds
CountyagainstsubstantiallythesamegroupofpharmaceuticalmanufacturersasinthesuitsbroughtbytheCalifornia
countiesandCityofChicago,includingJ&JandJPI,alleginganumberofclaimsrelatedtoopioidmarketingpracticesand
seekingpenaltiesandinjunctiveandmonetaryrelief.InMarch2016,defendantsfiledamotiontotransfervenueand
motionstodismissthecomplaint.
InAugust2016,theCountyofSuffolkinNewYorkfiledacomplaintagainstseveralpharmaceuticalmanufacturersin
NewYorkSupremeCourt,includingJ&JandJPI,allegingclaimsrelatedtoopioidmarketing,includingclaimsbasedon
deceptiveactsandpractices,falseadvertising,fraudandunjustenrichment.Thecomplaintseekspenaltiesandinjunctive
andmonetaryrelief.
InFebruary2017,theCountyofErieandtheCountyofBroomeinNewYorkeachfiledacomplaintinNewYorkSupreme
Courtagainstseveralpharmaceuticalmanufacturers,includingJPI.Bothcomplaintsallegeclaimsrelatedtoopioid
marketingpractices,includingstatutoryclaimsfordeceptiveactsandpractices,falseadvertising,andviolationof
NewYork’sSocialServicesLaw,andcommonlawcausesofactionforpublicnuisance,fraud,andunjustenrichment.
Eachcountyisseekingcompensatoryandpunitivedamagesandcosts.
Johnson&Johnson2016AnnualReport • 81Other
InSeptember2011,Synthes,Inc.(Synthes)receivedaCivilInvestigativeDemandissuedpursuanttotheFalseClaimsAct
fromtheUnitedStatesAttorney’sOfficefortheEasternDistrictofPennsylvania.Thedemandsoughtinformationregarding
allegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproducts.Syntheshas
produceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry.
InMay2012,Acclarent,Inc.(Acclarent)receivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusettsrequestingdocumentsbroadlyrelatingtothesales,marketingandallegedoff-labelpromotionbyAcclarent
oftheRELIEVASTRATUS®MicroFlowSpacerproduct(theRELIEVASTRATUS®Spacer).InMarch2016,Acclarent
executedacivilsettlementwiththeUnitedStatesJusticeDepartmentandotheragenciestoresolvethisinvestigation.
Johnson&Johnsonwasnotapartytothissettlementandtherewasnoadmissionofliability.Inaseparatematter,inJuly
2016,theformerPresident/CEOandVicePresidentofSalesofAcclarent(theformerAcclarentofficers),wereconvicted
ofmisdemeanorviolationsinconnectionwiththesaleandmarketingoftheRELIEVASTRATUS®Spacer.Thereareno
chargesagainstAcclarent,Ethicon,Inc.orJohnson&Johnsoninthismatter.
InAugust2012,DePuyOrthopaedics,Inc.,DePuy,Inc.(nowDePuySynthes,Inc.),andJohnson&JohnsonServices,Inc.
receivedaninformalrequestfromtheUnitedStatesAttorney’sOfficefortheDistrictofMassachusettsandtheCivil
DivisionoftheUnitedStatesDepartmentofJustice(theUnitedStates)fortheproductionofmaterialsrelatingtothe
DePuyASR™XLHipdevice.InJuly2014,theUnitedStatesnotifiedtheUnitedStatesDistrictCourtfortheDistrictof
MassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttotheFalseClaimsActagainstthe
companies.InFebruary2016,theDistrictCourtgrantedthecompanies’motiontodismisswithprejudice,unsealedthe
quitamcomplaint,anddeniedthequitamrelators’requestforleavetofileafurtheramendedcomplaint.Thequitam
relatorsappealedthecasetotheUnitedStatesCourtofAppealsfortheFirstCircuit.TheFirstCircuit’sdecisioninthe
caseispending.SinceOctober2013,agroupofStateAttorneysGeneralhaveissuedCivilInvestigativeDemands
relatingtothedevelopment,salesandmarketingofseveralofDePuyOrthopaedics,Inc.’shipproducts.Thestatesare
seekingmonetaryandinjunctiverelief.InJuly2014,theOregonDepartmentofJustice,whichwasinvestigatingthese
mattersindependentlyoftheotherstates,announcedasettlementofitsASRXLHipdeviceinvestigationforatotal
paymentof$4milliontotheStateofOregon.
InOctober2012,Johnson&JohnsonwascontactedbytheCaliforniaAttorneyGeneral’sofficeregardingamulti-state
AttorneyGeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby
Johnson&Johnson’ssubsidiary,Ethicon,Inc.(Ethicon).Johnson&JohnsonandEthiconhavesinceenteredintoaseries
oftollingagreementswiththe47statesandtheDistrictofColumbiaparticipatinginthemulti-stateinvestigationandhave
respondedtoCivilInvestigativeDemandsservedbycertainoftheparticipatingstates.Thestatesareseekingmonetary
andinjunctiverelief.InMay2016,CaliforniaandWashingtonfiledcivilcomplaintsagainstJohnson&JohnsonandEthicon
allegingviolationsoftheirconsumerprotectionstatutes.InAugust2016,Kentuckyfiledasimilarcomplaintagainstthe
companies.Johnson&JohnsonandEthiconhaveenteredintoanewtollingagreementwiththeremaining44statesand
theDistrictofColumbia.
InDecember2012,Therakos,Inc.(Therakos),formerlyasubsidiaryofJohnson&JohnsonandpartoftheOrtho-Clinical
Diagnostics,Inc.(OCD)franchise,receivedaletterfromthecivildivisionoftheUnitedStatesAttorney’sOfficeforthe
EasternDistrictofPennsylvaniainformingTherakosthattheUnitedStatesAttorney’sOfficewasinvestigatingthesales
andmarketingofUvadex®(methoxsalen)andtheUvarXts®Systemduringtheperiod2000tothepresent.TheUnited
StatesAttorney’sOfficerequestedthatOCDandJohnson&Johnsonpreservedocumentsthatcouldrelatetothe
investigation.TherakoswassubsequentlyacquiredbyanaffiliateofGoresCapitalPartnersIII,L.P.inJanuary2013,and
OCDwasdivestedinJune2014.FollowingthedivestitureofOCD,Johnson&JohnsonretainsOCD’sportionofany
liabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleofTherakos.InMarch2014and
March2016,theUnitedStatesAttorney’sOfficerequestedthatJohnson&Johnsonproducecertaindocuments,and
Johnson&Johnsoniscooperatingwiththerequests.
InJune2014,theMississippiAttorneyGeneralfiledacomplaintinChanceryCourtofTheFirstJudicialDistrictofHinds
County,MississippiagainstJohnson&JohnsonandJohnson&JohnsonConsumerCompanies,Inc.(nowJohnson&
JohnsonConsumerInc.)(JJCI).Thecomplaintallegesthatdefendantsfailedtodiscloseallegedhealthrisksassociated
withfemaleconsumers’useoftalccontainedinJOHNSON’S®BabyPowderandJOHNSON’S®ShowertoShower
(aproductnolongersoldbyJJCI)andseeksinjunctiveandmonetaryrelief.Thismatteriscurrentlyscheduledfortrialin
September2017.
InMarch2016,JanssenPharmaceuticals,Inc.(JPI)receivedaCivilInvestigativeDemandfromtheUnitedStates
Attorney’sOfficefortheSouthernDistrictofNewYorkrelatedtoJPI’scontractualrelationshipswithpharmacybenefit
82 • Johnson&Johnson2016AnnualReportmanagersovertheperiodfromJanuary1,2006tothepresentwithregardtocertainofJPI’spharmaceuticalproducts.The
demandwasissuedinconnectionwithaninvestigationundertheFalseClaimsAct.
InJanuary2017,JanssenPharmaceuticals,Inc.(JPI)receivedaCivilInvestigativeDemand(CID)fromtheUnitedStates
DepartmentofJustice(DOJ)relatingtoallegationsconcerningthesalesandmarketingpracticesofOLYSIOTM.JPIis
cooperatingwithDOJinappropriatelyrespondingtotheCID.
InFebruary2017,Johnson&JohnsonreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusettsseekingtheproductionofrecordspertainingtopaymentstoany501(c)(3)charitableorganizationthat
providesfinancialassistancetoMedicarepatients.Multiplepharmaceuticalcompanieshavepubliclyreportedreceiptof
similarsubpoenasandongoinginquiries.
Inrecentyears,Johnson&JohnsonhasreceivednumerousrequestsfromavarietyofUnitedStatesCongressional
Committeestoproduceinformationrelevanttoongoingcongressionalinquiries.ItisthepolicyofJohnson&Johnsonto
cooperatewiththeseinquiriesbyproducingtherequestedinformation.
GeneralLitigation
InJune2009,followingthepublicannouncementthatOrtho-ClinicalDiagnostics,Inc.(OCD)hadreceivedagrandjury
subpoenafromtheUnitedStatesDepartmentofJustice,AntitrustDivision,inconnectionwithaninvestigationthathas
sincebeenclosed,multipleclassactioncomplaintswerefiledagainstOCDbydirectpurchasersseekingdamagesfor
allegedpricefixing.Thesecaseswereconsolidatedforpre-trialpurposesintheUnitedStatesDistrictCourtforthe
EasternDistrictofPennsylvaniaasInreBloodReagentAntitrustLitigation.InAugust2012,theDistrictCourtgranteda
motionfiledbytheplaintiffsforclasscertification.InApril2015,theUnitedStatesCourtofAppealsfortheThirdCircuit
reversedtheclasscertificationrulingandremandedthecasetotheDistrictCourtforfurtherproceedings.InOctober
2015,theDistrictCourtagaingrantedthemotionbytheplaintiffsforclasscertification.InJuly2016,OCDfiledamotion
forsummaryjudgment.OCDwasdivestedin2014andJohnson&Johnsonretainedanyliabilitythatmayresultfromthese
cases.
InSeptember2011,Johnson&Johnson,Johnson&JohnsonInc.andMcNeilConsumerHealthcareDivisionofJohnson&
JohnsonInc.receivedaNoticeofCivilClaimfiledbyNickFieldintheSupremeCourtofBritishColumbia,Canada(the
BCCivilClaim).TheBCCivilClaimisaputativeclassactionbroughtonbehalfofpersonswhoresideinBritishColumbia
andwhopurchasedduringtheperiodbetweenSeptember20,2001andinoraboutDecember2010oneormorevarious
McNeilinfants’orchildren’sover-the-countermedicinesthatweremanufacturedattheFortWashington,Pennsylvania
facility.TheBCCivilClaimallegesthatthedefendantsviolatedtheBCBusinessPracticesandConsumerProtectionAct,
andotherCanadianstatutesandcommonlaws,bysellingmedicinesthatwereallegedlynotsafeand/oreffectiveordid
notcomplywithCanadianGoodManufacturingPractices.TheclasscertificationhearingscheduledforOctober2015
wasadjourned,andthereiscurrentlynodatesetforthathearing.
InMay2014,twopurportedclassactionswerefiledinfederalcourt,oneintheUnitedStatesDistrictCourtfortheCentral
DistrictofCaliforniaandoneintheUnitedStatesDistrictCourtfortheSouthernDistrictofIllinois,againstJohnson&
Johnson(J&J)andJohnson&JohnsonConsumerCompanies,Inc.(nowJohnson&JohnsonConsumerInc.)(JJCI),alleging
violationsofstateconsumerfraudstatutesbasedonnondisclosureofallegedhealthrisksassociatedwithtalccontained
inJOHNSON’S®BabyPowderandJOHNSON’S®ShowertoShower(aproductnolongersoldbyJJCI).Bothcases
seekinjunctivereliefandmonetarydamages;neitherincludesaclaimforpersonalinjuries.InOctober2016,bothcases
weretransferredtotheUnitedStatesDistrictCourtfortheDistrictCourtofNewJerseyaspartofanewlycreatedfederal
multi-districtlitigation.InDecember2016,J&JandJJCIfiledamotiontodismissoneofthecases.
InAugust2014,UnitedStatesCustomsandBorderProtection(USCBP)issuedaPenaltyNoticeagainstJanssenOrtho
LLC(JanssenOrtho),assessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolate(theactive
pharmaceuticalingredientinPREZISTA®)inconnectionwithitsimportationintotheUnitedStates.InOctober2014,
JanssenOrthosubmittedaPetitionforReliefinresponsetothePenaltyNotice.InMay2015,USCBPissuedan
AmendedPenaltyNoticeassessingsubstantialpenaltiesandJanssenOrthofileditsPetitionforReliefinJuly2015.
InMarchandApril2015,over30putativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourts
aroundtheUnitedStatesagainstJohnson&JohnsonVisionCare,Inc.(JJVCI),othercontactlensmanufacturers,
distributors,andretailers,allegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlenses.The
complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers
concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumers.Theplaintiffsareseekingdamagesand
injunctiverelief.AlloftheclassactioncasesweretransferredtotheUnitedStatesDistrictCourtfortheMiddleDistrictof
Johnson&Johnson2016AnnualReport • 83FloridainJune2015.TheplaintiffsfiledaConsolidatedClassActioncomplaintinNovember2015,andinDecember
2015,JJVCIandotherdefendantsfiledmotionstodismiss.InJune2016,theCourtdeniedthemotionstodismiss.
Discoveryisongoing.
InApril2015,Johnson&JohnsonVisionCare,Inc.(JJVCI)filedacomplaintintheUnitedStatesDistrictCourtforthe
DistrictofUtahagainsttheStateofUtahseekingadeclaratoryjudgmentthatalawpassedbytheStatetobanunilateral
pricingpoliciessolelyinthecontactlensmarketviolatestheCommerceClauseoftheUnitedStatesConstitution.The
CourtdeniedJJVCI’smotionforapreliminaryinjunction.JJVCIappealed.ArgumentontheappealwasheldinAugust
2015.InDecember2016,theappellatecourtdeniedJJVCI’sappeal.
InApril2015,AdimmuneCorporationLtd(Adimmune)commencedanarbitrationintheInternationalCourtofArbitration–
InternationalChamberofCommerceagainstCrucellSwitzerlandAG(nowJanssenVaccinesAG)andCrucellHolland
B.V.(nowJanssenVaccines&PreventionB.V.)(collectively,Crucell).AdimmuneclaimsthatCrucellbreachedcertain
agreementsrelatingtothesupplyoffluantigenwhenCrucellceasedpurchasingfluantigenfromAdimmune.InDecember
2015,AdimmunefileditsStatementofClaimseekingmonetarydamages.ThearbitrationhearingtookplaceinNovember
2016andthepartiesareawaitingaruling.
InAugust2015,twothird-partypayorsfiledapurportedclassactionintheUnitedStatesDistrictCourtfortheEastern
DistrictofLouisianaagainstJanssenResearch&Development,LLC,JanssenOrthoLLC,JanssenPharmaceuticals,Inc.,
Ortho-McNeil-JanssenPharmaceuticals,Inc.andJohnson&Johnson(aswellascertainBayerentities),allegingthatthe
defendantsimproperlymarketedandpromotedXARELTO®assaferandmoreeffectivethanlessexpensivealternative
medicationswhilefailingtofullydiscloseitsrisks.Thecomplaintseeksdamagesinanunspecifiedamount.
Johnson&JohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtundertheComprehensive
EnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,andcomparablestate,localor
foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
22. Restructuring
TheCompanyannouncedrestructuringactionsinitsMedicalDevicessegmenttobetterservetheneedsofpatientsand
customersintoday’sevolvinghealthcaremarketplace.TheCompanyisundertakingactionstostrengthenitsgo-to-market
model,acceleratethepaceofinnovation,furtherprioritizekeyplatformsandgeographies,andstreamlineoperationswhile
maintaininghighqualitystandards.
TheCompanyestimatesthat,inconnectionwithitsplans,itwillrecordpre-taxrestructuringrelatedchargesof
approximately$2.0billionto$2.4billion.In2016,theCompanyrecordedapre-taxchargeof$685million,ofwhich$45
millionwasincludedincostofproductssoldand$149millionwasincludedinother(income)expense.Seetablebelow
foradditionaldetails.Totalprojectcostsof$1.275billionhavebeenrecordedsincetherestructuringhasbeen
announced.
Additionally,aspartoftheplan,theCompanyexpectsthattherestructuringactionswillresultinpositioneliminationsof
approximately4to6percentoftheMedicalDevicessegment’sglobalworkforceoverthenexttwoyears,subjecttoany
consultationproceduresincountries,whererequired.Approximately1,500positionshavebeeneliminatedsincethe
restructuringwasannounced.
TheCompanyestimatesthatapproximatelyone-halfofthecumulativepre-taxcostswillresultincashoutlays,including
approximately$500millionofemployeeseverance.Approximatelyonehalfofthecumulativepre-taxcostsarenon-cash,
relatingprimarilytofacilityrationalization,inventorywrite-offsandintangibleassetwrite-offs.
84 • Johnson&Johnson2016AnnualReportThefollowingtablesummarizestheseverancechargesandtheassociatedspendingunderthisinitiativethroughthefiscal
yearended2016:
(DollarsinMillions) Severance AssetWrite-offs Other** Total
2015restructuringcharge $484 86 20 590
2015activity (86) (3) (89)
Reservebalance,January3,2016 484 – 17 501
Currentyearactivity:
Charges – 249 436 685
Cashpayments (104) – (452) (556)
Settlednoncash — (249) – (249)
Reservebalance,January1,2017* $380 — 1 381
* Cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenext18monthsinaccordancewiththeCompany’splans
andlocallaws.
**Otherincludesprojectexpensesuchassalariesforemployeessupportingtheinitiativeandconsultingexpenses.
Johnson&Johnson2016AnnualReport • 85Report of Independent Registered Public
Accounting Firm
TotheShareholdersandBoardofDirectorsofJohnson&Johnson
Inouropinion,theaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearnings,of
comprehensiveincome,ofequity,andofcashflowspresentfairly,inallmaterialrespects,thefinancialpositionof
Johnson&JohnsonanditssubsidiariesatJanuary1,2017andJanuary3,2016,andtheresultsoftheiroperationsand
theircashflowsforeachofthethreeyearsintheperiodendedJanuary1,2017inconformitywithaccountingprinciples
generallyacceptedintheUnitedStatesofAmerica.Alsoinouropinion,theCompanymaintained,inallmaterialrespects,
effectiveinternalcontroloverfinancialreportingasofJanuary1,2017,basedoncriteriaestablishedinInternalControl–
IntegratedFramework(2013)issuedbytheCommitteeofSponsoringOrganizationsoftheTreadwayCommission
(COSO).TheCompany’smanagementisresponsibleforthesefinancialstatements,formaintainingeffectiveinternal
controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting,
includedintheaccompanyingManagement’sReportonInternalControloverFinancialReporting.Ourresponsibilityisto
expressopinionsonthesefinancialstatementsandontheCompany’sinternalcontroloverfinancialreportingbasedon
ourintegratedaudits.WeconductedourauditsinaccordancewiththestandardsofthePublicCompanyAccounting
OversightBoard(UnitedStates).Thosestandardsrequirethatweplanandperformtheauditstoobtainreasonable
assuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementandwhethereffectiveinternalcontrol
overfinancialreportingwasmaintainedinallmaterialrespects.Ourauditsofthefinancialstatementsincludedexamining,
onatestbasis,evidencesupportingtheamountsanddisclosuresinthefinancialstatements,assessingtheaccounting
principlesusedandsignificantestimatesmadebymanagement,andevaluatingtheoverallfinancialstatement
presentation.Ourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol
overfinancialreporting,assessingtheriskthatamaterialweaknessexists,andtestingandevaluatingthedesignand
operatingeffectivenessofinternalcontrolbasedontheassessedrisk.Ourauditsalsoincludedperformingsuchother
proceduresasweconsiderednecessaryinthecircumstances.Webelievethatourauditsprovideareasonablebasisfor
ouropinions.
AsdiscussedinNote1totheconsolidatedfinancialstatements,theCompanychangedthemannerinwhichitaccounts
forandpresentscertainelementsofsharebasedpaymentsin2016.
Acompany’sinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe
reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith
generallyacceptedaccountingprinciples.Acompany’sinternalcontroloverfinancialreportingincludesthosepoliciesand
proceduresthat(i)pertaintothemaintenanceofrecordsthat,inreasonabledetail,accuratelyandfairlyreflectthe
transactionsanddispositionsoftheassetsofthecompany;(ii)providereasonableassurancethattransactionsare
recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting
principles,andthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof
managementanddirectorsofthecompany;and(iii)providereasonableassuranceregardingpreventionortimelydetection
ofunauthorizedacquisition,use,ordispositionofthecompany’sassetsthatcouldhaveamaterialeffectonthefinancial
statements.
Becauseofitsinherentlimitations,internalcontroloverfinancialreportingmaynotpreventordetectmisstatements.Also,
projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate
becauseofchangesinconditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
/s/PricewaterhouseCoopersLLP
FlorhamPark,NewJersey
February27,2017
86 • Johnson&Johnson2016AnnualReportManagement’s Report on Internal Control
Over Financial Reporting
UnderSection404oftheSarbanes-OxleyActof2002,managementisrequiredtoassesstheeffectivenessofthe
Company’sinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreport,basedonthatassessment,
whethertheCompany’sinternalcontroloverfinancialreportingiseffective.
ManagementoftheCompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial
reporting.TheCompany’sinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe
reliabilityoftheCompany’sfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith
generallyacceptedaccountingprinciples.
Internalcontrolsoverfinancialreporting,nomatterhowwelldesigned,haveinherentlimitations.Therefore,internalcontrol
overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial
statementpreparationandmaynotpreventordetectallmisstatements.Moreover,projectionsofanyevaluationof
effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin
conditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
TheCompany’smanagementhasassessedtheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingas
ofJanuary1,2017.Inmakingthisassessment,theCompanyusedthecriteriaestablishedbytheCommitteeof
SponsoringOrganizationsoftheTreadwayCommission(COSO)in“InternalControl-IntegratedFramework(2013).”
Thesecriteriaareintheareasofcontrolenvironment,riskassessment,controlactivities,informationandcommunication,
andmonitoring.TheCompany’sassessmentincludedextensivedocumenting,evaluatingandtestingthedesignand
operatingeffectivenessofitsinternalcontrolsoverfinancialreporting.
BasedontheCompany’sprocessesandassessment,asdescribedabove,managementhasconcludedthat,asof
January1,2017,theCompany’sinternalcontroloverfinancialreportingwaseffective.
TheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingasofJanuary1,2017hasbeenauditedby
PricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,asstatedintheirreport,whichappears
herein.
/s/AlexGorsky /s/DominicJ.Caruso
AlexGorsky DominicJ.Caruso
Chairman,BoardofDirectors ExecutiveVicePresident,
ChiefExecutiveOfficer ChiefFinancialOfficer
Johnson&Johnson2016AnnualReport • 87Shareholder Return Performance Graphs
SetforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnontheCompany’sCommonStockfor
periodsoffiveyearsandtenyearsendingDecember31,2016,againstthecumulativetotalreturnoftheStandard&
Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexandtheStandard&Poor’sHealthCareEquipment
Index.Thegraphsandtablesassumethat$100wasinvestedonDecember31,2011andDecember31,2006ineachof
theCompany’sCommonStock,theStandard&Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexand
theStandard&Poor’sHealthCareEquipmentIndexandthatalldividendswerereinvested.
5 Year Shareholder Return
Performance J&J vs. Indices
$240
Johnson & Johnson
$210
S&P 500 Index
S&P Pharmaceu(cid:2)cal Index $180
S&P Healthcare Equipment
Index $150
5-Year CAGR
$120
J&J 15.3%
S&P 500 14.6%
S&P Pharm 14.5%
$90
S&P H/C Equip 16.3% 2011 2012 2013 2014 2015 2016
2011 2012 2013 2014 2015 2016
Johnson&Johnson $100.00 $110.83 $149.19 $175.05 $177.08 $204.21
S&P500Index $100.00 $115.99 $153.55 $174.55 $176.95 $198.10
S&PPharmaceuticalIndex $100.00 $114.43 $154.73 $189.12 $200.06 $196.93
S&PHealthcareEquipmentIndex $100.00 $117.27 $149.74 $189.09 $200.39 $213.38
10 Year Shareholder Return
Performance J&J vs. Indices
$260
Johnson & Johnson
$220
S&P 500 Index
S&P Pharmaceu(cid:2)cal Index $180
S&P Healthcare Equipment
Index $140
10-Year CAGR
$100
J&J 9.0%
S&P 500 6.9%
S&P Pharm 9.0%
$60
S&P H/C Equip 7.3% 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Johnson&Johnson $100.00 $103.61 $95.56 $106.34 $105.72 $116.17 $128.75 $173.32 $203.36 $205.72 $237.24
S&P500Index $100.00 $105.57 $66.51 $84.10 $96.76 $98.80 $114.60 $151.71 $172.46 $174.83 $195.72
S&PPharmaceuticalIndex $100.00 $104.66 $85.61 $101.55 $102.34 $120.51 $137.90 $186.48 $227.91 $241.09 $237.32
S&PHealthcareEquipmentIndex $100.00 $105.13 $76.07 $97.97 $95.32 $94.55 $110.88 $141.58 $178.79 $189.47 $201.76
88 • Johnson&Johnson2016AnnualReportItem 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure
Notapplicable.
Item 9A. Controls and Procedures
DisclosureControlsandProcedures.AttheendoftheperiodcoveredbythisReport,theCompanyevaluatedthe
effectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedures.TheCompany’sdisclosurecontrols
andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatit
filesorsubmitsundertheExchangeActisrecorded,processed,summarizedandreportedwithinthetimeperiods
specifiedintheSEC’srulesandforms.Disclosurecontrolsandproceduresinclude,withoutlimitation,controlsand
proceduresdesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatitfilesor
submitsundertheExchangeActisaccumulatedandcommunicatedtotheCompany’smanagement,includingitsprincipal
executiveandprincipalfinancialofficers,orpersonsperformingsimilarfunctions,asappropriatetoallowtimelydecisions
regardingrequireddisclosure.AlexGorsky,ChairmanandChiefExecutiveOfficer,andDominicJ.Caruso,ExecutiveVice
President,ChiefFinancialOfficer,reviewedandparticipatedinthisevaluation.Basedonthisevaluation,Messrs.Gorsky
andCarusoconcludedthat,asoftheendoftheperiodcoveredbythisReport,theCompany’sdisclosurecontrolsand
procedureswereeffective
ReportsonInternalControlOverFinancialReporting.Theinformationcalledforbythisitemisincorporatedhereinby
referenceto“Management’sReportonInternalControlOverFinancialReporting”,andtheattestationregardinginternal
controlsoverfinancialreportingincludedinthe“ReportofIndependentRegisteredPublicAccountingFirm”includedin
Item8ofthisReport.
ChangesinInternalControlOverFinancialReporting.DuringthefiscalquarterendedJanuary1,2017,therewereno
changesintheCompany’sinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired
underRules13a-15and15d-15undertheExchangeActthathavemateriallyaffected,orarereasonablylikelyto
materiallyaffect,theCompany’sinternalcontroloverfinancialreporting.
TheCompanyisimplementingamulti-year,enterprise-wideinitiativetointegrate,simplifyandstandardizeprocessesand
systemsforthehumanresources,informationtechnology,procurement,supplychainandfinancefunctions.Theseare
enhancementstosupportthegrowthoftheCompany’sfinancialsharedservicecapabilitiesandstandardizefinancial
systems.ThisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessintheCompany’sinternalcontrolover
financialreporting.Inresponsetothisinitiative,theCompanyhasandwillcontinuetoalignandstreamlinethedesignand
operationofitsfinancialcontrolenvironment.
Item 9B. Other Information
Notapplicable.
Johnson&Johnson2016AnnualReport • 89PART III
Item 10. Directors, Executive Officers and Corporate Governance
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheAuditCommitteeunder
thecaption“Item1.ElectionofDirectors–BoardCommittees”;andthematerialunderthecaptions“Item1.Electionof
Directors”and“StockOwnershipandSection16Compliance–Section16(a)BeneficialOwnershipReporting
Compliance”intheProxyStatement;andthematerialunderthecaption“ExecutiveOfficersoftheRegistrant”inPartIof
thisReport.
TheCompany’sCodeofBusinessConduct,whichcoversallemployees(includingtheChiefExecutiveOfficer,Chief
FinancialOfficerandController),meetstherequirementsoftheSECrulespromulgatedunderSection406ofthe
Sarbanes-OxleyActof2002.TheCodeofBusinessConductisavailableontheCompany’swebsiteat
www.jnj.com/code-of-business-conduct,andcopiesareavailabletoshareholderswithoutchargeuponwrittenrequestto
theSecretaryattheCompany’sprincipalexecutiveoffices.AnysubstantiveamendmenttotheCodeofBusinessConduct
oranywaiveroftheCodegrantedtotheChiefExecutiveOfficer,theChiefFinancialOfficerortheControllerwillbe
postedontheCompany’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(andretainedonthewebsite
foratleastoneyear).
Inaddition,theCompanyhasadoptedaCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsand
ExecutiveOfficers.TheCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers
isavailableontheCompany’swebsiteatwww.investor.jnj.com/gov/boardconduct.cfm,andcopiesareavailableto
shareholderswithoutchargeuponwrittenrequesttotheSecretaryattheCompany’sprincipalexecutiveoffices.Any
substantiveamendmenttotheCodeoranywaiveroftheCodegrantedtoanymemberoftheBoardofDirectorsorany
executiveofficerwillbepostedontheCompany’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(and
retainedonthewebsiteforatleastoneyear).
Item 11. Executive Compensation
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors–DirectorCompensation,”“CompensationCommitteeReport,”“CompensationDiscussionand
Analysis”and“ExecutiveCompensationTables”intheProxyStatement.
Thematerialincorporatedhereinbyreferencetothematerialunderthecaption“CompensationCommitteeReport”inthe
ProxyStatementshallbedeemedfurnished,andnotfiled,inthisReportandshallnotbedeemedincorporatedby
referenceintoanyfilingundertheSecuritiesActof1933,asamended,ortheSecuritiesExchangeActof1934,as
amended,asaresultofthisfurnishing,excepttotheextentthattheCompanyspecificallyincorporatesitbyreference.
Item 12. Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item1.Stock
OwnershipandSection16Compliance”intheProxyStatement;andNote17“CommonStock,StockOptionPlansand
StockCompensationAgreements”oftheNotestoConsolidatedFinancialStatementsinItem8ofthisReport.
90 • Johnson&Johnson2016AnnualReportEquity Compensation Plan Information
ThefollowingtableprovidescertaininformationasofJanuary1,2017concerningthesharesoftheCompany’sCommon
Stockthatmaybeissuedunderexistingequitycompensationplans.
Numberof
Securitiesto
beIssuedUpon WeightedAverage NumberofSecurities
Exerciseof ExercisePriceof RemainingAvailablefor
Outstanding Outstanding FutureIssuanceUnderEquity
PlanCategory OptionsandRights OptionsandRights CompensationPlans(2)(3)
EquityCompensationPlansApprovedbySecurity
Holders(1) 137,289,904 $68.72 439,398,804
EquityCompensationPlansNotApprovedbySecurity
Holders — — —
Total 137,289,904 $68.72 439,398,804
(1) IncludedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbytheCompany’sshareholders:
2005Long-TermIncentivePlanand2012Long-TermIncentivePlan.
(2) Thiscolumnexcludessharesreflectedunderthecolumn“NumberofSecuritiestobeIssuedUponExerciseofOutstandingOptions
andRights.”
(3) The2005Long-TermIncentivePlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewere
underthe2012Long-TermIncentivePlan.
Item 13. Certain Relationships and Related Transactions, and Director
Independence
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors—DirectorIndependence”and“RelatedPartyTransactions”intheProxyStatement.
Item 14. Principal Accountant Fees and Services
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item5.
RatificationofAppointmentofIndependentRegisteredPublicAccountingFirm”intheProxyStatement.
Johnson&Johnson2016AnnualReport • 91PART IV
Item 15. Exhibits and Financial Statement Schedules
Thefollowingdocumentsarefiledaspartofthisreport:
1. FinancialStatements
ConsolidatedBalanceSheetsatendofFiscalYears2016and2015
ConsolidatedStatementsofEarningsforFiscalYears2016,2015and2014
ConsolidatedStatementsofComprehensiveIncomeforFiscalYears2016,2015and2014
ConsolidatedStatementsofEquityforFiscalYears2016,2015and2014
ConsolidatedStatementsofCashFlowsforFiscalYears2016,2015and2014
NotestoConsolidatedFinancialStatements
ReportofIndependentRegisteredPublicAccountingFirm
Allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial
statementsornotes.
2. ExhibitsRequiredtobeFiledbyItem60lofRegulationS-K
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheExhibitIndexinthisReport.
Item 16. Form 10-K Summary
RegistrantsmayvoluntarilyincludeasummaryofinformationrequiredbyForm10-KunderthisItem16.TheCompanyhas
electednottoincludesuchsummaryinformation.
92 • Johnson&Johnson2016AnnualReportSIGNATURES
PursuanttotherequirementsofSection13oftheSecuritiesExchangeActof1934,theregistranthasdulycausedthis
Reporttobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized.
Date:February27,2017
JOHNSON&JOHNSON
(Registrant)
By /s/A.Gorsky
A.Gorsky,Chairman,BoardofDirectors,
andChiefExecutiveOfficer
PursuanttotherequirementsoftheSecuritiesExchangeActof1934,thisreporthasbeensignedbelowbythefollowing
personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated.
Signature Title Date
/s/A.Gorsky Chairman,BoardofDirectors February27,2017
A.Gorsky ChiefExecutiveOfficer
(PrincipalExecutiveOfficer)
/s/D.J.Caruso
ChiefFinancialOfficer February27,2017
D.J.Caruso (PrincipalFinancialOfficer)
/s/R.A.Kapusta
ControllerandChiefAccountingOfficer February27,2017
R.A.Kapusta (PrincipalAccountingOfficer)
/s/M.C.Beckerle
Director February27,2017
M.C.Beckerle
/s/D.S.Davis
Director February27,2017
D.S.Davis
/s/I.E.L.Davis
Director February27,2017
I.E.L.Davis
/s/M.B.McClellan
Director February27,2017
M.B.McClellan
/s/A.M.Mulcahy
Director February27,2017
A.M.Mulcahy
/s/W.D.Perez
Director February27,2017
W.D.Perez
/s/C.Prince
Director February27,2017
C.Prince
/s/A.E.Washington
Director February27,2017
A.E.Washington
/s/R.A.Williams Director February27,2017
R.A.Williams
Johnson&Johnson2016AnnualReport • 93EXHIBIT INDEX
Reg.S-K
ExhibitTable
ItemNo. DescriptionofExhibit
3(i) RestatedCertificateofIncorporationeffectiveFebruary19,2016–IncorporatedhereinbyreferencetoExhibit3(i)ofthe
Registrant’sForm10-KAnnualReportforthefiscalyearendedJanuary3,2016.
3(ii) By-LawsoftheCompany,asamendedeffectiveJanuary26,2016–IncorporatedhereinbyreferencetoExhibit3.1the
Registrant’sForm8-KCurrentReportfiledJanuary26,2016.
4(a) UpontherequestoftheSecuritiesandExchangeCommission,theRegistrantwillfurnishacopyofallinstrumentsdefiningthe
rightsofholdersoflong-termdebtoftheRegistrant.
10(a) 2005Long-TermIncentivePlan–IncorporatedhereinbyreferencetoExhibit4oftheRegistrant’sS-8RegistrationStatement
filedwiththeCommissiononMay10,2005(fileno.333-124785).*
10(b) FormofStockOptionCertificate,RestrictedShareUnitCertificateandPerformanceShareUnitCertificateunderthe2005
Long-TermIncentivePlan–IncorporatedhereinbyreferencetoExhibits10.1,10.2and10.3oftheRegistrant’sForm8-K
CurrentReportfiledJanuary13,2012.*
10(c) 2012Long-TermIncentivePlan–IncorporatedhereinbyreferencetoAppendixAoftheRegistrant’sProxyStatementfiledwith
theCommissiononMarch14,2012.*
10(d) FormofStockOptionCertificate,RestrictedShareUnitCertificateandPerformanceShareUnitCertificateunderthe2012
Long-TermIncentivePlan–IncorporatedhereinbyreferencetoExhibits10.2,10.3and10.4oftheRegistrant’sForm10-Q
QuarterlyReportfiledMay7,2012.*
10(e) ExecutiveIncentivePlan(asamended)–IncorporatedhereinbyreferencetoExhibit10(f)oftheRegistrant’sForm10-KAnnual
ReportforthefiscalyearendedDecember31,2000.*
10(f) DomesticDeferredCompensation(CertificateofExtraCompensation)Plan–IncorporatedhereinbyreferencetoExhibit10(g)
oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2003.*
10(g) AmendmentstotheCertificateofExtraCompensationPlaneffectiveasofJanuary1,2009–Incorporatedhereinbyreferenceto
Exhibit10(j)oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2008.*
10(h) 2009CertificatesofLong-TermPerformancePlan–IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm
10-QQuarterlyReportforthequarterendedSeptember27,2009.*
10(i) AmendedandRestatedDeferredFeePlanforDirectors–IncorporatedhereinbyreferencetoExhibit10(k)oftheRegistrant’s
Form10-KAnnualReportforthefiscalyearendedJanuary1,2012.*
10(j) ExecutiveIncomeDeferralPlan(AmendedandRestated)–IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’s
Form10-QQuarterlyReportforthequarterendedSeptember30,2012.*
10(k) ExcessSavingsPlan–IncorporatedhereinbyreferencetoExhibit10(j)oftheRegistrant’sForm10-KAnnualReportforthe
fiscalyearendedDecember29,1996.*
10(l) AmendmentstotheJohnson&JohnsonExcessSavingsPlaneffectiveasofJanuary1,2009–Incorporatedhereinbyreference
toExhibit10(p)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedDecember28,2008.*
10(m) ExcessBenefitPlan(SupplementalRetirementPlan)–IncorporatedhereinbyreferencetoExhibit10(h)oftheRegistrant’sForm
10-KAnnualReportforthefiscalyearendedJanuary3,1993.*
10(n) AmendmentstotheExcessBenefitPlanofJohnson&JohnsonandAffiliatedCompanieseffectiveasofJanuary1,2009–
IncorporatedhereinbyreferencetoExhibit10(r)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearended
December28,2008.*
10(o) AmendmenttotheExcessBenefitPlanofJohnson&JohnsonandAffiliatedCompanies,effectiveasofJanuary1,2015–
IncorporatedhereinbyreferencetoExhibit10(q)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearended
December28,2014.*
10(p) ExecutiveLifePlanAgreement–IncorporatedhereinbyreferencetoExhibit10(i)oftheRegistrant’sForm10-KAnnualReport
forthefiscalyearendedJanuary3,1993.*
10(q) ExecutiveLifePlanAgreementClosureLetter–IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedMarch29,2015.*
10(r) Johnson&JohnsonRetirementSavingsPlan,Johnson&JohnsonSavingsPlanforUnionRepresentedEmployees,andJohnson&
JohnsonSavingsPlan–IncorporatedhereinbyreferencetoExhibits99.1,99.2and99.3oftheRegistrant’sFormS-8filedwith
theCommissiononMay6,2013.*
10(s) EmploymentAgreementforDr.PaulusStoffels–IncorporatedhereinbyreferencetoExhibit10.2oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedSeptember30,2012.*
10(t) SummaryofEmploymentArrangementsforSandraE.Peterson–IncorporatedhereinbyreferencetoExhibit10(t)ofthe
Registrant’sForm10-KAnnualReportfortheyearendedDecember30,2012.*
94 • Johnson&Johnson2016AnnualReport10(u) SeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies,AmendedandRestatedasofOctober1,2014–
IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterended
September28,2014.*
10(v) FirstAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)–IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportfor
thequarterendedJune28,2015.*
10(w) SecondAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)–IncorporatedhereinbyreferencetoExhibit10(x)oftheRegistrant’sForm10-KAnnualReportfor
thefiscalyearendedJanuary3,2016.*
12 StatementofComputationofRatioofEarningstoFixedCharges–Filedwiththisdocument.
21 Subsidiaries–Filedwiththisdocument.
23 ConsentofIndependentRegisteredPublicAccountingFirm–Filedwiththisdocument.
31(a) CertificationofChiefExecutiveOfficerPursuanttoSection302oftheSarbanes-OxleyAct–Filedwiththisdocument.
31(b) CertificationofChiefFinancialOfficerPursuanttoSection302oftheSarbanes-OxleyAct–Filedwiththisdocument.
32(a) CertificationofChiefExecutiveOfficerPursuanttoSection906oftheSarbanes-OxleyAct–Furnishedwiththisdocument.
32(b) CertificationofChiefFinancialOfficerPursuanttoSection906oftheSarbanes-OxleyAct–Furnishedwiththisdocument.
101 XBRL(ExtensibleBusinessReportingLanguage)ThefollowingmaterialsfromthisReportforthefiscalyearendedJanuary1,
2017,formattedinExtensiveBusinessReportingLanguage(XBRL):(i)ConsolidatedBalanceSheets,(ii)Consolidated
StatementsofEarnings,(iii)ConsolidatedStatementsofComprehensiveIncome,(iv)ConsolidatedStatementsofEquity,(v)
ConsolidatedStatementsofCashFlows,and(vi)NotestotheConsolidatedFinancialStatements.
* Managementcontractorcompensatoryplan.
AcopyofanyoftheExhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest
specifyingthedesiredexhibit(s)totheSecretaryattheprincipalexecutiveofficesoftheCompany.
TheFollowingExhibits,indicatedasbeingfiledwiththisdocument,areomittedfromtheprintedversionofthisAnnual
Report2016:
Exhibit12
Exhibit21
Exhibit23
Johnson&Johnson2016AnnualReport • 95[THISPAGEINTENTIONALLYLEFTBLANK]Exhibit31(a)
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,AlexGorsky,certifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedJanuary1,2017(the“report”)of
Johnson&Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea
materialfactnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementswere
made,notmisleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairly
presentinallmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,and
for,theperiodspresentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrols
andprocedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancial
reporting(asdefinedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandprocedures
tobedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodin
whichthisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityof
financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally
acceptedaccountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendofthe
periodcoveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthat
occurredduringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofan
annualreport)thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontrol
overfinancialreporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternal
controloverfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardof
directors(orpersonsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,
summarizeandreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificant
roleintheCompany’sinternalcontroloverfinancialreporting.
/s/AlexGorsky
AlexGorsky
ChiefExecutiveOfficer
Date:February27,2017
Johnson&Johnson2016AnnualReportExhibit31(b)
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,DominicJ.Caruso,certifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedJanuary1,2017(the“report”)of
Johnson&Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea
materialfactnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementswere
made,notmisleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairly
presentinallmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,and
for,theperiodspresentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrols
andprocedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancial
reporting(asdefinedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandprocedures
tobedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodin
whichthisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityof
financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally
acceptedaccountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendofthe
periodcoveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthat
occurredduringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofan
annualreport)thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontrol
overfinancialreporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternal
controloverfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardof
directors(orpersonsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,
summarizeandreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificant
roleintheCompany’sinternalcontroloverfinancialreporting.
/s/DominicJ.Caruso
DominicJ.Caruso
ChiefFinancialOfficer
Date:February27,2017
Johnson&Johnson2016AnnualReportExhibit32(a)
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,AlexGorsky,theChiefExecutiveOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1) theCompany’sAnnualReportonForm10-KforthefiscalyearendedJanuary1,2017(the“Report”)fully
complieswiththerequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2) theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionand
resultsofoperationsoftheCompany.
/s/AlexGorsky
AlexGorsky
ChiefExecutiveOfficer
Dated:February27,2017
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906ofthe
Sarbanes-OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompany
forpurposesofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityof
thatsection.
Johnson&Johnson2016AnnualReportExhibit32(b)
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,DominicJ.Caruso,theChiefFinancialOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1) theCompany’sAnnualReportonForm10-KforthefiscalyearendedJanuary1,2017(the“Report”)fully
complieswiththerequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2) theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionand
resultsofoperationsoftheCompany.
/s/DominicJ.Caruso
DominicJ.Caruso
ChiefFinancialOfficer
Dated:February27,2017
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906ofthe
Sarbanes-OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompany
forpurposesofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityof
thatsection.
Johnson&Johnson2016AnnualReport[THISPAGEINTENTIONALLYLEFTBLANK][THISPAGEINTENTIONALLYLEFTBLANK]ReconciliationofNon-GAAPFinancialMeasures
%Incr./
(DollarsinMillionsExceptPerShareData) 2016 2015 (Decr.)
Earningsbeforeprovisionfortaxesonincome-asreported $19,803 19,196 3.2%
Intangibleassetamortizationexpense 1,271 1,570
Restructuring/Other(1) 685 590
Litigationexpense,net 817 141
DePuyASRTMHipprogram 9 148
In-processresearchanddevelopment 29 224
Other 145 134
Earningsbeforeprovisionfortaxesonincome-asadjusted $22,759 22,003 3.4%
NetEarnings-asreported $16,540 15,409 7.3%
Intangibleassetamortizationexpense 931 1,113
Restructuring/Other 544 415
Litigationexpense,net 675 118
DePuyASRTMHipprogram 7 130
In-processresearchanddevelopment 23 162
Other 44 98
NetEarnings-asadjusted $18,764 17,445 7.6%
DilutedNetEarningspershare-asreported $5.93 5.48 8.2%
Intangibleassetamortizationexpense 0.33 0.39
Restructuring/Other 0.20 0.15
Litigationexpense,net 0.24 0.04
DePuyASRTMHipprogram – 0.05
In-processresearchanddevelopment 0.01 0.06
Other 0.02 0.03
DilutedNetEarningspershare-asadjusted $6.73 6.20 8.5%
OperationalDilutedNetEarningspershare-asadjustedat2014foreigncurrencyexchange
rates 6.76
Impactofcurrencyat2015foreigncurrencyexchangerates 0.05 (0.56)
OperationalDilutedNetEarningspershare-asadjustedat2015foreigncurrencyexchange
rates $6.78 6.20 9.4%
(1) Includes$45millionrecordedincostofproductssoldand$149millionrecordedinother(income)expensein2016,and
$81millionrecordedincostofproductssoldin2015.
TheCompanyprovidesearningsbeforeprovisionfortaxesonincome,netearningsandnetearningspershare(diluted)on
anadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestors.Amongother
things,thesemeasuresmayassistinvestorsinevaluatingtheCompany’sresultsofoperationsperiodoverperiod.In
variousperiods,thesemeasuresmayexcludesuchitemsasintangibleassetamortizationexpense,significantcosts
associatedwithacquisitions,restructuring,litigation,andchangesinapplicablelawsandregulations(includingsignificant
accountingortaxmatters).Thesespecialitemsmaybehighlyvariable,difficulttopredict,andofasizethatsometimeshas
substantialimpactontheCompany’sreportedresultsofoperationsforaperiod.Managementusesthesemeasures
internallyforplanning,forecastingandevaluatingtheperformancesoftheCompany’sbusinesses,includingallocating
resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargets.Unlikeearningsbeforeprovision
fortaxesonincome,netearningsandnetearningspershare(diluted)preparedinaccordancewithGAAP,adjusted
earningsbeforeprovisionfortaxesonincome,adjustednetearningsandadjustednetearningspershare(diluted)maynot
becomparablewiththecalculationofsimilarmeasuresforothercompanies.Thelimitationsofusingthesenon-GAAP
financialmeasuresasperformancemeasuresarethattheyprovideaviewoftheCompany’sresultsofoperationswithout
includingalleventsduringaperiod,suchasintangibleassetamortizationexpense,theeffectsofanacquisition,theOrtho-
ClinicalDiagnosticsdivestiture,restructuring,litigation,andchangesinapplicablelawsandregulations(including
significantaccountingortaxmatters)anddonotprovideacomparableviewoftheCompany’sperformancetoother
companiesinthehealthcareindustry.Investorsshouldconsidernon-GAAPfinancialmeasuresinadditionto,andnotas
replacementsfor,orsuperiorto,measuresoffinancialperformancepreparedinaccordancewithGAAP.
Johnson&Johnson2016AnnualReportBoard of Directors Senior Management
ALEXGORSKY ALEXGORSKY
Chairman,BoardofDirectors ChiefExecutiveOfficer
Chairman,ExecutiveCommittee
MARYC.BECKERLE
ChiefExecutiveOfficerandDirector, DOMINICJ.CARUSO*
HuntsmanCancerInstituteattheUniversityofUtah; ExecutiveVicePresident,ChiefFinancialOfficer
DistinguishedProfessorofBiology,
CollegeofScience,UniversityofUtah JOAQUINDUATO*
ExecutiveVicePresident,WorldwideChairman,Pharmaceuticals
D.SCOTTDAVIS
FormerChairmanandChiefExecutiveOfficer, PETERM.FASOLO*
UnitedParcelService,Inc. ExecutiveVicePresident,ChiefHumanResourcesOfficer
IANE.L.DAVIS RONALDA.KAPUSTA
Chairman,Rolls-RoyceHoldingsplc; CorporateController
FormerChairmanandWorldwideManagingDirector, ChiefAccountingOfficer
McKinsey&Company
ASHLEYMcEVOY
MARKB.McCLELLAN CompanyGroupChairman,ConsumerMedicalDevices
Director,Duke-RobertJ.Margolis,MD,
JORGEMESQUITA*
CenterforHealthPolicy
ExecutiveVicePresident,WorldwideChairman,Consumer
ANNEM.MULCAHY
SANDRAE.PETERSON*
FormerChairmanandChiefExecutiveOfficer,
ExecutiveVicePresident,GroupWorldwideChairman
XeroxCorporation
GARYJ.PRUDEN*
WILLIAMD.PEREZ
ExecutiveVicePresident,WorldwideChairman,MedicalDevices
RetiredPresidentandChiefExecutiveOfficer,
Wm.WrigleyJr.Company
MICHELLER.RYAN
Treasurer
CHARLESPRINCE
RetiredChairmanandChiefExecutiveOfficer,
MICHAELE.SNEED
CitigroupInc.
WorldwideVicePresident,GlobalCorporateAffairs
ChiefCommunicationsOfficer
A.EUGENEWASHINGTON
DukeUniversity’sChancellorforHealthAffairs;
THOMASJ.SPELLMANIII
PresidentandChiefExecutiveOfficer,
CorporateSecretary
DukeUniversityHealthSystem
AssistantGeneralCounsel
RONALDA.WILLIAMS
PAULUSSTOFFELS*
FormerChairmanandChiefExecutiveOfficer,
ExecutiveVicePresident,ChiefScientificOfficer
AetnaInc.
JENNIFERTAUBERT
CompanyGroupChairman,Pharmaceuticals,TheAmericas
MICHAELH.ULLMANN*
ExecutiveVicePresident,GeneralCounsel
KATHRYNE.WENGEL
WorldwideVicePresident,Johnson&JohnsonSupplyChain
*Member,ExecutiveCommittee
Johnson&Johnson2016AnnualReportPRINCIPALOFFICE STOCKLISTING JOHNSON&JOHNSONONLINE
OneJohnson&JohnsonPlaza Johnson&JohnsonCommonStock
Ourwebsite:www.jnj.com
NewBrunswick,NewJersey08933 ListedonNewYorkStockExchange
(732)524-0400 StockSymbol:JNJ
http://www.jnj.com/media-center
2017ANNUALMEETINGOFSHAREHOLDERS SHAREHOLDERRELATIONSCONTACT
Thursday,April27,2017 ThomasJ.SpellmanIII
www.facebook.com/jnj
CorporateSecretary
10:00a.m.(Eastern);Doorsopenat9:15a.m.
(732)524-2455
StateTheatre www.twitter.com/JNJCares
15LivingstonAvenue INVESTORRELATIONSCONTACT www.twitter.com/JNJNews
NewBrunswick,NewJersey
JosephJ.Wolk
Allshareholdersasoftherecorddateof VicePresident,InvestorRelations www.youtube.com/jnj
February28,2017areinvitedtoattend. (800)950-5089
AformalNoticeofAnnualMeeting, (732)524-1142 http://www.linkedin.com/company/
johnson-&-johnson
ProxyStatementandProxyhavebeen InvestorRelationswebsite:
madeavailabletoshareholders. www.investor.jnj.com
TheJohnson&Johnson2016Yearin
2016ANNUALREPORTONFORM10-KAND STOCKTRANSFERAGENTANDREGISTRAR Reviewisavailableonourwebsiteat
2017PROXYSTATEMENT
Questionsregardingstockholdings,
www.2016yearinreview.jnj.com.
Johnson&Johnson’sAnnualReportonForm10-K certificatereplacement/transfer,dividends Theinformationonthesewebsitesshould
forthefiscalyearendedJanuary1,2017is andaddresschangesshouldbedirectedto notbedeemedtobepartofthisAnnual
includedinthisAnnualReportinitsentirety,with ourstocktransferagentandregistrarat: Report.
theexceptionofcertainexhibits.TheForm10-K,
ComputershareTrustCompany,N.A.
completewithallofitsexhibits,isavailableonour P.O.Box30170
websiteatwww.investor.jnj.com/sec.cfm,andthe CollegeStation,TX77842-3170
SEC’swebsiteatwww.sec.gov.
Overnightmail:
Shareholdersmayalsoobtaincopiesofthe ComputershareTrustCompany,N.A.
exhibits,our2016AnnualReporton 211QualityCircle,Suite210
Form10-Kandour2017ProxyStatement, CollegeStation,TX77845
withoutcharge,uponwrittenrequesttothe (800)328-9033or(781)575-2718
OfficeoftheCorporateSecretaryatour Shareholderwebsite:
principalofficeaddress,orbycalling www.computershare.com/investor
(800)950-5089.
DividendReinvestmentPlan
ELECTRONICDELIVERYNOTIFICATION ThePlanallowsforfullorpartialdividend
The2017ProxyStatementandour2016Annual reinvestmentandadditionalweeklycash
Reportareavailableonourwebsite investmentsupto$50,000peryearin
www.investor.jnj.com/gov/ Johnson&JohnsonCommonStockwithout
annualmeetingmaterials.cfm.Shareholderswho pershareorservicechargesonstock C132107
receivepapercopiesofourProxyStatementand purchases.Ifyouareinterestedin
AnnualReportbymailcanelecttoreceiveinstead participatinginthePlanandneedan
ane-mailmessagewithalinktothosedocuments enrollmentformand/ormoreinformation,
ontheInternet.Registeredshareholdersmay pleasecallthePlanadministrator,
TheJohnson&Johnson2016AnnualReport
enrollinelectronicdeliveryat: ComputershareTrustCompany,N.A.at
containsmanyofthevaluabletrademarks
www.computershare-na.com/green.Beneficial (800)328-9033or(781)575-2718
andtradenamesownedandusedbythe
shareholders(whoholdsharesofJohnson& (outsidetheU.S.)oraccessonlineat
Johnson&JohnsonFamilyofCompaniesin
JohnsonCommonStockthroughabank,brokeror www.computershare.com/investor.
theUnitedStatesandinternationallyto
otherholderofrecord)generallycanenrollfor
distinguishproductsandservicesof
electronicdeliveryat:enroll.icsdelivery.com/jnj. HearingImpaired
outstandingquality.
Shareholderswhohaveinquiriesregarding
©Johnson&Johnson2017
stock-relatedmatterscancommunicate
directlywithComputershareTrustCompany,
N.A.viaatelecommunicationsdevice(TDD).
Thetelephonenumberforthisserviceis
(800)952-9245or(781)575-2692
(outsidetheU.S.).Caring for the world, one person at a time…
inspires and unites the people of